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INTRODUCTION AND LITERATURE REVIEW 
 
1. Introduction
Water is generally accepted to be a vital natural resource because of its significant roles in 
the environment, food production, hygiene and industry.  Increased urbanisation caused by 
the rapid increase in global population places strain on already stressed water supplies and 
sanitation facilities, especially in developing countries (FDIRI, 2014). According to the 
World Health Organisation (WHO), poor access to safe water and inadequate sanitation 
continues to be a danger to human health, especially in the African continent where more 
than 300 million people reside in water scarce environments (Vorosmarty et al., 2010).  
According to WHO (2008) ‘safe water’ to be consumed should meet the following 
requirements: it should be free from viral, bacterial and protozoic pathogens; it should meet 
national or international water quality guidelines for colour, taste and appearance, and 
chemicals present in the water should be present in a concentration of an acceptable 
standard.  However, improper sanitation facilities, inefficient wastewater treatment 
processes, political upheaval as well as the insufficient funding contribute significantly to 
people of developing and developed countries not having access to microbiologically safe 
water (WHO, 2002a). 
 
The absence of stringent water quality guidelines coupled with the infrequent monitoring 
of wastewater treatment plants and receiving surface waters are one of the major 




is sometimes discharged into surface waters used for domestic purposes such as drinking, 
bathing and washing as well as in the preparation of food. Inadequately treated water used 
for these purposes are often home to a plethora of potentially pathogenic microorganisms 
such as Vibrio spp., Escherichia coli and emerging pathogens such as Legionella spp. 
These microorganisms are the causative agents for a variety of gastro-intestinal infections 
and diarrheal diseases and if untreated, could even lead to death (Nataro and Kaper, 1998).  
Inadequately treated wastewater has also been identified as a reservoir of antibiotic 
resistant bacteria (ARB) which could affect the treatment of infections and promote the 
dissemination of resistance amongst bacteria in aquatic environments (Marti et al., 2013). 
It is therefore imperative that frequent monitoring of wastewater treatment plants 
(WWTPs) and the receiving water bodies be carried out to investigate the efficiency of 
these plants used in the treatment of wastewater in comparison with acceptable standards, 
in order to safeguard the health of the public. 
 
1.1 The current state of water resources in South Africa 
According to the South African Water Research Commission (SAWRC) and the 
Department of Water Affairs and Forestry (DWAF), South Africa is the 30th driest country 
in the world, having average rainfall levels of approximately 465 mm, and an average 
annual runoff of less than 50 000 million m3 (DWAF, 2013). However, this scarcity is not 
only attributed to the lack of available supply, but also due to failure of infrastructure, 
environmental changes as well as deteriorating water quality (Hedden and Cilliers, 2014).  




growth rate of 1%. The country has 12 water boards which supply potable water to more 
than 28 million people, however, this is still below the maximum supply capacity of 39 
million (DWAF, 2013). This scarcity of water not only affects food security, the production 
of energy and environmental integrity but also results in conflict between human and 
animal populations who share the same water resources (Kusiluka et al., 2005).  
 
According to DWAF (2013), approximately 4.9 million people do not have access to basic 
sanitation. Informal settlement dwellers are therefore forced to rely on untreated water 
resources such as dams, pools, rivers and springs for drinking and other domestic purposes, 
and as a result, they are frequently attacked by water-borne diseases (El-Jakee et al., 2009; 
DWAF, 2013).  Although sanitary infrastructure has been provided to a number of rural 
communities, these facilities are often not in working order or are unhealthy for use due to 
the number of residents far outnumbering the number of facilities available.  Therefore, 
residents are again forced to use available water sources for their daily water needs. Almost 
all aquatic environments are polluted by a number of microbial pathogens stemming from 
human use.  These pollutants are obtained from point and non-point sources.  Point source 
pollution enters the environment at various and different locations through the direct route 
of discharge of either treated or untreated domestic sewage, acid mine drainage and 
industrial effluent.  Non-point pollution sources include urban and agricultural waste run-
off, sewage and septic tank leakages as well as sewer overflows, and accounts for almost 






1.2 Wastewater Treatment Plants 
The South African Water Act was established in 1956 and stipulated that wastewater be 
treated to an acceptable standard prior to discharge into receiving water bodies (Hedden 
and Cilliers, 2014). However, economic expansion and population explosion coupled with 
pressure from international authorities to meet certain quality guidelines exerted pressure 
on water and sanitation authorities in the country, and as a result many wastewater 
treatment plants fail (Morrison et al., 2001; Mema, 2002). Water resources are 
contaminated largely by wastewater effluent, which is defined as a mixture of raw sewage, 
primary, secondary and tertiary effluents (Naidoo and Olaniran, 2014).   
 
Currently, there are 1286 municipal and privately owned WWTPs in South Africa, 
discharging approximately 21.3 km3 of treated water back into the countries river systems. 
However, only 14% of river water is re-used by the municipality, and the rest is available 
as secondary water sources to the public (DWAF, 2013; Hedden and Cilliers, 2014). Many 
wastewater treatment facilities fail to treat water adequately, and final effluent of poor 
microbial quality then enter public waters such as rivers and lakes. Such activities affect 
the quality of water, and serve as a reservoir for a multitude of diseases.  Therefore, the 
DWAF has implemented an incentive-based certification process known as the Green Drop 
certification process whereby critical performance indicators such as design and capacity 
of WWTPs, technical skills of employees as well as the adherence of effluent to set 
standards are assessed. Each WWTP in each of the 9 provinces in South Africa are 
evaluated and given a score based on set criteria (DWAF, 2013). In 2013, a national 




Africa are functioning adequately (DWAF, 2013). Water quality can be determined by the 
assessment of three attributes, namely the physical, chemical and biological characteristics 
of the water, each differing in accordance with its intended purpose (Kregar, 2004).  The 
quality of water varies depending on the area in which it is found, seasonal changes as well 
as the type of soil and rocks through which it passes.  The regular monitoring of water 
quality is therefore an important step in protecting public health (Franck, 2004).  The lack 
of above-mentioned monitoring procedures together with the declining state of wastewater 
treatment infrastructure in South Africa has contributed to the incidence of numerous 
water-borne illnesses as demonstrated by outbreaks of cholera, typhoid fever and diarrheal 
diseases occurring in the Mpumalanga, Kwa-Zulu Natal and Eastern Cape provinces 
respectively (Mema, 2002). 
 
1.3 Wastewater treatment in KwaZulu-Natal 
The province of KwaZulu-Natal is situated on the east coast of South Africa and it’s 
geography is characterized by a number of rivers, valleys and associated catchments.  This 
province is home to approximately one hundred and fifty WWTPs ranging from small to 
macro sized plants.  An audit conducted by the Department of Water Affairs in 2009 stated 
that there are concerns regarding the treatment of wastewater and subsequent discharge 
into receiving water bodies within the province.  This audit determined that a majority of 
WWTPs failed to meet at least three or more of the respective discharge standards as 
stipulated by the South African water quality guidelines.  The main problems which were 
identified include: plants’ operation at a capacity which exceeded their hydraulic design 




control problems; funding constraints; the age of the treatment plant as well as the use of 
inappropriate technology. 
 
According to Mema (2002), burst sewage pipes resulted in the release of raw sewage into 
the Durban harbour in 2008.  Poor management of wastewater treatment facilities and 
failure to repair burst pipes by the municipality were identified as the cause of the problem 
which resulted in the death of numerous fish and other marine life.  Reports by Mema 
(2002) also identified industrial growth, ineffective industrial on-site treatment facilities 
and the failure to implement proper environmental laws as major contributors to high 
coliform counts in the water catchments of Kwa-Zulu Natal.  This could be seen clearly 
when evaluating treated effluent at the Northern Wastewater Treatment Plant in Durban, 
KwaZulu-Natal where COD values ranged between 50.33 mg/L and 276.33mg/L over a 1 
year sample period, exceeding the limit of 30 mg/L as stipulated by the DWAF (Naidoo 
and Olaniran, 2014). Such case studies then necessitate the need for treatment facilities 
having improved management and infrastructure as well as more frequent monitoring 
programs, which exploit the use of indicator microorganisms to monitor water quality. 
 
1.4 Microbiological quality of water 
According to Grabow (1996), the detection of each pathogenic organism in water is 
technically difficult and time consuming therefore microbiological indicators have been 
used for decades as a means to monitor pollution of water sources.  An ideal indicator 




x The concentration of the indicator organism should have a quantitative relationship 
to the risk of disease associated with exposure; 
x The indicator organism should not be pathogenic and be present in higher numbers 
than that of the pathogen; 
x The indicator organism should be easy to quantify; 
x The indicator should be present whenever the pathogen is present; 
x The indicator organism should not reproduce in water and its growth characteristics 
should be similar to that of its associated pathogen; 
x Tests to determine the concentration of the indicator organism should be easy, rapid 
and inexpensive; 
x The indicator organism should be specific to a source. 
Since no single organism meets all of the above-mentioned requirements, it has been 
advised that several indicator organisms be used for water quality assessments.  In addition 
to microbial analysis, the survival of microorganisms depends on the physico-chemical 
characteristics of the water.  Such characteristics include: Biological Oxygen Demand 
(BOD); Chemical Oxygen Demand (COD); Total suspended solids (TSS); Total dissolved 
solids (TDS); pH; temperature; turbidity; salinity, electrical conductivity (EC) and 
resistivity.  These parameters are also known to impact on the efficiency of water treatment 








1.5 Escherichia coli 
Escherichia coli (E. coli) plays a central role in water bacteriology and has been used as an 
indicator of fecal pollution originating from human and warm blooded animals. Its 
presence in water samples can be confirmed through IMViC biochemical testing and 
testing for the presence of the β-glucuronidase enzyme using chromogenic media. The 
appearance of pathogenic E. coli O157:H7 has been associated with various diseases in 
humans, and at present, six groups of E. coli pathotypes have been identified (Doyle et al., 
1997). Virulence of these pathogens is dependent on both genetic determinants as well as 
gene expression (Doyle et al., 1997). The detection of specific virulence attributes of any 
strain of E. coli allows for the determination of the potential reservoirs of virulence genes, 
which also play a key role in the detection of new strains of the organism.  Such aspects 
are useful when determining the origin of emerging disease.   
 
The production of enterotoxins by disease causing bacteria such as E. coli is the primary 
determinant in the establishment of diseases such as diarrhea in humans (Sanchez and 
Holmgren, 2005). The most prevalent pathotype of E. coli, Enterohemorrhagic E. coli 
(EHEC) is characterized by the presence of two Shiga-like toxins, Stx1 and Stx2 which 
increase the harshness of the disease caused by this pathogen.  Other pathotypes such as 
Enterotoxigenic E. coli (ETEC) also mediate infection through the production of 
enterotoxins whilst Enteroinvasive E. coli (EIEC) cause infections by attaching to host 
cells.  The principal symptom caused by all six pathotypes of E. coli infections involves 
the onset of diarrhea in the human host (Kothary and Babu, 2001).  Diarrheal diseases 




those infected with HIV/AIDS, and are also involved in the establishment of haemolytic 
uremic syndrome. 
 
The use of E. coli as a microbial indicator for water quality monitoring is a concept that 
has been widely accepted and used for many years, and the presence of E. coli in water 
indicates that it is unsuitable for consumption (Ahmed et al., 2005).  E. coli is a common 
inhabitant of the intestinal microflora of both humans and other warm blooded animals.  
Due to its prevalence in the intestine and faeces of such animals, its presence in water is an 
indication of faecal contamination (Gleeson and Gray, 1997). 
 
The majority of the identified strains of E. coli are harmless, however, over the past decade, 
a number of strains were identified to be pathogenic, and the cause of numerous gastro-
intestinal infections (Umoh et al., 2006). E. coli O157:H7 has been identified as the 
pathogenic strain responsible for majority of severe cases of diarrhoea (Galane and le Roux, 
2001).  It has several characteristics which are uncommon amongst other strains of E. coli.  
These characteristics include: An inability to ferment sorbitol within a 24 hour period; 
inability to produce β-glucuronidase; contains the eaeA gene; cannot grow well or at all at 
temperatures ≥44.5 ºC; tolerant to acidic environments; increased resistance to 
streptomycin and tetracycline when compared to normal E. coli strains (Padhye and Doyle, 
1991; Feng, 1995; Doyle et al., 1997). 
The differentiation of a pathogenic strain from a harmless one is based on the virulence 
properties, mechanisms of pathogenicity, clinical syndromes as well as the serotyping of 




et al., 1997).  All strains of E. coli, which are classified as pathogenic are further classified 
into 6 major virotypes. These virotypes, referred to as diarrheagenic E. coli, are are 
classified as enterohemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), 
enteroinvasive E. coli (EIEC), enteropathogenic E. coli (EPEC), enteroaggregative E. coli 
(EAEC) and diffusely adherent E. coli (DAEC), with each group having a unique virulence 
factor profile (Doyle et al., 1997). 
 
1.5.1 Enteropathogenic E. coli  
Until the 1970s, serotyping was the only method used to distinguish EPEC strains from 
normal flora as no biochemical, microbiological and animal tests were available for 
differentiation at that time. Currently, the presence of specific virulence markers can be 
used to determine the presence of EPEC (Jafari et al., 2012). The mechanisms of 
pathogenesis of EPEC do not resemble other strains, since they are neither associated with 
heat labile enterotoxins, heat stable enterotoxins or invasiveness (Jafari et al., 2012). EPEC 
initiates attaching and effacing lesions in the host cell to which they adhere and 
subsequently invade.  Classically, EPEC attaches to Hep-2 cells of the intestinal mucosa to 
form a pattern of attachment.  Chromosomal virulence and EPEC adherence factors are 
necessary for the full expression of adherence, and the intimate attachment to these 
epithelial cells is enabled by intimin, an outer membrane protein encoded for by the eaeA 
gene.  Affected cells respond by calcium influx, a redisposition of cytoskeletal elements 
and protein phosphorylation which lead to an increase in intestinal secretions (Wilshaw et 
al., 2000).  Zoonotic reservoirs of EPEC have not been encountered therefore the only 





EPEC symptoms are similar to that of other diarrheagenic strains and include fever, 
vomiting and watery diarrhea.  They are amongst the most important pathogens infecting 
children less than 2 years of age in the developing world who in most cases, contract the 
disease via a direct faecal-oral route (Mossel et al., 1995; Wilshaw et al., 2000; Aslani and 
Bouzari, 2012).  Over the last several decades however, the significance of EPEC infections 
has declined which may be attributed to the promotion of breast feeding or the over-
estimation of this organism to cause disease when only serotyping methods were used for 
detection (Aslani and Bouzari, 2012). 
 
1.5.2 Enterotoxigenic E. coli   
According to Jafari et al. (2012), ETEC is the most important but under recognized 
bacterial cause of diarrhea and cholera-like diseases in humans living in areas without 
proper sanitation and clean water.  Strains of ETEC are known to adhere specifically to the 
microvilli of the small intestine epithelial cells and produce site specific enterotoxins, 
which are defined as extracellular proteins or peptides which affect intestinal epithelial 
cells (Nagy and Fekete, 1999).  They cause watery diarrhea with the absence of blood, 
mucus or pus in humans globally, with symptoms of fever and vomiting also being reported 
(Kothary and Babu, 2001). ETEC strains capable of causing disease are characterised by 
the presence of either a large molecular weight heat-labile enterotoxin (LT) or by small 
molecular weight heat-stable peptide toxins (ST), which ultimately determine virulence 





Individuals prone to ETEC infections are young children residing in tropical countries 
(Brussow et al., 1992). Children younger than 2 years of age were reported to be most 
symptomatic of ETEC infections when compared to infected adults in the area. In addition, 
ETEC is responsible for “travellers diarrhea”, with approximately 20 – 60% of people 
travelling to low-income areas contracting the disease. An incidence rate of 60% was also 
observed by Hunter (2003). ETEC infections caused through human contact is rare and 
occurs most frequently through the interaction between people and contaminated food and 
water sources.  Inadequate chlorination and contamination by E. coli in water distribution 
systems was identified as the cause of an ETEC outbreak amongst 175 Israeli military 
personnel and 54 civilians according to Huerta et al. (2000).  ETEC has also been identified 
in the farming industry where it is known to cause disease in both cattle and young pigs 
(Jafari et al., 2012). 
 
1.5.2.1 Pathogenesis of ETEC infections 
According to Nagy and Fekete (1999), the pathogenesis of all ETEC infections involves 
two steps: intestinal colonisation and the elaboration of the respective enterotoxins.  This 
is done through the adherence of either fimbriae or pili to the epithelial cells of the small 
intestine within the host.  These pili, by which all ETEC strains are characterised, act as a 
ligand to bind the bacterial cell to carbohydrate receptors on the epithelial cell surface.  Pili, 
together with species-specific fimbriae are termed colonization factor antigens (CFAs), and 
are often associated with attachment to the gastrointestinal tract.  All CFAs are 
characterised based on their morphology and broadly grouped into three categories: rigid 




morphology of CFAs within the bacterial cell plays a role in determining host specificity. 
After attachment to the epithelial cells, toxins are translocated through the cell via trans-
Golgi vesicular transport.  These toxins can be labile (LTs) or stable (STs) (Nagy and 
Fekete, 1995). 
 
1.5.2.1.1 Labile Toxins  
LTs are large oligomeric toxins that consist of two antigenic types namely LT-I and LT-II 
(Hunter, 2003).  Both types are found in E. coli strains but only LT-I is known to be 
pathogenic to humans and animals.  Antigenic type LT-II is not known to cause disease 
and is frequently found in animals and rarely in humans (Prescott et al., 2005).  LT-I causes 
diarrhea by a chain of intracellular reactions by binding to specific gangliocides on the 
epithelial cells of the small intestine and activating membrane bound adenylate cyclase.  
This leads to an increase in cyclic adenosine monophosphate (cAMP), and ultimately, an 
increase in osmoregularity within the lumen of the host, causing water to be drawn into the 
gut.  This, in conjunction with the excretion of chloride into the gut lumen and a decrease 
in the absorption of sodium by the host cells lead to watery diarrhea (Hunter, 2003). 
1.5.2.1.2 Stable Toxins 
STs are small monomeric toxins which contain multiple cysteine residues and disulphide 
bonds which are responsible for its’s heat stable properties (Prescott et al., 2005).  Similar 
to LTs, STs contain two antigenic types, namely STa and STb (Hunter, 2003).  STa is an 
18 amino acid peptide which functions by binding to an enzyme, guanylate cyclase C.  
Binding to this enzyme, which is present in the luminal membrane of enterocytes, results 




compared to LT mechanisms where it results in the increase of chloride excretion.  STb, a 
larger amino-acid peptide functions differently, in which cAMP levels and chloride 
transport is not affected.  This antigenic type results in the net increase of bicarbonate 
excretion (Hunter, 2003). 
 
1.5.3 Enteroinvasive E. coli 
EIEC was first identified as the causative agent of diarrheal disease in 1971, however 
evidence suggests it dates back as early as the second world war (Jafari et al., 2012).  
Symptoms of an infection resemble that of shigellosis caused by Shigella spp.  Like 
Shigella, EIEC are biochemically anaerogenic, non-lactose fermenting and lysine 
decarboxylase negative (Doyle et al., 1997).  They cause disease by invading the epithelial 
cells, multiplying intracellularly, and moving laterally to penetrate adjacent cells (Hunter, 
2003).  Their ability to invade cells is associated by the presence of a plasmid encoding 
numerous outer membrane proteins which are responsible for their invasive abilities (Doyle 
et al., 1997).  This process is often the cause of inflammation and results in death of the 
host cells and non-bloody but watery diarrhea (Flowers et al., 1992). 
 
1.5.4 Enterohaemorrhagic E. coli  
Amongst the six characterized groups of diarrheagenic E. coli, EHEC strains are probably 
the most important emerging pathogen of the past decade, with recent outbreaks occurring 
in the United States of America and the United Kingdom. They are the causative agents for 
numerous diarrheal outbreaks globally, with patients often suffering from complications 




being identified as the major cause of renal failure amongst children (Leelaporn et al., 
2003; Khan and Naim, 2011). EHEC strains are subdivided into pathotypes with the most 
important being the Shiga-toxin producing E. coli (STEC).  STEC refers to those strains of 
E. coli which produce one or more members of a class of cytotoxins referred to as shiga 
toxins (O’ Brien et al., 1982).  The most dominant serotype of STEC, E. coli O157:H7 is 
most frequently associated with human disease.  
 
STEC is often found in the intestine of cattle, sheep and goats, which is considered the 
major reservoir of EHEC/STEC (Figure 1.1) (Raji et al., 2006). However, sporadic 
outbreaks have been reported to occur in chicken, pigs and horses (Beutin et al., 1993).  
Highly sensitive techniques involving enrichment procedures in broth culture followed by 
immune-magnetic separation and subsequent plating allow for strains of STEC to be 
detected in animal faeces (Chapman et al., 1994).  The excretion of several serotypes of 
STEC in faeces is dependent upon the age and weaning of the animal, with the lowest rate 






Figure 1.1: The central role of cattle in the transmission of STEC to humans (Gyles, 
2006). 
 
1.5.4.1 STEC as a causative agent for human disease  
Over 500 serotypes of STEC have been isolated from infected individuals, but less than 10 
of these belong to the O serotype responsible for the majority of fatal infections (Blanco et 
al., 2004).  Human infection can be due to direct faecal-oral route from an infected animal 
or human, through contaminated water or most frequently through the consumption of 
inadequately cooked meat products, raw milk, and unpasteurised drinks (Figure 1.2) 
(Hunter, 2003).  The infectious dose for E. coli O157:H7 is significantly low, requiring less 
than 50 to 100 microorganisms (Tilden et al., 1996).  The renal system has been identified 
to be the most frequent target of STEC infections, but cases involving the lungs, pancreas, 
heart and central nervous system have been reported (Griffin and Tauxe, 1991).  All 
infectious serotypes are characterised by the production of previously mentioned Shiga-






Figure 1.2: An overview of diseases in humans caused by EHEC/STEC (Gyles, 2006). 
 
1.5.4.2 The production of Shiga toxins in EHEC 
Shiga toxins are believed to be the principal operator of diseases caused by EHEC (Khan 
and Naim, 2011).  They are prototypes of the Shiga-like toxin family and are produced by 
Shigella dysenteriae serotype 1 and are known to increase the harshness of the disease 
caused by this bacterium (Gyles, 2006).  Shiga-like toxins are similar to Shiga toxins in 
structure and function but are produced largely by certain strains of E. coli. However, it 
has also been identified in strains of Citrobacter freundii, Enterobacter cloacae, 
Aeromonas hydrophila and Aeromonas caviae (Paton and Paton, 1998).  
 
Immunocompromised individuals such as young children and the elderly are most 
susceptible to diseases caused by shiga-like toxin producing bacteria.  These bacteria which 




which is characterised by symptoms such as haemolytic anaemia, renal failure and 
thrombocytopenia (Paton and Paton, 1998).  These toxins bind to cells and are subsequently 
encytocysed.  Thereafter, only the enzymatically active part of the molecule enters the host 
cell cytosol and inhibits protein synthesis, thereby killing the cell (Sandvig and van Deurs, 
1996).  Two broad types of toxins (stx) have been recognised, stx1 and stx2, with variants 
of these types existing as well (Zhang et al., 2002). Genes encoding these toxins in both E. 
coli and S. dysenteriae are usually phage-borne. 
 
1.5.4.3 Types of Shiga toxins 
Stx1 is a highly conserved molecule which is almost identical to the toxins produced by S. 
dysenteriae (Khan and Naim, 2011; Gyles, 2006).  Two variants of Stx1 have been 
identified, Stx1c and Stx1d.  Stx1c is found frequently in strains originating from sheep 
either alone or in conjunction with other variants, and rarely causes mild disease in humans 
(Friedrich et al., 2002).  When compared to stx1, stx2 has more variants within its group, 
which include stx2c, stx2c2, stx2d, stx2e, stx2f and stx2g (Khan and Naim, 2011). 
Although stx2 shares less than 60% homology with the stx1 toxin, stx2 and its variants all 
differ significantly in their biological activity and its association with disease (Gyles, 
2006).  Pathogenic strains of STEC can either express one or both of the above-mentioned 
toxins. It has been reported that the development of critical infections does not entirely 
depend on the amount of toxin present but rather on the type.  Within the stx2 antigenic 
type, stx2 and stx2c have been reported to be associated with elevated virulence and the 




disease (Khan and Naim, 2011).  Other variants of both stx1 and stx2 have been identified 
but reports on their clinical significance have not been established (Friedrich et al., 2002). 
 
1.5.4.4 Structure of Shiga toxins 
Shiga toxins are holotoxins which belong to a family of toxins named the AB protein 
toxins.  Protein toxins are defined as toxins which have one enzymatically active part (A), 
and another part which binds to the host cell surface (B) (Figure 1.3) (Sandvig, 2001; Tesh 
and O’Brien, 1991and Fraser et al., 1994).  The 32kDa A subunit, which is referred to as 
the functional domain, is non-covalently associated with the 7.7kDa B subunit also known 
as the recognition pentamer (Khan and Naim, 2011). 
 
1.5.4.4.1 A subunit 
The A subunit is a chain like structure composed of two smaller subunits called A1 and 
A2.  These smaller subunits are linked by disulphide bonds and function differently within 
the A subunit.  A2 is responsible for the attachment of the A subunit to the B subunit 
whereas A1 is an N-glycosidase which utilizes enzyme activity to cleave a specific adenine 
base from 28 S rRNA which would result in an inhibition of protein synthesis (Khan and 
Naim, 2011; Gyles, 2006). 
1.5.4.4.2 B subunit 
The B subunit is responsible for the binding of the Shiga toxin to mammalian cells by 
interacting with membrane glycolipids (Tesh and O’Brien, 1991).  These neutral glycolipid 
globotriasoylceramide (Gb3) membranes serve as functional receptors for both stx1 and 




affinity to Gb3 with stx1 having the greater affinity (Khan and Naim, 2011).  Entry of Gb3 






Figure 1.3: (A) A schematic and (B) crystallographic representation of a Shiga toxin 













1.5.4.5 Entry of Shiga toxins into host cells 
 
1.5.4.5.1 Binding 
Shiga toxins bind selectively to cells containing a toxin binding site.  The most common 
cell receptor for toxins is Gb3 where both the carbohydrate and the lipid tail components 
play an important role in the toxin-receptor interaction (Sandvig and van Deurs, 1996). 
 
1.5.4.5.2 Endocytosis 
After binding, the toxin-receptor complex is transported to a clathrin-coated domain in a 
process mediated by the toxin (Figure 1.4) (Sandvig, 2001).  During the transportation 
process, a coated vesicle produced by the pinching of a fragment of the cell membrane 
harbours the toxin molecules on its internal surface.  These vesicles then fuse with 
lysosomal vesicles, leading to the destruction of the protein toxin.  This then creates a 
protective barrier for the cell. In cells which are susceptible to this mechanism, Stx is 
transported to the Golgi apparatus. 
 
 The A subunit then enters the cytosol where it is nicked by trypsin to form the two 
component subunits A1 and A2 as previously mentioned (Gyles, 2006).  Reduction of the 
disulphide bond linking these subunits releases the active subunit A1, which by enzymatic 
reactions, inactivates the 60S ribosomal subunit of the host cells. Inactivation of this 
subunit occurs by an irreversible process involving the removal of a single adenine base 
from 28S rRNA within the subunit (Obrig, 2010).   This leads to the inhibition of peptide 





Figure 1.4: Receptor mediated uptake and transport of Shiga toxins from the membrane 
to the cytosol (Gyles, 2006) 
 
In addition to this, Shiga toxins can exert detrimental effects on eukaryotic cells using two 
other mechanisms:  
1. The generation of depurinated 28S rRNA introduces a signal transduction response 
which is quite unique.  This response is known as a ribotoxic stress response (RSR) and 
leads to the activation of factors such as cytokines and chemokines which have the 
potential to cause cell apoptosis. 
2. Binding of the toxin or the B- subunit to the receptor potentially initiates a cytoplasmic 




Hence, the expression of Shiga toxins in eukaryotic cells exerts different responses which 
include death by apoptosis or necrosis and inflammation (Obrig, 2010). 
 
1.5.5 Enteroadherant and Diffusely Adherant E.coli 
As stated by Lior (1996), Cravioto et al. (1979) recognized that most EPEC adhered to 
HEp-2 cells in culture, and that presented adherence phenotypes could be used to 
differentiate EPEC strains. However, it was later observed that many non-pathogenic 
strains also had the ability to adhere to HEp-2 cells but the observed phenotype was 
different, in which the phenotype was diffuse when compared to the localized phenotype 
of EPEC strains.  These diffusely adherent strains were later divided into two new sub-
categories termed: (1) aggregative, and (2) true diffuse (Nataro et al., 1987).  This later 
became two independent categories known as: Enteroaggregative Escherichia coli (EAEC) 
and Diffusely Adherant Escherichia coli (DAEC) (Vial et al., 1988). 
 
1.5.5.1 EAEC 
EAEC are currently defined as E. coli isolates, which lack the ability to secrete heat labile 
or heat stable toxins, and which adhere to HEp-2 cells in an aggregative pattern. In addition, 
pathogenesis is characterized by the ability to produce enterotoxins and cytotoxins and to 
induce inflammation of cells (Nataro et al., 1998) In many regions of the world, EAEC is 
recognized as the leading cause of sporadic diarrhea, with contaminated food suspected to 
be the leading source of infection (Cohen et al., 2005; Nataro et al., 2006). Most individuals 
infected with EAEC typically have watery, mucoid diarrhea with little to no fever however, 




stools, which is suspected to be strain dependent. In animal models, pathogenic and non-
pathogenic EAEC strains adhere to the mucosal epithelium of piglets forming a mucous 
blanket. It is suspected that this “biofilm” may contribute to the ability to cause diarrhea 
and to persist in the human gut.  Nataro et al. (1998) proposed a 3 stage model for 
pathogenesis of EAEC strains: Stage I: Adherence to intestinal mucosa, mediated by 
fimbriae; Stage II: The formation of pits in goblet cells leading to mucus hyper-secretion 
and the formation of a mucus-containing biofilm packed with EAEC; and Stage III: 
Elaboration of toxins or inflammation resulting in a damaged mucosa. Genes encoding for 
the aggregative phenotype and dispersin, an antiaggregatve protein used in adhesion are 
contained in a large plasmid termed pAA. 
 
1.5.5.2 DAEC 
Diarrheagenic strains of E. coli, which present a diffuse adherence pattern on cultured HEp-
2 cells are termed DAEC (Servin, 2005). A majority (75%) of strains contain adhesions 
belonging to the Afa/Dr family, and since Germani et al. (1996) demonstrated that only 
those strains which were positive to the daaC probe (which recognized conserved regions 
in Afa/Dr adhesion operons) were found most frequently in infected patients, more 
attention has been placed on DAEC strains harboring Afa/Dr adhesions (Kaper et al., 
2004). The Afr/Dr family of adhesions contain adhesions such as Dr, AfaE-I, AfaE-II, 
AfaEIII, which are implicated in DAEC as well as UPEC strains (le Bouguenec and Servin, 
2006). Some of them recognize the decay-accelerating factor CD55 as receptors and upon 
binding, can promote the dismantling of the actin network in intestinal cells. However, 




children. Therefore, Scaletsky et al. (2002), states that the role of DAEC in diarrhea 
remains controversial, as “pathogenic” strains have been detected in children with and 
without diarrhea.  
1.6 Diarrheal diseases 
According to the WHO, approximately 88% of diarrheal diseases worldwide are caused by 
the consumption and use of unsafe water and improper sanitation and hygiene (WHO, 
2002).  Diarrheal diseases are responsible for approximately 2.5 million deaths every year.  
Most affected are children under the age of 5, those suffering from malnutrition, immuno-
compromised individuals, the elderly, or people predisposed to other illnesses such as 
diabetes (Theron and Cloete, 2002). The susceptibility of these individuals to infection is 
further increased due to the constant use of antimicrobial drugs, which have led to the 
selection of ARB. Enteric pathogens such as bacteria, viruses and protozoa are responsible 
for the spread of water-borne diseases via the faecal oral route (Theron and Cloete, 2002).  
Studies by Theron and Cloete (2002) also stated that the survival of these pathogens depend 
on numerous factors such as; the infectious dose required to cause disease; the 
microbiological quality of the water such as the nutrient levels and water temperature; the 
survival of the microorganism in the water; seasonal changes; the presence or absence of 
water treatment practices as well as the physico-chemical quality of the water. 
 It is important to note that the definition of microbiologically safe water is blurred when 
attempting to assess the impact of water borne diseases on public health, and that water 
deemed safe for healthy individuals may have a severe impact on infants, immuno-




prevalent amongst HIV infected individuals and are also recognised as a common symptom 
of water-borne diseases (Momba et al., 2002).  Malabsorption caused by the diarrhea 
results in drastic weight loss.  This, in addition to unhygienic conditions, poor water quality 
and the lack of antiretroviral drugs further enhance the effects of diarrheal diseases 
(Carcamo et al., 2005).  Previous studies have determined that water-borne pathogens were 
most prevalent amongst HIV/AIDS infected individuals.  It was then established that 
morbidity and mortality rates due to diarrheal disease are further compounded in countries 
with a high HIV/AIDS prevalence rate (Levine et al., 1991).   
 
In a case study conducted by Momba et al. (2002), which aimed to determine the 
prevalence of E. coli O157:H7 in drinking water and its association with HIV/AIDS 
infected individuals in the Eastern Cape, South Africa, it was established that 25.56% in a 
total of 180 water samples were positive for E. coli O157:H7.  Of the 360 tested stool 
samples, 36.39% were positive, and 56.50% of positively identified samples originated 
from a HIV/AIDS infected individuals suffering from diarrhea. A similar study carried out 
by Obi et al. (2007) aimed to establish the range and incidence rate of human gastro-
intestinal disease causing microorganisms from the faeces of both diarrheic and non-
diarrheic individuals who tested either HIV-positive or HIV-negative.  In addition, drinking 
water sources were also tested for the range and incidence rate of a number of enteric 
microorganisms including Salmonella spp., Campylobacter spp., and E. coli.  Results from 
this study show a link between the level of enteric pathogens detected in drinking water, 
and the rate of diarrheal diseases in HIV-positive individuals.  Although the profile of 




of these pathogens were higher in infected individuals.  Such studies have demonstrated 
the link between the quality of drinking water and HIV.  HIV/AIDS positive individuals 
were more susceptible to infections caused by water-borne pathogens when compared to 
their healthy counterparts (Lubeck et al., 1993).  These pathogens which are responsible 
for majority of infections are also known to produce extended spectrum β-lactamases and 
as a result, most variants are resistant to cephalosporins, penicillin and monobactums. 
 
1.7 Integrons 
According to Ravi et al. (2014) and Gillings (2014), integrons are stable genetic platforms, 
which assist with the assembly and expression of exogenous mobile genes known as gene 
cassettes. Integrons were first characterized in the late 1980’s, and it was then that it was 
regarded as the genetic system responsible for the gathering of resistance determinants 
(Martinez et al., 1988). The importance of these structures within clinical and agricultural 
settings is demonstrated by the continued surveillance of their prevalence and evolution. 
Integrons themselves are non-mobile but are found on mobile genetic elements (MGEs) 
such as plasmids and transposons, which act as vehicles for the transfer of integron encoded 
genes between species.  Integrons are widely known for their role in the dissemination of 
antibiotic resistance genes (ARGs) mainly amongst gram-negative bacterial pathogens. A 
common promoter ensures the correct expression of gene cassettes, which almost always 
contain ARGs. The number of gene cassettes within an integron may vary, but the highest 
number of cassettes observed thus far is eight (Mazel, 2006).   Through evaluation of the 
evolutionary history of chromosomal embedded integrons (chromosomal integrons), it was 
discovered that integrons have been in the bacterial genome for a long time and that these 




within MGEs i.e mobile integrons (Mazel, 2006). 
1.7.1 Structure of integrons 
The general structure of an integron (Figure 1.5) consists of 3 core elements whose 
combined function involved the capture and subsequent expression of genes located on 
gene cassettes: (1) An integrase gene (intI) which encodes an integron integrase (IntI), 
belonging to the tyrosine recombinase family.  This gene is responsible for the integration 
of the gene cassette to the attachment site through recombination of incoming gene 
cassettes with the second core feature, an integron associated recombination site att1 
(Mazel, 2006 and Gillings, 2014).  (2) One of two types of recombination sites which is 
dependent on location (a) att1: which is located on the integron and is the primary site if 
attachment of gene cassettss (b) attC: is found on the gene cassette (Fluit et al., 2004).  
According to Ravi et al (2014), these sites are essential in the recombination of gene 
cassettes.  An intergron-associated promoter, which comprises of an outward promoter, is 
responsible for expression and directing transcription of the recombined gene cassettes as 
they lack the ability of independent expression (Gillings, 2014). 
1.7.2 Structure of gene cassettes 
According to Cambray et al. (2010), successive integration at the attI site results in the 
assembly of different gene cassette arrays. Gene cassettes are compact DNA elements, 
which have a simple basic structure and are intended to be mobilized by the integrase of 
the integron. They consists of a single open reading frame bound by the recombination site 
attC, which exhibits significant homology that allows for the production of stable 




(Cameron et al., 1986; Stokes et al., 1997). Recombination between attI and attC is the 
most common form of cassette insertion and ensures the integration of circular gene 
cassettes, which is a reversible process and allows for the excision of circular free DNA 
elements if needed (Gillings, 2014). 
 
Figure 1.5: Structure of an integron: process by which circular gene cassettes are 








1.7.2.1 Expression, diversity and function of gene cassettes 
As previously mentioned, gene cassettes rely on an external promoter for expression. Most 
work thus far has been based on the class 1 integron system, where cassette expression is 
driven by either the Pc1 or Pc2 promoters, located on the IntI gene and attI respectively 
(Levesque et al., 1994;Collis and Hall, 1995).  Gene cassette expression is governed by the 
proximity to the promoter.  Promoters found on the IntI gene drive expression in the 
associated array but the strength of the expression decreases as cassettes are located further 
away from the associated promoter (Collis and Hall, 1995;Coyne et al., 2010).  Promoters 
responsible for cassette expression have also been identified in the attI region of class 2 
integrons, and within the intI region of class 3 integrons (Levesque et al., 1994;Collis and 
Hall, 1995).  It then appears that probably all integrons possess a promoter located within 
the attI-intI region.  However, when there are hundreds of gene cassettes, it becomes 
impossible for a single promoter to drive the expression of all cassettes and it is believed 
that these cassettes are either silent or that they carry their own internal promoters. 
As with integrons, gene cassettes are widely disseminated in environmental samples and 
are found in riverine sediment, springs, estuaries, biofilms, plant surfaces and a vast array 
of soils (Stokes et al., 2001; Holmes et al., 2003; Gillings, 2014).  Homology and codon 
usage analysis has demonstrated that open reading frames within gene cassettes originated 
in diverse bacterial phyla, further demonstrating the diversity of the gene cassettes 
themselves (Mazel, 2006; Boucher et al., 2007; Koenig et al., 2009). Gene cassettes offer 
an enormous reservoir of originality. A combined analysis of meta-genomic and 
chromosomal cassettes revealed that approximately only 20% of cassettes have adequate 




2007). However, 65% of cassettes and their encoded polypeptides have no known 
homologues in any DNA or protein database, further highlighting the novel nature of gene 
cassettes.  This 20 % of gene cassettes are of environmental origin and whose functions 
include secondary metabolism, plasmid maintenance, virulence, and surface properties.  
In addition, a review done by Gillings (2014), reveal that toxin-antitoxin systems are 
commonly found within or adjacent to integrons, and that the loss of these systems kill the 
cells which harbor them due to the longer half-life of the toxin as compared to the antitoxin 
which inactivates it.  These systems are also found in integrons where their presence is 
believed to stabilize chromosomal arrays and maintain integron-bearing plasmids within 
cells (Szekeres et al., 2007; Yuan et al., 2011; Guerout et al., 2013).  Functions associated 
with virulence and host relationships are also a common trait encoded by gene cassettes. 
These functions include but are not limited to: lipocalin (Barker and Manning, 1994), 
capsular polysaccharide (Smith and Siebeling, 2003), enterotoxin (Ogawa and Takeda, 
1993) and lipases (Holmes et al., 2003).  Other inferred functions are vast and span DNA 
modification; functions related to phage, polysaccharide biosynthesis, amino acid synthesis 
and efflux systems (Boucher et al., 2007; Gillings et al., 2009).  Gene cassettes are 
therefore an essential component of bacterial adaptation and play a major role in the 
generation of adaptive diversity by integrons (Koenig, 2011). 
Integrons are now regarded to be at the forefront of genomic innovation as it has two key 
advantages: (1) The integration of new genetic material into the existing bacterial genome 
does not disturb existing genes as it is integrated at a specific recombination site. (2) Newly 
integrated genes are instantly subjected to natural selection due to it being expressed via 




within a population of integron-containing cells, each containing different gene cassettes, 
and that newly generated variants may confer genes having advantageous properties.  
1.7.3 Evolution of integrons 
Integrons are said to have evolved from similar structures termed “super-integrons”, which 
unlike integrons, are always chromosomally located (Mazel, 2006).  The first super-
integrons were discovered in Vibrio spp. and although similar in structure, super-integrons 
can harbor more than 20 gene cassettes due to their larger size. In addition, these gene 
cassettes are not expressed by a common promoter, but rather through independent 
expression (Mazel et al., 1998).  Integrons are defined by the presence of IntI.  Integrases 
within the integron are defined by the presence of a unique 16 amino acid conserved motif, 
which is essential for activity (Messier and Roy, 2001).  When evaluated, Boucher et al. 
(2007) and Cambray et al. (2010) determined that more than 15 % of genome sequenced 
bacteria contained an integron, when based on the presence of the IntI gene.  
Integrons have been identified in a variety of natural environments such as forest soils, 
desert soils, hot springs and deep-sea sediment (Elsaied et al., 2007).  Over the last decade, 
hundreds of different integron families have been identified and distinguished based on the 
relative homology of the intI gene.  Based on their respective integrase genes, integrons 
have been divided into three broad groups (1) Clinically important class 1 and 3 integrons; 
integrons found in proteobacteria in freshwater and soil environments (2) integrons found 
on the STX integrative conjugative element and pRSV1 plasmid from Vibrio; class 2 
integrons; gammaproteobacteria from marine environments (3) integrons whose integrase 




Gillings et al. (2005) and Boucher et al. (2011) state that the location of integrons has vital 
evolutionary and functional consequences as the presence of integrons on mobile elements 
such as plasmids and transposons allows for dissemination into new taxa, while it’s 
presence on chromosomes allows for the generation of genomic complexity and phenotypic 
diversity.  By comparing phylogenetic trees based on the 16S rRNA gene, it was 
demonstrated that lateral gene transfer of integrons can occur between bacterial species 
which reside in similar environments.  Based on these comparisons, it can be deduced that 
the integron system dates back at least hundreds of millions of years and that over this time 
period, there has been a considerable amount of lateral gene transfer between different 
bacterial groups (Mazel, 2006;Boucher et al., 2007;). 
1.7.4 Types of integrons 
Integrons are located on MGEs (transposons), on chromosomes or on both.  Mobile 
integrons (MIs), and chromosomal integrons (CIs) have distinct characteristics, which 
reflect their different evolutionary histories (Cambray et al., 2010). 
1.7.4.1 Mobile integrons (MIs) 
MIs associated with mobile DNA elements can be carried by conjugative plasmids 
(Cambray et al., 2010).  These elements act as natural genetic vehicles for the transfer of 
genes between the same bacterial species and even between distantly related groups.  The 
longest array of gene cassettes is 8 and was reported by Naas et al. (2001). Gene cassettes 
associated with MIs display functional homogeneity, as they are mostly involved in 
antibiotic resistance (Cambray et al., 2010).  According to Fluit et al. (2004) and Partridge 




identified.  These genes encode for resistance towards numerous classes of antimicrobial 
agents such as aminoglycosides, chloramphenicol, trimethoprim, streptothricin, rifampicin, 
erythromycin, quinolones, β-lactams and antiseptics belonging to the family of quaternary 
ammonium compounds (Mazel, 2006;Fluit et al., 2007;Partridge et al., 2009; Cambray et 
al., 2010). 
1.7.4.1.1 Classification of integrons 
to date, five classes of integrons have been discovered based on sequence similarity of 
encoded integrases (40 - 58% identity). Class I is the most widespread and clinically 
important and is therefore the most characterized.  It is associated with both functional and 
non-functional transposons derived from Tn402 and is found in approximately 22 to 59% 
of gram-negative clinical isolates such as Acinetobacer spp., E. coli and Salmonella 
(Gallego and Towner, 2001; Cambray et al., 2010).  Class II integrons are the second most 
common class and are often associated with the Tn7 family of transposons.  It is commonly 
found in Salmonella and Shigella species (Gonzalez et al., 1998;Orman et al., 2002).  The 
integrase gene found in class II integrons (IntII) generally contains a mutation at codon 
179, which results in the production of a non-functional protein (Hansson et al., 2002).  
Class III integrons are highly similar to Classes I and II integrons but are less prevalent.  
They are related to the Tn402 transposon. Classes IV and V have only been associated with 
Vibrio species through their role in the development of trimethoprim resistance (Mazel, 
2006). Gillings et al. (2008), Stokes et al. (2006) and Van Melderen et al. (2009) have 
reported the discovery of bacterial isolates belonging to classes I and III, whose integrons 
are not associated with resistance genes. These integrons harbored cassettes encoding genes 




conferring antibiotic resistance but also play a role in mediating bacterial adaptation. 
1.7.4.1.2 Class I integrons 
Class I integrons have been named so as they were the first to be discovered.  In addition, 
these intrgeons were able to move by lateral DNA transfer to a wide range of other bacteria 
and had the ability to accumulate ARGs (Gillings et al., 2014).  Movement by lateral DNA 
transfer meant that this class of integrons had the following properties: they were located 
on the chromosome of Betaproteobacteria found as a part of the human food chain; ability 
to move between locations on the chromosome and to other bacterial species; it was carried 
by at least 0.002% of bacteria in unaffected soils (Gaze et al., 2011; Gillings et al., 2014); 
ability to acquire a wide range of gene cassettes (Biskri et al., 2005) and frequent 
association with qac genes which encode for versatility in efflux pumps (Gillings et al., 
2009).  
Upon inspection of metagenomic DNA of bacteria from environmental sources, it was 
revealed that diverse genes belonging to intI can be detected, however, when the 
metagenomic DNA of clinical isolates were examined, identical DNA sequences of intI 
were discovered.  This suggests a common ancestor of class I integrons in clinical isolates 
which are possibly responsible for the spread of antibiotic resistance amongst gram-
negative bacterial pathogens (Gillings et al., 2008b; Gillings et al., 2014).  The origin of a 
class I integron can be best described as that an integron found in an environmental 
betaproteobacteria was captured by a transposon belonging to the Tn402 family.   
The gene cassette found within this integron contained a resistance gene qac which infers 




resulted in the deletion of the qac terminus.  The property of Tn402 transposon to target 
res sites on plasmids then allowed for this Tn402-classI integron hybrid to be transposed 
into a wide variety of plasmids (Kholodi et al., 1995; Gillings et al., 2008a; Gillings et al., 
2014; Gillings et al., 2014).  Such insertion and deletion events have therefore resulted in 
the generation of extensive internal variations in cassette arrays, which has allowed for the 
production of over 130 different gene cassettes (Partridge et al., 2009).  
A recent study conducted by Gillings et al. (2014) proposed that class I integron-integrase 
gene intI could serve as a generic marker for anthropogenic pollutants.  This idea was 
supported by independent studies conducted by Gaze et al. (2011), Pruden et al. (2012) 
and Jechalke et al. (2013b) where correlations were observed between intI and associated 
genetic elements with various measures of human impact.  Gillings et al. (2014) further 
lists four characteristics, which promote the use of intI as a generic marker as follows: 
x intI is frequently linked to genes which confer resistance to disinfectants, heavy 
metals and a vast array of antibiotics (Liebert et al., 1999; Partridge et al., 2001). 
x It has already infiltrated pathogenic and commensal bacteria of both humans and 
animals (Goldstein et al., 2001; Stokes and Gillings, 2011). 
x Class I integrons reside in bacteria, which have rapid generation times and is often 
located on MGEs, which are frequently transferred between bacteria.  This allows 
the abundance of intI to rapidly change in response to environmental stress. 
x The common forms of intI are recently assembled under selection pressure imposed 





1.7.4.2 Chromosomal integrons (CIs) 
Upon investigation of the V. cholerae genome in the late 1900s, a cluster of repeated DNA 
sequences were discovered.  This was later revealed to be a distinct type of integron located 
on chromosome 2 of the V. cholerae serotype O1 biotype E1 Tor strain N16961 (Barker et 
al., 1994; Mazel et al., 1998).  This integron was located on the chromosome only and 
possessed a distinct integrase which seemed to be related to integrases of MIs, but were not 
associated with any MGEs (Heidelberg et al., 2000).  Research conducted in March 2010 
on the genomes of chromosomal integrons revealed that approximately 17% of sequenced 
integrons possessed integron integrases.  
Based on these results, phylogenetic relationships were established between integrases and 
allowed for the distinction of three major groups of CIs (Cambray et al., 2010): (1) The 
proteobacteria group of integrons obtained from soil and freshwater environments (2) The 
γ-proteobacteria group obtained from marine environments and; (3) The inverted integrase 
group in which the attI site is found at the 3c end of the integrase.   
Gene cassette arrays of CIs can contain up to 217 gene cassettes as observed in Vibrio 
vulnificus, however combinations of fewer cassettes and even no cassettes have been 
observed.  CIs with large cassette arrays (>20) and a high degree of identity with attC sites 
(>80%) have been termed “superintegrons” as previously mentioned.  Superintegrons have 
been identified in most Vibrio species genomes, in Pseudomonas alcaligenes and in 
numerous Xanthomonas species (Cambray et al., 2010; Coleman et al., 2004; Rowe-





1.7.5 Mobility of integrons 
According to Guo et al. (2011), integrons move through bacterial species and transfer 
multi-drug resistance properties.  SOS response systems in bacterial cells are responsible 
for controlling the expression of the integrase gene.  This response then drives the 
regulation of gene cassettes within the integron.  According to Hocquet et al. (2012), the 
expression of gene cassettes are higher if the cassette is closer to the att1 site, and that the 
transfer of integrons through horizontal gene transfer is also likely to occur due to the close 
proximity of bacterial species. Ravi et al. (2014) states that the emergence of multi-drug 
resistance mainly due to the close proximity of certain bacteria with antimicrobial agents.  
 
Studies by Guo et al. (2011) indicated that integrons had the ability to generate new 
linkages for antibiotic resistance in areas of high exposure to antimicrobial agents, which 
then further highlights the notion that antimicrobial selective pressure plays an important 
role in acquiring resistance genes.  
1.8 Antibiotic resistance 
The development of antibiotics and their use to treat bacterial infections can be regarded 
as one of the major achievements of the 20th century.   Antibiotics have been known for 
hundreds of years and in some cases thousands of years – although not in pure form. Since 
the discovery of penicillin and streptomycin in the 1940s, millions of lives have been saved 
(Marti et al., 2013).  Antibiotics are not only used to treat infections, they are also 
components of livestock feed and are indispensable in the medical field during organ 




(Marti et al., 2013). They are composed of an extensive range of both structural and 
molecular families whose sole purpose is to inhibit bacterial growth when available at 
optimal concentrations (Gillings and Stokes, 2012).  In addition to bacterial inhibition, 
antimicrobial agents may act as signaling compounds or regulatory molecules in the 
environment when produced at sub-inhibitory levels (Aminov, 2009; Martinez et al., 2009; 
Gillings and Stokes, 2012).  
 
While antibiotics are currently obtained by chemical synthesis, the first antibiotics were of 
natural origin.  Now, millions of metric tons of antibiotics are produced and distributed by 
humans each year (Gillings and Stokes, 2012).  Antibiotics are largely used for human and 
veterinary purposes, however, a large portion of antibiotics are incompletely metabolized 
in the gut of humans and animals and are released into the environment unchanged, where 
they persist and may even become mobile (Sarmah et al., 2006;Le-Minh et al., 2010). 
 
Majority of the antibiotics found in environmental settings today seems to originate from 
industry, which affects the role antibiotics play in natural ecosystems (Davies and Davies, 
2010). Based on chemical structure and mode of action, all antimicrobial agents have been 
grouped into representative classes, whose targets and modes of action are represented in 








Table 1.1: Classes of antimicrobial agents, targets and modes of antimicrobial resistance  











Translation Phosphorylation, acetylation, 















Translation Hydrolysis, glycosylation, 
phosphorylation, efflux, altered 
target 
Lincosamides Clindamycin Translation Nucleotidylation, efflux, altered 
target 
Streptogramins Synercid Translation C-O lyase, acetylation, efflux, 
altered target 
Oxazolidinones Linezoid Translation Efflux, altered target 
Phenicols Chloramphenicol Translation Acetylation, efflux, altered target 
Quinolones Ciprofloxacin DNA replication Acetylation, efflux, altered target 
Pyrimidines Trimethoprim C1 metabolism Efflux, altered target 
Sulfonamides Sulfamethoxazole C1 metabolism Efflux, altered target 
Rifamycins Rifampicin Transcription ADP-ribosylation, efflux, altered 
target 
Lipopeptides Daptomycin Cell membrane Altered target 
Cationic peptides Colistin Cell membrane Altered target, efflux 




1.8.1 Antibiotic resistance: A global concern 
The concept of antibiotic resistance has become a global concern as more disease causing 
organisms are becoming resistant to commonly prescribed antibiotics.  The result of this is 
prolonged illness and in some cases, death (Marti et al., 2013).  This problem is heightened 
by the fact that drug resistance is not only towards a single class of antibiotics, but to many 
classes which result in multi-drug resistant and extreme drug resistant bacteria. The concept 
of multi drug resistance is defined as having an acquired non-susceptibility to at least one 
agent in three or more antimicrobial categories, while extreme drug resistance is defined 
as the non-susceptibility to at least one agent in all but two or fewer antimicrobial 
categories. 
 
The idea of antibiotic resistance was not previously recognized as a global issue due to a 
constant supply of novel antibiotics. However, the overuse of antimicrobial agents has lead 
to an increased survival pressure on relevant microorganisms and it is now an ever- 
increasing problem. This problem is further compounded by international travel, trade and 
immigration.  
 
1.8.2 Origin of ARGs 
Allen et al. (2009) and D’Costa et al. (2011) reported that the analysis of metagenomic 
DNA from soil and permafrost reveal ancient lineages of resistance genes which confer 
resistance to aminoglycosides, tetracyclines, glycopeptides, and β-lactams which pre-dates 
the antibiotic era.  This concurs with reports by Gillings (2014) and Gillings and Stokes 




originated in natural environments from environmental organisms, and that humans have 
disturbed the dynamics of this system through the overuse of antimicrobial agents.  The 
current database of resistance genes spans over 20 000 genes but it is considered to be only 
a fraction of the total genes contained in the environment (Liu and Pop, 2009).  Therefore, 
history and current scientific discoveries show that natural environments contain a vast 
array of potential resistance genes, and that bacteria have the ability to acquire these genes 
through lateral gene transfer if the need arises. 
 
1.8.3 Acquisition of bacterial resistance 
Many bacterial species are inherently resistant to certain antibiotics due the possession of 
certain characteristics.  According to Sayah et al. (2005), there exists four general 
mechanisms of resistance in bacterial populations and each of these mechanisms are 
controlled by the action of specific genes.  These mechanisms include: the modification or 
inactivation of antimicrobial agents through the action of enzymes; impermeability of the 
bacterial cell wall or membrane; expulsion of the drug using cellular efflux pumps as well 
as the alteration of target receptors (Figure 1.6).  These resistance mechanisms can be 
acquired through the uptake of transposons, plasmids and integrons into the cell (Prescott 
et al., 2005). Bacteria who do not have natural resistance properties acquire resistance 






















Figure 1.6: Behavioural and molecular mechanisms of resistance (Brooks and Brooks, 
2014) 
 
Transformation, transduction and conjugation are some examples of lateral gene transfer 
which bacteria employ (Stokes and Gillings, 2011).  Transformation involves the 
acquisition of DNA encoding resistance determinants from the environment, while 
transduction is defined as the movement of DNA between cells through the use of 
bacteriophages. The process of conjugation is the most studied and widely described and 




MGEs such as plasmids, transposons, integrons and genomic islands are transferred 
between bacteria (Davies and Davies, 2010; Stokes and Gillings, 2011; Gillings and 
Stokes, 2012). 
 
1.8.4 The role of WWTPs in the spread of antibiotic resistance 
Wastewater treatment plants can be regarded as the interface between human waste and the 
aquatic and soil environments. Effluent from hospitals, households, industries and animal 
husbandries are suspected to be the main anthropogenic sources of antibiotics, which 
converge at WWTPs and contribute to the final ecosystem of the plant. This ecosystem 
consists of organics, chemicals and microbiological waste (Stalder et al., 2012). WWTPs 
have been identified as hotspots for antibiotic resistance gene transfer because they 
combine several favorable factors such as a high bacterial cell density, a nutrient rich 
environment and a constant influx of antibiotics and ARB (Dröge et al., 2000). In addition, 
antibiotics which are potentially present in WWTPs, could select for antibiotic-resistant 
bacteria as seen in studies involving erythromycin (Louvet et al., 2010).  According to 
Stalder et al. (2012), this co-existance of bacteria and antibiotics in WWTPs increases the 
frequency of genetic variations and the possible emergence of novel mechanisms of 
resistance. Human and animal commensal bacteria have been the main focus in the study 
of ARB in WWTPs due to their closeness with humans and the ability to isolate and identify 
them easily (Rizzo et al., 2013).  Approximately 109 – 1012 colony forming units (CFU) of 
bacteria per day, per inhabitant are discharged by WWTPs in their final effluent and 




importance of WWTPs in the accumulation and spread of ARB in the environment (Novo 
and Manaia, 2010).   
 
Mobile genetic elements such as plasmids carrying ARGs have repeatedly been detected 
and isolated from WWTPs but their direct involvement mediating ARG transfer in WWTPs 
has not yet been demonstrated due to technical difficulties experienced when studying 
bacterial donor/recipient relationships (Sørensen et al., 2004;Rizzo et al., 2013).  To date, 
three approaches have been investigated to monitor the transfer of plasmids through 
conjugation namely: 1) Culture based approach involving the inoculation of an 
environmental sample with a known donor (genetic element of interest) and recipient 
bacterium with selectable characteristics.  Transconjugants are then recovered and 
enumerated on selective media (Kolwalchuk et al., 2004); 2) Fluorescence based approach 
involving the use of genetically modified plasmid derivatives, which express a fluorescent 
protein once it leaves the donor cell. It is assumed that all transconjugants should appear 
fluorescent when viewed under a fluorescent microscope (Sørensen et al., 2005); and 3) 
the molecular-based approach which makes use of q-PCR to monitor the dissemination of 
a given plasmid in the vastness of microbial community DNA, based on the fact that 
conjugative transfer of the plasmid is a certain form of DNA replication, and that the 
plasmid to donor DNA ratio increases when the plasmid of interest disseminates into 
indigenous populations (Bonot and Merlin, 2010).  Genes encoding resistance to all classes 
of antibiotics are rife in effluent of WWTPs and from the diversity of genes detected, it 
was concluded that every mechanism available in nature to resist antibiotics has the 




1.8.4.1 The effect of wastewater treatment on ARB removal 
A generalized wastewater treatment process involves three steps namely: primary, 
secondary and tertiary treatment.  Primary treatment involves the removal of solids by 
physical treatment, while secondary treatment utilizes biological and chemical processes 
to remove organic matter.  During tertiary treatment, all components that were not removed 
by secondary treatment are eliminated.  These additional processes include nutrient 
removal, the removal of toxic compounds, and the removal of additional organic and 
suspended solids.  The wastewater treatment process also allows for the removal for a 
portion of antimicrobial agents from wastewater through the sorption to biosolids and 
degradation during treatment processes such as the secondary and tertiary processes, but 
not all antibiotics are completely removed (Giger et al., 2003;Batt et al., 2006). Wagner 
and Loy (2002), and Guardabassi et al. (2002) state that there is a significant reduction in 
bacterial number as well as a reduction in the total number of resistant bacteria during the 
wastewater treatment process.  However, according to Goni-Urriza et al. (2000), the 
reduction in resistant bacterial populations is insufficient as wastewater and sometimes 
treated wastewater contain higher proportions of resistant bacterial populations in relation 
to the respective proportions contained in surface waters.  A possible explanation for this 
is that several factors contribute to WWTPs being a favourable environment for the 
dissemination and proliferation of ARB, which in turn could transfer resistance genes to 






Researchers have used cultivation and resistance testing, as well as the detection of 
resistance encoding genes in wastewater and sewage sludge to study the resistance of 
selected organisms against beta-lactams, quinolones, tetracycline, trimethoprim and other 
sulfonamides and have concluded that the presence of resistant bacteria and their respective 
resistance genes do not correspond to the activity and spectrum of antimicrobial 
compounds found in the environment (Kummerer, 2004; Schluter et al., 2007).   Studies 
by Reinthaler et al. (2003) on sewage sludge and receiving surface waters of WWTPs in 
Austria revealed the presence of 767 resistant E. coli isolates.  Further testing revealed that 
untreated sludge could serve as a source of resistant microorganisms, which could enter 
the environment through agricultural reprocessing and by the application of sludge as 
ground fertilizer.  
 
1.9 Scope of the present study 
The absence of strict guidelines for treated wastewater effluent, insufficient funding, 
infrastructure and skilled staff together with the infrequent monitoring of wastewater 
treatment plants in Durban, South Africa results in the discharge of improperly treated 
effluent into receiving surface waters, which is often the only source of water for many 
South Africans. As a result, potentially pathogenic bacteria such as E. coli are released into 
the environment.  These isolates have been identified as causative agents for numerous 
diarrheal diseases and are fast becoming resistant to commonly prescribed drugs. In 
addition, these isolates are capable of transferring resistance determinants to non-resistant 
strains, which further exacerbates the problem. Most studies on water quality conducted in 




the detection and characterization of E. coli isolates recovered from treated wastewater 
effluent and receiving river sources is scarce.  This is especially worrisome considering 
that between 160 and 200 infants below the age of 5 die per day in South Africa due to 
diarrheal diseases. This project therefore aimed at evaluating the prevalence of E. coli in 
treated wastewater effluent and receiving rivers of two independent wastewater treatment 
plants in Durban, South Africa, as well as to establish possible correlations between the 
physico-chemical profiles of the water samples and the microbial loads. Additionally, the 
antibiotic resistance profiles and virulence determinants of the E. coli isolates were 
characterized. Isolates were screened for the presence of integrons and gene cassettes and 
the ability to transfer these resistance determinants to susceptible strains were evaluated. 
Random Amplified Polymorphism DNA (RAPD) analysis was employed to establish 
possible correlations between the phenotypic and genotypic attributes of the E. coli isolates. 
 
1.9.1 Hypotheses 
It is hypothesized that E. coli isolates recovered from treated wastewater effluent and 
receiving aquatic milieu are resistant to commonly used antimicrobial agents and/or 
harbour antibiotic resistance determinants.  It is further hypothesized that most of these 
isolates have diverse phenotypic and genotypic antimicrobial resistance patterns and 









The following objectives were established: 
1.9.2.1 To determine the prevalence of E. coli in the treated wastewater effluent and 
respective receiving surface waters of two independent wastewater treatment 
facilities.  
1.9.2.2 To determine the physico-chemical parameters of the water samples and correlate 
them with levels of microbial contamination.  
1.9.2.3 To characterize antimicrobial resistance phenotypes of recovered E. coli isolates. 
1.9.2.4 To determine the virulence gene signatures of these isolates.  
1.9.2.5 To determine the genetic diversity amongst the E. coli isolates. 
 
1.9.3 Aims 
The following aims were pursued: 
1.9.3.1 To enumerate the presumptive E. coli population in the water sample using a 
membrane filtration technique and the appropriate selective media for a six month 
period.  
1.9.3.2 To analyze various physico-chemical parameters such as Biological Oxygen 
Demand (BOD), Chemical Oxygen Demand (COD), temperature, turbidity, pH, 
Total Suspended Solids (TSS), Total Dissolved Solids (TDS), Electrical 
conductivity (EC) and resistivity in the collected water samples.  
1.9.3.3 To confirm the identity of the E. coli isolates from water samples using biochemical 




1.9.3.4 To determine the relationship between E. coli populations and physico-chemical 
parameters using statistical analysis. 
1.9.3.5 To determine the antibiotic resistance profiles of the confirmed bacterial isolates 
using the standard Kirby-Bauer disc diffusion assay. 
1.9.3.6 To determine the presence of classes 1, 2 and 3 integrase genes. 
1.9.3.7 To determine the presence of gene cassette arrays within integron positive isolates. 
1.9.3.8 To determine the identity of gene cassettes via Restriction Fragment Length 
Polymorphism (RFLP) and sequence analysis. 
1.9.3.9 To determine the location of identified integrons via PCR. 
1.9.3.10 To determine if integrons are transferrable from resistant to non-resistant E. coli 
strains using conjugation experiments. 
1.9.3.11 To obtain the DNA fingerprint profile of integron positive isolates using RAPD 
analysis. 













PREVALENCE OF VIRULENT AND MULTIPLE-ANTIBIOTIC RESISTANT 
Escherichia coli IN TREATED EFFLUENT OF TWO WASTEWATER 




The poor operational status of some wastewater treatment plants often result in the discharge of 
inadequately treated effluent into receiving surface waters. This is of significant public health 
concern as there are many informal settlement dwellers that rely on these surface waters for their 
domestic use.  This study investigated the treatment efficiency of two independent wastewater 
treatment plants (WWTPs) in Durban, South Africa and determined the impact of treated effluent 
discharge on the physico-chemical and microbial quality of the receiving water bodies over a 6-
month sampling regime.  Presumptive E. coli isolates were confirmed using biochemical tests and 
detection of the mdh gene via PCR.  Six major virulence genes namely: eae, hly, fliC, stx1, stx2 and 
rfbE were also detected via PCR while antibiotic resistance profiles of the isolates were determined 
using Kirby-Bauer disc diffusion assay. The physico-chemical parameters of the water samples 
ranged variously between 9 - 313.33 mg/L, 1.52 – 76.43 NTUs and 6.30 – 7.87 for COD, turbidity 
and pH respectively, while the E. coli counts ranged between 0 and 31.2 x 103 cfu/ml. Of the 200 
confirmed E. coli isolates, the hly gene was detected in 28%, fliC in 20%, stx2 in 17%, eae in 14%, 
with stx1 and rfbE in only 4% of the isolates. Notable resistance was observed towards 
trimethoprim (97%), tetracycline (56%) and ampicillin (52.5%). These results further highlight the 
poor operational status of these WWTPs and emphasize the need for improved water quality 







The absence of stringent water quality guidelines coupled with the infrequent monitoring 
of wastewater treatment plants (WWTPs) and receiving surface waters are major 
contributors to unsafe water (WHO, 2002). Water is accepted to be a vital natural resource 
because of its basic roles in the environment, food production, hygiene and industry.  
According to the World Health Organisation (WHO), poor access to safe water and 
inadequate sanitation continues to be a danger to human health, especially in the African 
continent where more than 300 million people reside in water scarce environments (WHO, 
2002). In addition, inefficient wastewater treatment processes, political upheaval as well 
as insufficient funding contribute significantly to people of developing and developed 
countries not having access to microbiologically safe water (WHO, 2002).  South Africa is 
defined as a semi-arid country with high water stress (40-60%), as the average rainfall (450 
mm per annum) is below the global average (Momba et al., 2002; Adewumi et al., 2010).   
 
The South African population has undergone major demographic changes since the 
abolishment of apartheid in 1994, with an annual population growth rate of over 3.34%, 
however, the level of natural resources have remained unchanged. This has led to a scarcity 
of water, which not only affects food security, energy production and environmental 
integrity but also results in conflict between human and animal populations who share the 
same water resources (Kusiluka et al., 2005). The South African Water Act was established 
in 1956 and aimed to treat wastewater effluent to an acceptable standard prior to discharge 
into receiving water bodies.  However, economic expansion and population growth and the 




authorities in the country, and as a result many WWTPs did not function optimally 
(Morrison et al., 2001;Mema, 2002).  Water resources are then contaminated largely by 
wastewater effluent, which is defined as a mixture of raw sewage, primary, secondary and 
tertiary effluents (Toze, 2004).  Consequently, informal settlement dwellers who rely on 
untreated water sources (dams, rivers and springs) for drinking and domestic purposes are 
exposed to a plethora of potentially pathogenic microorganisms such as Vibrio spp., E. coli 
and emerging bacterial pathogens such as Legionella spp. which are the causative agents 
for a variety of gastro-intestinal infections and diarrheal diseases. The inadequate 
monitoring procedures together with the declining state of wastewater treatment 
infrastructure in South Africa has hugely contributed to the incidence of numerous water-
borne illnesses as demonstrated by outbreaks of cholera, typhoid fever and diarrheal 
diseases occurring in the Mpumalanga, KwaZulu-Natal and Eastern Cape provinces 
respectively (Mema, 2002).  
 
Durban, located in KwaZulu-Natal province, is situated on the east coast of South Africa, 
and is characterized by a number of rivers, valleys and associated catchments. The province 
is home to approximately one hundred and fifty wastewater treatment plants ranging from 
small to macro sized plants. The Durban Metropolitan Area produces over 1.8 million tons 
of solid and liquid waste annually, with approximately 455 000 tons of waste being 
discharged through marine pipelines (www.environment.gov.za/enviro-
info/sote/citysoe/durban/durban.pdf). Following an audit carried out in 2009, majority of 
the WWTPs in the province failed to meet at least three or more of the respective discharge 




(DWAF, 1996). The detection of potentially pathogenic organisms in water is technically 
difficult and time consuming, therefore microbiological indicators have been used for 
decades as a means to monitor pollution of water sources (Grabow, 1996).  No single 
microorganism meets the requirements of an ideal indicator organism however; E. coli is 
recognized as an indicator of fecal pollution due to its presence in the intestinal tract of 
humans and other warm-blooded animals.  
 
Pathogenic E. coli has been associated with various diseases in humans, and at present, six 
groups of E. coli pathotypes have been identified (Doyle et al., 1997).   Pathogenic E. coli 
strains are classified into 6 major virotypes: enterohemorrhagic E. coli (EHEC), 
enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), enteropathogenic E. coli 
(EPEC), enteroaggregative E. coli (EAEC) and diffusely adherent E. coli (DAEC), with 
each group having a unique virulence factor profile (Doyle et al., 1997). Of these, EHEC 
strains are probably the most important emerging pathogen of the past decade, with recent 
outbreaks occurring in the United States of America and the United Kingdom. They are the 
causative agents for numerous diarrheal outbreaks globally, with patients often suffering 
from complications such as haemolytic-uremic syndrome (HUS) and hemorrhagic colitis, 
with HUS being identified as the major cause of renal failure amongst children. 
Enterohemorrhagic E. coli strains are further subdivided into pathotypes with the most 
significant being the Shiga-toxin producing E. coli (STEC) strains, which produce one or 
more Shiga toxins (O’ Brien et al., 1982). Reservoirs of STEC include the intestine of 
cattle, sheep and goats; however, sporadic outbreaks have been reported to occur in 





Inadequately treated wastewater has been identified as a reservoir of antibiotic resistant 
bacteria (ARB), worldwide (Rizzo et al., 2013). The occurrence of these ARB affects the 
treatment of infections and promotes the dissemination of resistance amongst bacteria in 
aquatic environments. In addition to use in human medicine, antibiotics are widely used as 
a feed additive to prevent livestock diseases.  It is poorly absorbed in the gut of animals 
and is excreted in large amounts, thus leading to the high load found in wastewater influent 
(Akiyama and Savin, 2010). Even at low concentrations, antibiotics may act as signaling 
compounds and select for ARB.  Resistance to specific antibiotics can be acquired through 
the uptake of mobile genetic elements into the cell (Akiyama and Savin, 2010).  
 
In addition to microbial analysis, the survival of microorganisms depends on the physico-
chemical characteristics of the water, including: Biological Oxygen Demand (BOD); 
Chemical Oxygen Demand (COD); Total Suspended Solids (TSS); Total Dissolved Solids 
(TDS); pH; temperature; turbidity; salinity, electrical conductivity and resistivity.  These 
parameters are known to impact on the efficiency of water treatment processes and could 
themselves be affected by drastic climatic changes (DWAF, 1996).  As the clinical impacts 
of E. coli infections are considerable, monitoring of pathogenic strains in environmental 
reservoirs has become a serious concern, worldwide (Rebello and Regua-Mangia, 2014).  
Therefore, the current study investigated the efficiency of two independent WWTPs 
situated in Durban, South Africa over a six month sampling regime and the impacts of the 
treated effluent discharge from these WWTPs on the receiving surface waters. The 




equally established. The antimicrobial resistance profiles and virulence gene signatures of 
positively identified E. coli isolates were also determined. 
 
2.2 Materials and Methods 
 
2.2.1 Description of study site 
Two independent wastewater treatment plants were selected for this study; the Northern 
Wastewater Treatment Plant (NWWTP) and the New Germany Treatment Works 
(NGTWs) situated in the geographical coordinates of 29° 48ˈ 45.62"S, 30°59ˈ 45.22"E and 
29°48ˈ 21.68"S, 30°53ˈ 50.44"E, respectively. The NWWTP has a treatment capacity of 
approximately 70 Ml/d and has been awarded a Greendrop score of 86% for the year 2011 
by the eThekwini Municipality. Ninety two percent of influent consists of domestic 
wastewater whilst the remaining 8% is of industrial origin. The uMgeni River, into which 
treated effluent is discharged, has a catchment area of 4416 km2 and is approximately 255 
km long from source to mouth.  The river receives tributaries from the Klaarkloof, 
Impolweni and the Umsunduzi Rivers before entering the Indian Ocean. The NGTWs is a 
smaller plant with a 7 Ml/d treatment capacity and has been awarded a Greendrop score of 
87% for the year 2011. It processes approximately 15% industrial wastewater and 85% 
domestic sewage before discharging into the Aller River, which is a small but significant 
tributary on the lower uMgeni.  It is estimated that close to 2 million people live within the 
catchment area of the uMgeni River, therefore these rivers are a source of water for 





2.2.2 Collection of samples 
Duplicate wastewater samples were collected monthly in 5 L plastic containers, over a six 
month period (March – August 2012) from four pre-determined points. These points are: 
before chlorination (BC), discharge point (DP), 500 m upstream from the discharge point 
(US), and 500 m downstream from the discharge point (DS). The containers were washed 
with de-ionized water and sterilized with 70% (v/v) alcohol prior to use.  The alcohol was 
left in the container to maintain sterility and rinsed using the sample water at the point of 
collection.  In areas of the river where there were no water current, samples were collected 
using a sampling stick by collecting water and pouring it into the container.  If a current 
did exist, the mouth of the container was placed opposing the water current which permitted 
the flow of water into the container. The containers were then sealed, stored away from 
sunlight and transported on ice to the University of KwaZulu-Natal (Westville Campus) 
and stored at 4 ºC.  Samples were analyzed within 48 h of collection. 
 
2.2.3 Determination of physico-chemical parameters 
All samples were inverted several times to re-suspend any sediment. The temperatures of 
the water samples were taken on site using a mercury-in-glass thermometer (Lloyds register 
quality company). Parameters that were tested in the laboratory include: pH using a 
Beckman 320 pH meter; turbidity using a 2100 P turbidimeter (HACH); BOD/5, resistivity, 
salinity, TDS and conductivity using a HQ 40d multi meter and parameter specific probes 
(HACH), COD using a Spectroquant NOVA 60 (Merck); as well as TSS using standard 
methods. Nitrate and phosphate analyses were conducted by Aquatico Scientific (Pty) Ltd. 




2.2.4 Enumeration and presumptive identification of E. coli 
Wastewater samples were serially diluted with sterile distilled water.  Membrane filtration 
was carried out according to standard methods where 50 ml of the appropriate dilution was 
filtered through a 0.45 µm pore size cellulose nitrate filter (Pall, USA). Each filter was then 
placed on a 45 mm petri plate containing Chromocult Coliform Agar (Merck) and 
incubated at 37 °C for 24 h. Presumptive E. coli populations were enumerated and 
expressed as colony forming units per milliliter (cfu/ml).  All presumptive isolates (18-24 
h old) were then subjected to IMViC biochemical testing using E. coli HB101 as a positive 
control. 
 
2.2.5 Molecular identification of E. coli isolates 
Confirmation of the E. coli isolates were carried out via PCR amplification of the conserved 
mdh genes (Wose Kinge et al., 2012). DNA was isolated from the isolates using the boiling 
method and used as template in the PCR assay. The 25 µl PCR mixture assay contained 
2.5 µl DNA template, 5 µl of 200 µM dNTP, 3 µl of 2.5 mM MgCl2, 2.5 µl of 10 × reaction 
buffer, 1.25 U Taq DNA Polymerase, 9.25 µl RNAse free water and 1.25 µl each of 10 µM 
primer (Table 2.1). Amplification of the target gene was performed in a T100 Thermal 
Cycler (Bio-rad, USA) under the following conditions: Initial denaturation at 94 °C for 3 
min, 30 cycles of denaturation at 94 °C for 20 sec, annealing at 60 °C for 30 sec and 
elongation at 72 °C for 30 sec. Amplified DNA was resolved by electrophoresis on a 1.5 
% agarose gel (Seakem), and products visualized after staining of gel with ethidium 
bromide (5µg/ml) using the Chemigenius Bioimaging System (Syngiene). E. coli ATCC 




2.2.6 Antimicrobial resistance profiling 
All isolates confirmed via PCR were inoculated into nutrient broth and incubated at 37 ºC 
for 24 h. Cultures were then standardized to a 0.5 Mcfarland standard according to CLSI 
(2013) and swabbed onto Mueller-Hinton agar. Determination of the antibiotic resistance 
profile of each isolate was done using the Kirby-Bauer disc diffusion assay using the 
following antibiotics (µg per disc): Penicillins: ampicillin (10), amoxicillin (10); Cephems: 
cephalothin (30), cefazolin (30), ceftazidime (30); Tetracyclines: tetracycline (30), 
doxycycline (10); Phenicols: chloramphenicol (30); Aminoglycosides: amikacin (30), 
gentamicin (10); Quinolones: nalidixic acid (30); Fluoroquinolones: norfloxacin (10), 
ciprofloxacin (5); Monobactams: aztreonam (30); Fosfomycin: fosfomycin (200). Plates 
were incubated at 37 ºC for 24 h. The diameters (in millimeters) of the clear zones of growth 
inhibition around the antimicrobial disc, including the 10 mm disc diameter, were 
measured. The breakpoints used to categorize isolates as resistant, susceptible or 
intermediate to each antimicrobial agent were those recommended by the CLSI (2013).  E. 












2.2.7 Virulence gene profiling 
A multiplex PCR procedure was used to detect the presence of six virulence genes in all 
confirmed isolates (Bai et al., 2010). DNA was extracted according to manufacturer’s 
instructions using a ZR Fungal/Bacterial DNA MiniPrep™ kit (Zymo Research).  The 25 
µl PCR assay mixture contained 1 µl of each primer (Table 2.1), 0.25 µl of Taq DNA 
Polymerase, 1.5 µl of 1 mM dNTP, 7.5 µl MgCl2, 2.5 µl of 10 × reaction buffer, 1 µl of 
DNA and 1.25 µl of RNAse free water. E. coli O157:H7 (ATCC 35150) was used as a 
positive control.  Amplification of target genes was performed in a T100 Thermal Cycler 
(Biorad, USA) under the following conditions: Initial denaturation at 94 ºC for 5 min, 25 
cycles of denaturation at 94 ºC for 30 sec, annealing at 65 ºC for 30 sec and elongation at 
68 ºC for 75 sec.  A final elongation step was done at 68 ºC for 7 min. Amplified DNA was 
resolved by electrophoresis on a 1.2 % agarose gel (Seakem), and products visualized after 
staining of gel with ethidium bromide (0.5 µg/ml) using the Chemigenius Bioimaging 
System (Syngiene) (Bai et al., 2010). The prevalence of virulence genes were expressed as 
a percentage (n=200). 
 
2.2.8 Statistical analysis 
The co-efficient of correlation between E. coli populations and the physicochemical 
parameters were calculated by the Pearson correlation test.  Statistical significance was set 







Table 2.1: Primers used in this study (;) 
 
Target Gene  Sequence(5ˈÆ3ˈ) Expected product 
size (bp) 
Reference 
mdh-F CGTTCTGTTCAAATGGCCTCAGG 392  
(Wose Kinge et al., 2012) mdh-R ACTGAAAGGCAAACAGCCAAG 




(Bai et al., 2010) 
fliC-R GGC AGC AAG CGG GTT GGT C 
stx1-F TGT CGC ATA GTG GAA CCT CA 655 
stx1-R TGC GCA CTG AGA AGA AGA GA 
stx2-F CCA TGA CAA CGG ACA GCA GTT 477 
stx2-R TGT CGC CAG TTA TCT GAC ATT C 
eae-F CAT TAT GGA ACG GCA GAG GT 375 
eae-R ACG GAT ATC GAA GCC ATT TG 
rfbE-F CAG GTG AAG GTG GAA TGG TTG TC 296 
rfbE-R TTA GAA TTG AGA CCA TCC AAT AAG 




2.3.1 Enumeration and identification of E. coli 
Figures 2.1 shows the presumptive E. coli populations obtained from treated wastewater 
effluent and receiving aquatic milieu over a six month period.  All values obtained for final 
effluent at both the NWWTP and NGTWs exceeded the acceptable limit of 0/100 cfu/ml 
for E. coli in water used for domestic purposes (DWAF, 1996). The E. coli population 
obtained at the DP of NWWTP during March, April and August increased by 53.10%, 
61.55% and 6.45%, respectively when compared to values at BC (Figure 1a). However, in 




compared to BC, with treatment efficiency rates being 62.82%, 25% and 19.25%, 
respectively. The highest E. coli population was obtained at BC in May at both WWTPs. 
E. coli was not detected at the DS points for March and April, and at the DP in August at 
the NGTWs (Figure 1b). Treatment efficiency rates of 98.78%, 95.55%, 8.33%, 99.97% 


























Figure 2.1: Presumptive E. coli population obtained at (a) Northern Wastewater 


































































2.3.2 Physico-chemical parameters 
The profiles of the physico-chemical variables of the water samples obtained at the 
NWWTP and NGTWs are depicted in Tables 2.2 and 2.3, respectively. The temperatures 
(°C) of the water samples at NWWTP ranged from 13.50 – 26.00 for BC; 12.67 – 25.00 
for DP, 13.00 – 26.00 for US and 12.00 – 25.5 for DS while the BOD values (mg/L) 
obtained ranged between 1.40 – 4.01 for BC; 2.23 – 5.13 for DP; 4.52 – 8.49 for US and 
5.06 – 7.34 for DS over the six month period (Table 2.2).  COD concentrations (mg/L) 
ranged between 90.44 – 310.11 for BC; 9 – 291.22 for DP, and 51.00 – 311.72 and 89.39 
– 311.72 for US and DS sampling points of uMgeni River, respectively.  Conductivity 
levels ranged between 606.00 – 2115.67 µS/cm across all points during the sampling 
period, while TDS concentrations ranged between 342.67 – 418.00 mg/L for BC; 368.33 – 
475.00 mg/L for DP; 370.00 – 1067.00 mg/L for US and 294.67 – 348.67 mg/L for DS.  
TSS values obtained at the NWWTP ranged between 0.013 – 0.096 g/L for BC; 0.016 – 
0.066 g/L for DP; 0.010 – 1.244 g/L for US and 0.010 – 5.925 g/L for DS.  The pH values 
obtained did not vary significantly between sampling points with values ranging between 
6.85 –7.76 across all points.  The highest turbidity (71.02 ± 6.25) was recorded at the 
discharge point in the month of April while nitrate levels (mg/L) (Table 2.4) obtained in 
the study ranged between <0.057 – 5.980 for BC; <0.057 – 3.920 for DP; 0.785 – 2.400 for 
US and 0.318 – 1.780 for DS.  
 
The temperature profiles observed at NGTWs were lower when compared to NWWTP 
with ranges of 13.50 – 26.00 while BOD values (mg/L) for the NGTWs ranged between 




respectively (Table 2.3). The COD concentrations (mg/L) observed were considerably 
higher across all sampling points when compared to the NWWTP with ranges of 154.33 – 
312.78 for BC; 124.17 – 309.00 for DP; 26.33 – 309.39 for US and 72.28 – 313.61 at the 
DS point.  Conductivity (µS/cm) fell within the ranges 878.33 – 1148.33 for BC; 884.00 – 
1253.67 for DP; 321.67 – 706.66 for US and 615.00 – 939.67 for the DS points.   Salinity 
(%) ranged between 0.39 – 0.57 for BC; 0.43 – 0.62 for DP; and 0.15 – 0.34 and 0.30 – 0.4 
for the US and DS points respectively, while TDS (mg/L) fell within the ranges of 386.67 
– 567.33 for BC; 433.67 – 621.33 for DP; 154.30 – 344.67 for US and 299.00 – 462.00 for 
the DS sampling point.  TSS and pH values obtained were similar for both plants. Turbidity 
values were observed to be lower for majority of the study period across all sampling points 
with values ranging 1.34 – 20.78 NTU for BC; 1.44 – 24.58 NTU for DP; and between 
3.18 – 8.75 NTU and 7.32 – 19.76 NTU for the US and DS points respectively at the 
NGWWTWs.  The highest values were recorded in August for both plants across all points. 
 
Nitrate levels ranged between <0.057 – 5.980 mg/L for BC; <0.057 – 3.920 mg/L for DP; 
0.785 – 2.400 mg/L for US and 0.318 – 1.780 mg/L for DS, while the phosphate 
concentrations ranged between 1.829 – 12.377 mg/L for BC; 0.751 – 9.021 mg/L for DP; 
0.025 – 2.173 mg/L for US and 0.381 – 1.439 mg/L for the DS point at the NWWTP (Table 
2.4).  Analysis of water samples at the NGWWTWs yielded nitrate levels between <0.057 
– 2.809 mg/L for BC; <0.057 – 2.351 mg/L for DP; 0.800 – 2.380 mg/L for US and 0.514 
– 2.290 mg/L for DS.  Finally, the phosphate concentrations ranged between 0.025 – 1.091 
mg/L for BC; <0.025 – 1.467 mg/L for DP; <0.025 – 1.894 mg/L for US and <0.025 – 




The correlation matrices of the different physico-chemical parameters measured for the 
NWWTP and NGTWs is presented in Table 2.5 and 2.6, respectively. COD and pH had no 
significant correlations with other variables in both treatment plants. Significant positive 
correlations were observed between and amongst conductivity (0.999 at p<0.05) and TDS 
(1.000 at p<0.05) with salinity for the NWWTP.  E. coli negatively correlated with BOD    
(-0.719 at p<0.05), whilst resistivity had significant positive correlations (0.627, 0.625 and 
0.623 at p<0.05) with salinity, conductivity and TDS, respectively.  At the NGTWs, a 
significant positive correlation was observed between TDS (0.780 and 0.999 at p<0.05) 
and salinity and conductivity, respectively.  BOD (0.661 at p<0.05) correlates positively 
with salinity and negatively (-0.529 at p<0.05) with temperature.  Negative correlations 
were also be observed between TSS (-0.657 and -0.554 at p<0.05) and salinity and BOD, 
respectively.  Turbidity negatively correlated with temperature (-0.409 at p<0.01) whilst 
resistivity (0.439 at p<0.01) and conductivity (0.755 at p<0.05) had positive correlations 
with salinity. 
 
2.3.3 Antimicrobial resistance and virulence gene signatures of confirmed E. coli 
isolates  
The antibiogram of 200 E. coli isolates confirmed via PCR detection of mdh gene (Figure 
2.2) is depicted in Figure 2.3. The highest resistance was observed against tetracycline 
(56%), and this was followed by ampicillin (52.5%), amoxicillin (40%) and doxycycline 
(31%). Furthermore, 27%, 21.5%, 20.5%, 18% and 16.5% of the isolates were resistant 
towards nalidixic acid, ciprofloxacin, norfloxacin, chloramphenicol and cephalothin, 




and 7.5% of the isolates were resistant to ceftazidime.  All isolates tested were susceptible 
to amikacin and cefazolin. The presence of virulence genes is depicted in Figure 2.4 while 
the virulence gene distribution among the E. coli isolates is depicted in Figure 2.5. The 
most prevalent gene was the hly gene, which was detected in 28% of the isolates.  This was 
followed by the fliC gene (20%), stx2 (17%), and eae (14%).  The rfbE and stx1genes were 
found in only 4% of the isolates, while 13% of tested isolates did not harbor any of the 










Table 2.2:  Physico-chemical parameters of water samples from the Northern Wastewater Treatment Plant and receiving surface water bodies 
            



















TSS     
(mg/L) 
                       
MARCH bc 26 ± 0.00 0.41 ± 0.00 839.67 ± 0.58 1191.00 ± 1.00 411.33 ± 0.58 7.91 ± 0.33 7.11 ± 0.05 104.77 ± 0.00 2.23 ± 0.36 0.010 ± 0.00 
  dp 25 ± 0.00 0.44 ± 0.00 888.00 ± 1.00 1126.00  ± 1.00 436 ± 0.00 23.4 ± 12.13 7.36 ± 0.07 9.00 ± 0.00 5.13 ± 0.18 0.030 ± 0.02 
  us 26 ± 0.00 0.37 ± 0.00 757.67 ± 2.52 1320.33  ± 4.51 370 ± 1.00 16.67 ± 0.38 7.25 ± 0.09 161.33 ± 0.00 5.62 ± 1.01 1.240 ± 4.29 
  ds 25.5 ± 0.00 0.35 ± 0.00 714.67 ± 2.08 1400.00 ± 4.36 348.67 ± 1.15 15.27 ± 0.12 7.24 ± 0.06 191.94 ± 0.58 5.62 ± 0.24 1.130 ± 1.02 
APRIL bc 22 ± 0.00 0.38 ± 0.00 783.33 ± 2.08 1276.67  ± 2.89 383 ± 1.00 53.98 ± 2.94 7.38 ± 0.33 127.88 ± 0.01 3.30 ± 0.97 0.096 ± 0.01 
dp 22 ± 0.00 0.44 ± 0.01 903.67 ± 2.08 1106.67  ± 2.31 444 ± 1.00 71.02 ± 6.25 7.22 ± 0.21 152.88 ± 0.01 3.44 ± 0.67 0.066 ± 0.02 
us 21 ± 0.00 0.49 ± 0.00 997.67 ± 2.89 1004.00  ± 0.00 491 ± 1.73 18.35 ± 1.56 7.29 ± 0.17 310.11 ± 1.02 8.49 ± 0.47 0.015 ± 0.00 
ds 21 ± 0.00 0.33 ± 0.00 676.33 ± 0.58 1478.67  ± 2.31 329.33 ± 0.58 14.6 ± 0.23 7.4 ± 0.28 303.00 ± 0.00 6.33 ± 0.21 0.012 ± 0.00 
MAY bc 21.93 ± 0.12 0.42 ± 0.00 853.00 ± 0.00 1173.00  ± 0.00 418 ± 0.00 20.65 ± 1.21 7.02 ± 1.21 54.89 ± 0.00 1.41 ± 0.41 0.035 ± 0.00 
dp 21 ± 0.00 0.48 ± 0.00 966.00 ± 0.00 1036.00  ± 1.00 475 ± 0.00 14.22 ± 0.17 7.06 ± 0.17 9.00 ± 0.00 4.31 ± 0.26 0.016 ± 0.00 
us 22 ± 0.00 1.08 ± 0.01 2115.67 ± 0.58 473.00  ± 0.00 1067 ± 3.46 13.58 ± 0.9 6.87 ± 0.9 35.39 ± 18.02 9.61 ± 0.22 0.013 ± 0.00 
ds 22 ± 0.00 0.30 ± 0.00 621.00 ± 2.65 1612.33  ± 3.51 302 ± 1.00 13.58 ± 0.79 6.85 ± 0.79 306.72 ± 2.75 7.34 ± 0.47 5.925 ± 9.12 
JUNE bc 13.5 ± 0.00 0.34 ± 0.00 703.00 ± 1.00 1423.33  ± 2.52 342.67 ± 0.58 7.3 ± 0.08 7.3 ± 0.08 113.33 ± 0.00 4.01 ± 0.41 0.017± 0.00 
dp 12.67 ± 0.29 0.37 ± 0.00 757.33 ± 2.08 1320.33  ± 3.21 368.33 ± 2.08 7.29 ± 0.06 7.29 ± 0.06 300.00 ± 0.00 4.31 ± 0.26 0.020± 0.00 
us 13 ± 0.00 0.54 ± 0.00 1082.33 ± 2.08 924.00  ± 1.73 534.33 ± 1.15 7.59 ± 0.06 7.59 ± 0.06 113.83 ± 4.42 9.61 ± 0.22 0.006 ± 0.00 
ds 12 ± 0.00 0.31 ± 0.00 633.33 ± 0.58 1580.00  ± 1.73 308 ± 0.00 7.8 ± 0.05 7.8 ± 0.05 89.38 ± 0.71 7.34 ± 0.47 0.011 ± 0.00 
JULY bc 14.8 ± 0.00 0.34 ± 0.01 724.67 ± 6.51 1370.67  ± 7.37 348.33 ± 7.37 6.61 ± 3.03 7.2 ± 0.32 116.55 ± 2.05 2.13 ± 0.5 0.030 ± 0.00 
dp 15.3 ± 0.17 0.42 ± 0.00 849.67 ± 1.15 1177.00 ± 7.37 416.33 ± 0.58 6.61 ± 1.94  7 ± 0.81 291.22 ± 0.60 3.10 ± 0.03 0.028 ± 0.00 
us 14.93 ± 0.12 0.72 ± 0.00 1428.67 ± 4.16 700.00  ± 1.73 710 ± 4.36 7.29 ± 3.03   6.96 ± 0.67 311.72 ± 0.80  7.80 ± 2.36 0.007 ± 0.00 
ds 15.83 ± 0.29 0.29 ± 0.00 606.00 ± 1.73 1650.33  ± 4.04 294.67 ± 0.58 10.89 ± 6.94  6.93 ± 1.08 311.72 ± 0.80 6.75 ± 2.37 0.016 ± 0.00 
AUGUST bc 21 ± 0.00 0.37 ± 0.00 754.67 ± 3.79 1319.33  ± 6.81 370.33 ± 2.08 56.37 ± 0.35 6.85 ± 0.11 310.11 ± 0.00 1.54 ± 0.3 0.037 ± 0.11 
dp 19 ± 0.00 0.41 ± 0.00 840.00 ± 1.00 1190.33  ± 1.53 411.67 ± 0.58 68.53 ± 0.57 7.09 ± 0.04 182.78 ± 0.00 2.23 ± 0.28 0.048± 0.00 
us 20 ± 0.00 0.44 ± 0.00 899.00 ± 3.61 1112.33  ± 4.73 441.33 ± 1.53 28.73 ± 0.06 7.12 ± 0.03 105.89 ± 0.00 7.8 ± 0.21 0.023 ± 0.00 




 Table 2.3: Physico-chemical parameters of water samples from the New Germany Treatment Works and receiving surface water bodies 
Month   Sampling 
Point 
Temp       
(°C) 
Sal                
(%) 
Cond          
(μs/cm) 
Resist              
(Ω/m) 




pH COD       
(mg/L) 
BOD      
(mg/L)  






bc 25.67 ± 0.29 0.44 ± 0.01 878.33 ± 21.22 1125.67 ± 5.51 436 ± 2.00 6.65 ± 0.00 7.12 ± 0.00 154.33 ± 0.38 2.20 ± 0.13 0.038 ± 0.03 
dp 26 ± 0.00 0.48 ± 0.01 970.33 ± 11.59 1023.67  ± 1.53 477.33 ± 5.51 5.71 ± 0.00 7.18 ± 0.00 239.05 ± 1.21 3.12 ± 0.27 0.279 ± 0.27 
us 26 ± 0.00 0.21 ± 0.00 431.33 ± 2.89 2320.00  ± 7.32 207.97 ± 1.70 5.16 ± 0.00 7.52 ± 0.00 141.67 ± 0.25 7.79 ± 0.83 0.003 ± 0.00 
ds 25.5 ± 0.00 0.30 ± 0.00 615.00 ± 1.73 1622.67  ± 7.51 299 ± 1.00 7.32 ± 0.00 7.51 ± 0.00 313.61 ± 0.70 4.97 ± 0.59 0.016 ± 0.01 
APRIL bc 20.17 ± 0.29 0.39 ± 0.01 790.33 ± 3.06 1265.33  ± 4.51 386.67 ± 1.53 1.34 ± 0.21 6.82 ± 0.25 199.28 ± 4.04 3.75 ± 0.29 0.045 ± 0.05 
dp 20.17 ± 0.29 0.43 ± 0.01 884.00 ± 4.58 1131.33  ± 6.03 433.67 ± 2.08 1.44 ± 0.02 6.70 ± 0.15 180.34 ± 0.76 3.72 ± 0.14 0.085 ± 0.10 
us 17.67 ± 0.58 0.16 ± 0.00 328.67 ± 1.53 304.33  ± 1.53 157.67 ± 0.71 8.75 ± 0.60 6.92 ± 0.18 102.27 ± 2.24 9.26 ± 0.24 0.004 ± 0.00 
ds 19 ± 0.00 0.30 ± 0.00 627.33 ± 0.58 1594.33  ± 2.08 305.33 ± 0.58 17.10 ± 0.12 7.01 ± 0.09 115.39 ± 1.60 9.34 ± 0.83 0.012 ± 1.33 
MAY bc 19.00 ± 0.00 0.57 ± 0.00  1148.33 ± 5.51 871.00  ± 4.00 567.33 ± 2.52 25.20 ± 4.04 6.93 ± 0.03 312.76 ± 0.64 3.15 ± 0.25 0.046 ± 0.06 
dp 18.50 ± 0.00 0.62 ± 0.01 1253.67 ± 3.06 797.67  ± 2.52 621.33 ± 1.53 22.30 ± 9.2 6.93 ± 0.11 245.33 ± 1.15 4.72 ± 0.16 0.031 ± 0.04 
us 13.67 ± 0.58 0.17 ± 0.00 363.67 ± 1.15 2.75  ± 0.01 174.67 ± 0.64 8.77 ± 6.46 6.63 ± 0.23 305.61 ± 8.01 11.04 ± 0.97 0.011 ± 0.00 
ds 16.07 ± 0.12 0.46 ± 0.00 939.67 ± 1.15 1064.33  ± 1.15 462 ± 1.00 16.03 ± 2.04 6.83 ± 0.31 302.67 ± 10.64 9.76 ± 0.55 0.057 ± 0.06 
JUNE bc 18.00 ± 0.00 0.53 ± 0.01 1084.33 ± 2.08 925.33  ± 1.15 534.33 ± 1.53 7.68 ± 3.41 7.6 ± 0.03 307.17 ± 3.27 4.17 ± 0.01 0.038 ± 0.00 
dp 17.50 ± 0.00 0.58 ± 0.00 1166.33 ± 2.08 857.33  ± 1.53 577.33 ± 1.15 7.47 ± 1.78 7.61 ± 0.07 110.33 ± 0.38 4.35 ± 0.77 0.027 ± 0.36 
us 16.00 ± 0.00 0.18 ± 0.00 383.67 ± 0.58 2610  ± 0.00 184.53 ± 0.31 6.87 ± 3.19 7.93 ± 0.00 26.33 ± 4.61 9.85 ± 1.09 0.000 ± 0.00 
ds 13.87 ± 0.12 0.40 ± 0.00 826.67 ± 1.53 1209.33  ± 1.15 404.67 ± 0.58 9.13 ± 5.70 7.81 ± 0.03 72.28 ± 1.21 6.94 ± 0.24 0.016 ± 0.00 
JULY bc 16.50 ± 0.00 0.47 ± 0.01 974.67 ± 0.58 1026.67± 0.58 467 ± 3.00 20.67 ± 0.69 6.73 ± 0.23 193.67 ± 0.00 2.37 ± 0.30 0.014 ± 0.00 
dp 17.00 ± 0.00 0.52 ± 0.01 1069 ± 1.00 935.33  ± 0.58 525.67 ± 2.31 24.50 ± 4.35  6.60 ± 0.34 308.67 ± 0.00 4.44 ± 0.56 0.009 ± 0.00 
us 13.50 ± 0.00 0.15 ± 0.00 321.67 ± 0.58 3110  ± 0.00 154.17 ± 0.23 7.40 ± 5.74   6.34 ± 0.05 309.39 ± 0.32  8.14 ± 3.31 0.002 ± 0.00 
ds 14.50 ± 0.00 0.34 ± 0.00 706.67 ± 1.53 1415  ± 2.65 344.67 ± 0.58 19.80 ± 4.27  6.47 ± 0.54 298.06 ± 1.73 6.87 ± 2.94 0.007 ± 0.00 
AUGUST bc 16.80 ± 0.00 0.42 ± 0.01 849.33 ± 1.53 1187  ± 6.64 416.67 ± 0.58 19.73 ± 0.00 6.65 ± 0.00 139.56 ± 0.00 4.10 ± 0.31 0.021 ± 0.00 
dp 16.50 ± 0.00 0.47 ± 0.00 958.00 ± 2.00 1044  ± 2.00 471 ± 1.00 16.80 ± 0.00 7.11 ± 0.00 309.00 ± 0.00 4.49 ± 0.38 0.021 ± 0.00 
us 14.50 ± 0.00 0.34 ± 0.00 706.67 ± 7.51 1419  ± 1.36 344.67 ± 3.51 40.40 ± 0.00 7.12 ± 0.00 207.55 ± 0.00 10.61 ± 0.63 0.000 ± 0.00 
ds 12.00 ± 0.00 0.37 ± 0.00 757.33 ± 2.31 1320.67  ± 4.04 369.67 ± 1.15 14.10 ± 0.00 7.26 ± 0.00 311.78 ± 0.00 8.84 ± 0.60 0.015 ± 0.00 
BC: Before chlorination; DP: Discharge point; US: Upstream; DS: Downstream; Temp: Temperature; Salinity; Cond: Conductivity; Resist: Resistivity; TDS: Total dissolved solids; COD: Chemical 
oxygen demand; BOD: Biological oxygen demand; TSS: Total suspended solids 
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  Nitrate (mg/L) Phosphate (mg/L) Nitrate (mg/L) Phosphate (mg/L) BC < 0.057 3.509 1.81 0.904 
DP < 0.057 3.473 1.401 0.797 
US 1.062 0.051 1.062 0.051 




     
BC < 0.057 2.105 2.809 1.091 
DP < 0.057 2.097 2.351 0.859 
US 0.856 0.232 1.292 0.168 




     
BC 0.156 2.72 < 0.057 0.051 
DP 0.202 2.338 < 0.057 < 0.025 
US 1.028 1.08 0.843 < 0.025 




     
BC 5.98 12.377 3.76 1.048 
DP 3.92 9.021 1.99 0.876 
US 2.4 2.173 2.38 0.655 




     
BC 1 1.829 0.472 0.025 
DP 0.892 0.751 0.573 0.093 
US 0.785 -0.025 1.03 0.025 




     
BC 0.148 1.696 1.42 0.931 
DP < 0.057 1.994 1.96 1.467 
US < 0.057 0.115 2.29 0.591 
DS 1.47 0.163 0.8 1.894 
BC: Before chlorination; DP: Discharge point; US: Upstream; DS: Downstream 
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Table 2.5: Correlation coefficient for the different physico-chemical variables and E. coli 
population at the Northern Wastewater Treatment Plant 
 
 
Table 2.6: Correlation coefficient for the different physico-chemical parameters and E. coli 
population at the New Germany Treatment Plant 
 
Salin: Salinity; Cond: Conductivity,Turb: Turbidity; COD: Chemical oxygen demand; BOD: Biological 
oxygen demand; TSS: Total suspended solids; EC: E. coli; Temp: Temperature; Resist: Resistivity. 
 
** Correlation is significant at p < 0.05 level (2-tailed) 
*  Correlation is significant at p < 0.01 level (2-tailed) 
ns Not significant 
 
 
Variables Salin. Cond. TDS Turb. pH COD BOD TSS EC Temp. Resist. 
Salin. 1.000 .999** 1.000** -.024 ns -.255 ns -.341 ns .103 ns -.353 ns .063 ns .024 ns .627** 
Cond.   1.000 1.000** -.023 ns -.261 ns -.337 ns .095 ns -.353 ns .069 ns .028 ns .625** 
TDS    1.000 -.018 ns -.263 ns -.337 ns .097 ns -.352 ns .067 ns .025 ns .623** 
Turb.      1.000 -.141 ns -.032 ns -.300 ns .249 ns .226 ns -.266 ns .152 ns 
pH        1.000 -.105 ns .412* -.210 ns -.325 ns .097 ns .083 ns 
COD          1.000 .168 ns .166 ns -.294 ns .238 ns -.319 ns 
BOD            1.000 -.065 ns -.719** .147 ns -.190 ns 
TSS              1.000 -.153 ns -.498* -.172 ns 
EC                1.000 .250 ns .132 ns 
Temp.                  1.000 -.165 ns 
Resist.                    1.000 
Variables Resist. Temp. Salin. Cond. TDS pH BOD TSS EC Turb. COD 
Resist. 1.000 0.012 ns .439* 0.317 ns 0.329 ns -0.221 ns 0.240 ns -0.413 ns -0.092 ns -0.147 ns 0.035 ns 
Temp.   1.000 -0.166 ns -0.097 ns -0.104 ns -0.158 ns -.529** 0.364 ns 0.032 ns -.409*  0.180 ns 
Salin.     1.000 .755** .780** -0.016 ns .661** -.657** -0.117 ns -0.223 ns 0.094 ns 
Cond.       1.000 .999** -0.041 ns 0.351 ns -0.337 ns -0.108 ns -0.258 ns 0.011 ns 
TDS         1.000 -0.034 ns 0.371 ns -0.359 ns -0.114 ns -0.257 ns 0.019 ns 
pH           1.000 -0.116 ns -0.136 ns -0.390 ns 0.169 ns -0.222 ns 
BOD             1.000 -.554** -0.030 ns 0.179 ns -0.025 ns 
TSS               1.000 0.148 ns -0.235 ns 0.076 ns 
EC                 1.000 -0.002 ns 0.186 ns 
Turb.                   1.000 -0.251 ns 




Figure 2.2: Representative gel image depicting the presence of mdh (392bp) in E. coli isolates  




Figure 2.3: Antibiogram of the E. coli isolates recovered from treated effluents and receiving 































Figure 2.4: Representative gel image depicting the presence of six virulence genes in selected E. 
coli isolates 
Where: L1: MW DNA Marker; L2-L3: Positive control; L5-L5: hly; L6-L7: rfbE; L8-L9: eae and stx1; L10-L11: stx2 and L12-L13: fliC  
 
 
Figure 2.5: Virulence gene distribution among the E. coli isolates recovered from treated effluents 



























Monitoring of the NWWTP and the respective receiving water bodies over the six-month period 
revealed dramatic fluctuations in E. coli populations as shown in Figure 1a. Increases in the E. coli 
population at the DP during the months of March, April and August could be attributed to the 
inefficiency of the plant as a result of a plant upgrade. During the months of May, June and July, 
the NWWTP was efficient in reducing the microbial load at the DP when compared to BC, having 
treatment efficiency rates of 62.82%, 25.00% and 19.25%, respectively. Although informal 
settlement dwellers were seen washing clothes and dumping household waste at the US and DS 
sampling points of the uMgeni River, E. coli populations at these points were relatively low 
compared to populations at the discharge point. In addition, poorly maintained pipes which 
transport final effluent to the discharge point could be a possible source of contamination of 
receiving water bodies. E. coli populations at the NGTWs as depicted in Figure 1b. Although the 
treatment plant was efficient in reducing the E. coli population at the discharge point during all 
sampling months, E. coli counts did not fall within the recommended guideline. The relatively low 
counts of E. coli obtained at the discharge point could be attributed to the fact that the plant is of a 
smaller capacity and treated approximately 1% of the total carrying capacity of 7 megalitres per 
day.  According to the Government Gazette (DWAF, 1984), effluent should not contain any 
substance in a concentration capable of producing any colour, odour or taste.  During most months 
of sampling it was noted that water at the BC and DP sampling points at the NGTWs were amber 
in colour due to dyes from nearby industries. It may be assumed that the presence of these 
chemicals may be inhibitory to bacterial growth and may have contributed to low E. coli counts at 
the plant.  Various informal settlements, industries, and a school is located alongside the Aller 
River where the US and DS samples were taken.  This however, did not seem to be a contributing 
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factor to the E. coli load at these points as the E. coli counts at these points were lower when 
compared to the discharge point.  
 
Beyond microbial measurements, safe water also has physico-chemical characteristics which are 
readily affected by climatic events and impact on the survival of microorganisms and the efficiency 
of treatment processes (DWAF, 1996).  The increase or decrease in water temperature depends 
mainly on climatic conditions, sampling times, the number of sunshine hours and also on 
characteristics such as turbidity, humidity and plant cover. Seasonal variations was noted in the 
temperature profiles obtained at both WWTPs, with the lowest temperature values obtained at the 
DS points in winter, whilst the highest values were obtained in autumn at the BC and DP. With 
these two exceptions, all values fell within the recommended guideline of 25 °C (DWAF, 1984). 
BOD is a measure of how much of oxygen is required to completely oxidise the pollutant (Momba 
et al., 2002).  The current South African guideline for BOD for final effluent or river sources is 5 
mg/L (DWAF, 1999), while the European Union guidelines stipulate that BOD levels should be 
between 3 – 6 mg/L for the protection of aquatic life and fisheries (Chapman, 1996).  By this 
standard, it can be noted that all BOD values for the BC and DP points at both treatment plants 
were within specified guidelines. The highest values were obtained for the US points of both rivers, 
suggesting that the WWTPs were not the only contributors to the organic pollution load. A 
significant (r=-0.719 at p<0.05) relationship existed between BOD and E. coli at the NWWTP. 
The highest values for COD (311.72 ± 0.8) at the NWWTP were obtained at the US and DS sample 
points which indicate the presence of other point sources of pollution.  COD concentrations at the 
DS point were higher than that observed at the DP, implying that WWTP effluent had little 
contribution to elevated COD concentrations further down the river.  The COD values obtained at 
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the NGTWs were comparatively higher than values obtained at NWWTP probably due to the 
influent being mainly of industrial origin.  The standard for COD of water used for domestic 
purposes is 30 mg/L (DWAF, 1984).  With the exception of samples from the DP point with COD 
values of 9 mg/L in both March and May at the NWWTP, and the US point of NGTWs with a 
COD value of 26.33 ± 1.21mg/L during the month of June, all COD values obtained were not 
within recommended guidelines. A positive correlation (r=0.755 at p<0.05) is noted between COD 
and salinity at NGTWs.  In addition, results obtained indicate that the NGTWs is a direct source 
of pollution of receiving water bodies, as the COD concentrations increased at the DP when 
compared to concentrations at the BC point over the six month period. This is in agreement with 
studies conducted by Fatoki et al. (2001), and Morrison et al. (2001), which state that the 
contribution of COD to effluent and receiving water bodies in South Africa is significant.  Elevated 
COD concentrations have been shown to have a negative impact not only on receiving water 
sources but on aquatic life present as well. 
 
According to the South African guidelines for water for domestic use, TDS concentrations for final 
effluent and receiving surface waters should be between 0 and 450 mg/L (DWAF, 1996). Results 
obtained indicate that both treatment plants investigated in this study were inefficient in reducing 
the TDS concentration throughout the sampling period as the TDS concentration increased at the 
DP sampling point by an average of 10.79% and 9.4%, respectively relative to BC.  The highest 
TDS concentration was recorded for the US point (1067.00 ± 0.00) in May, whilst the lowest 
(294.67 ± 0.58) was found at the DS in July. With the exception of April, all TDS values obtained 
at the DP sampling point at the NGTWs were not within specified guidelines.  The lower TDS 
values obtained at the US point, and the higher values at the DS sampling point together with 
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elevated concentrations at the DP sampling point suggests that the NGTWs is a source of 
contamination of receiving water bodies and contribute to the TDS concentrations at the DS point. 
It is therefore not surprising that TDS had strong positive correlations with conductivity and 
salinity at both treatment plants.  According to McCulloch et al. (1993), elevated TDS 
concentrations in surface waters are toxic to freshwater animals as they cause osmotic stress and 
affect the osmoregularity capability of the organisms.  
 
There is no standard for the turbidity of effluent discharge in South Africa. However, water used 
for domestic purposes should have <1.0 NTU (DWAF, 1996).  All values obtained at both 
treatment plants were not within specified guidelines. For the NWWTP, the turbidity values at the 
DP were higher when compared to the BC point for most of the sampling period.  This could be 
attributed to the upgrade of the plant infrastructure being undertaken at the plant during the 
sampling period.  A comparison of the six months of sampling across both plants revealed the 
highest turbidity in August.  This may be a result of surface runoff and soil erosion into receiving 
water bodies caused by the heavy rains experienced during this month.  The high turbidity values 
obtained therefore excludes all water sources for direct domestic use (Fatoki et al., 2001). 
According to Ekholm and Krogenus (1998), highly turbid water is difficult to disinfect and is often 
associated with the growth of pathogenic organisms.The nutrient analysis of all water samples can 
be seen in Table 2.4.  According to Igbinosa and Okoh (2009), nitrate is the most highly oxidised 
form of nitrogen compounds and is commonly found in surface and groundwater, as it is an end 
product of aerobic decomposition of organic nitrogenous matter. Unpolluted water usually only 
contains minute amounts of nitrate (Jaji et al. 2007). The South African standard for nitrate in 
sewage effluent is 1.5 mg/L NO3- as N (DWAF, 1984). This study showed dramatic fluctuations 
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in nitrate concentrations across all sampling points at both plants.  The NWWTP was efficient in 
reducing the nitrate concentration for final effluent by 34.5% and 10.80% for the months of June 
and July, respectively, with an increase in concentration observed at the DP sampling point during 
April and May.  All values, except for those obtained in May at the DS point, and all points during 
the month of June, did meet the recommended standards.  The elevated nitrate concentrations 
observed at some of the US and DS points when compared to the DP suggest that there are other 
point sources of nitrate contamination on the surface of the water.  On the contrary, NGTWs was 
not as efficient in reducing nitrate levels in final effluent when compared to the NWWTP, having 
treatment efficiency rates of 16.30% and 47.1% for the months of April and June, respectively.  
The nitrate levels increased at the DP sampling point during July and August, suggesting that the 
plant was responsible for contributing to nitrate contamination of surface waters.  All values 
obtained during the month of June, together with samples from the DP in April and August, as 
well as the DS point in August did not meet the specified guidelines.  It is important to note that 
the nitrate levels in treated final effluent could serve as a source of eutrophication for receiving 
water bodies.  The nitrate levels at the US and DS points could be a result of diffuse sources from 
agricultural and settlement runoff (Igbinosa and Okoh, 2009).  Nitrate has been identified as a 
pollutant and could lead to excessive growth and the proliferation of toxic algal blooms when 
found in elevated concentrations (Santos et al., 2008). Orthophosphates are generally a limiting 
factor in aquatic environments, and at levels above 0.1 mg/L in water, orthophosphates usually 
result in increased eutrophication (Osode and Okoh, 2009). There is no target quality range for 
phosphate concentrations in final effluent used for domestic or recreational purposes according to 
South African guidelines, however, the level of phosphate in water that reduces the likelihood of 
algal and other plant growth is 0.005 mg/L (DWAF, 1996).  By this standard, all values obtained 
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at both treatment plants and respective receiving surface water sources were not within specified 
limits. The NGTWs was efficient in reducing the phosphate concentrations in final effluent from 
April – June, whilst an increased phosphate load was obtained after treatment during July and 
August. The high values obtained at the DP sampling point at both plants suggest an inadequate 
removal of phosphate by the wastewater treatment facility.  Increased levels along other sampling 
points may be attributed to a variety of activities such as municipal, agricultural and domestic run-
off from surrounding areas. 
 
Chloramphenicol is a drug rarely used in non-life threatening situations and works by inhibiting 
protein synthesis.  Therefore, resistance to this drug is rare. However, higher resistance (18%) to 
chloramphenicol was observed in this study compared to similar studies.  Aminoglycosides are a 
similar class of antimicrobials that bind to ribosomes and therefore prevent protein synthesis.  A 
similar trend in resistance to gentamicin which belongs to this class was seen in previous studies 
(Ram et al., 2008). Studies by Olaniran et al. (2009) showed resistance towards amikacin among 
E. coli isolates recovered from river sources in Durban however, all isolates in this study were 
susceptible.  According to Goni-Urriza et al. (2000), the low levels of resistance to this class may 
be due to its reduced use, as it has been known to be associated with kidney and auditory nerve 
damage. Due to the low toxicity of β-Lactams and Tetracycline antimicrobials, it is commonly 
used to treat bacterial infections.  This has been a major contributing factor to the increased 
resistance levels observed in many studies.  β-lactams work by inhibiting the final step in cell wall 
synthesis.  Among the E. coli isolates tested, the most common resistance was to tetracycline, 
ampicillin, amoxicillin and doxycycline with a percentage resistance of 56%, 52.5%, 40% and 
31%, respectively. Resistance to this group of antimicrobial agents has been attributed mainly to 
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the acquisition of mobile genetic elements between bacterial strains (WHO, 2014). A similar trend 
of resistance was also observed in studies by Luczkiewicz et al. (2010). An increase in tetracycline, 
chloramphenicol and ampicillin resistance observed in this study was in agreement with the 
findings of Olaniran et al. (2009). Reports by WHO (2014), name E. coli as an organism of 
international concern due to an emerging resistance to fluoroquinolones and cephalosporins.  
Quinolones are one of the most frequently used drugs for the treatment of urinary tract infections 
whilst cephalosporins are used in more severe cases (WHO, 2014). Reports based on twenty nine 
publications in South Africa revealed a higher resistance to fluoroquinolones than cephalosporins. 
This study indicates that 20.5% and 21.5% of the isolates were resistant to norfloxacin and 
ciprofloxacin, respectively. In addition, isolates exhibited resistance towards cephalothin (16.5%), 
ceftazidime (7.5%) and cefazolin (0%), clearly indicating a similar trend as observed across the 
country.  It is then suggested that populations exhibiting these resistance patterns be initiated with 
broader therapy such as carbapenems when the use of cephalosporins is considered (WHO, 2014).  
Urban wastewater treatment plants are among the main sources of antibiotics’ release into the 
environment and could be a contributing factor to the dissemination of antibiotic resistance in the 
environment if effluent is not properly treated (Rizzo et al., 2013). In addition, changes in the 
nutrient composition could also lead to selective pressures which favour antibiotic resistance (Ram 
et al., 2008).  According to Olaniran et al. (2009), multiple antibiotic resistance among E. coli may 
also be due to the spread of genetic elements such as plasmids and integrons amongst the 
organisms. 
The virulence gene profiles of tested isolates revealed a high prevalence of the hly gene similar to 
that reported by Ram et al. (2008). However, the frequency of potentially pathogenic E. coli 
observed in this study is lower than those reported by Ram et al. (2008) and Obi et al. (2004).  The 
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low prevalence of Shiga toxigenic genes obtained was insufficient to make any definite 
comparisons or draw conclusions, however, it was noted that the eaeA gene was found in 
conjunction with either stx1 or stx2 in 14% of the tested isolates.  This gene is essential in the 
attachment stage of pathogenesis where attachment to Hep-2 epithelial cells within a host is 
enabled by intimin, an outer membrane protein which is encoded for by the eaeA gene (Wilshaw 
et al., 2003).  The combination of eaeA and either stx1 or stx2 is characteristic of EHEC. 
Pathogenic strains of STEC can either express stx1, stx2, or both. It has been reported that the 
development of critical infections does not entirely depend on the amount of toxin present but 
rather on the type, with stx2 being most pathogenic due to variants which exists within the group 
(Khan and Naim, 2011). Human infection can be due to direct fecal-oral transmission from an 
infected animal or human, through contaminated water or most frequently through the 
consumption of inadequately cooked meat products, raw milk, and unpasteurized drinks (Hunter, 
2003).  However, it should be noted that the presence of a virulence gene only indicates a potential 
to cause disease.  Even if the virulence factor is active, it may not be sufficient to cause disease, as 
disease is a complex process which contains various steps which include entry into the body, 











This study was carried out to evaluate the efficiency of two independent wastewater treatment 
plants and the impact of discharged effluent from these plants on receiving water bodies.  The 
results revealed that both treatment plants were efficient at some point in reducing the E. coli load 
of the effluent, but not to acceptable standards in water for domestic use.  The treatment plant did 
exhibit final effluent qualities that were of acceptable limits for physico-chemical parameters such 
as temperature; pH and BOD but fell short for others such as turbidity, nitrate and phosphate.  This 
study therefore shows that inefficiently treated effluent is one of the major contributors to the 
pollution of surface waters.  Pollution from industry and domestic practices further compounds the 
problem, resulting in surface waters of poor microbiological and physico-chemical quality. The 
study also revealed that incomplete elimination of bacteria during wastewater treatment resulted 
in the entry of antibiotic resistant bacteria into receiving streams with effluent input as some of the 
isolates tested in this study exhibit multiple antimicrobial resistance, which may compromise the 
treatment of infections caused by these organisms.  Although the prevalence of virulence genes 
amongst E. coli isolates investigated in this study is lower when compared to similar studies, their 
detection in these strains cannot be disregarded as it indicates the potential pathogenic nature of 
these isolates. The pollution of water sources continues to be a global challenge, especially in rural 
communities where residents rely on these water sources for daily domestic and recreational use.  
In addition, the decrease in water quality leads to increased treatment costs of potable and industrial 
process water as well as agricultural yields (Osode and Okoh, 2009).  It is therefore important that 
frequent water quality monitoring be carried out and that strict water quality guidelines be set and 
enforced by the South African government.  Problems may also be alleviated by upgrading these 





PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF Escherichia coli 
ISOLATES RECOVERED FROM TREATED WASTEWATER EFFLUENT AND 
RECEIVING AQUATIC MILIEU IN DURBAN, SOUTH AFRICA 
Abstract 
The extensive and uncontrolled use of antimicrobial agents in veterinary medicine, agriculture and by 
humans has led to the rise in resistance to new and commonly used antimicrobial agents. This phenomenon 
is proof that bacteria have the ability to exchange and rearrange genomic sequences to gain resistance traits 
through the horizontal gene transfer (HGT) of mobile genetic elements such as integrons.  In this study, 
200 Escherichia coli isolates recovered from treated effluent of two wastewater treatment plants and their 
respective receiving rivers were screened for their antimicrobial resistance as well as for the prevalence of 
classes 1, 2 and 3 integrons.  The presence and identity of gene cassettes was determined via PCR, 
Restriction Fragment Length Polymorphism (RFLP) and sequence analysis, while conjugation experiments 
were conducted to determine if plasmid encoded integrons are transferrable to recipient strains. The results 
revealed high resistance rates towards tetracycline (56%), ampicillin (52.5%) and trimethoprim (50.5%).   
Class 1 integrons were detectd in 50.5% of isolates while class 2 was found in only 1%.  Gene cassettes 
were detected in all integron-positive isolates with the most abundant gene being dfrA17, which encodes 
resistance to trimethoprim.  All detected integrons were located on both the plasmid and chromosome found 
to be transferrable to recipient strains. Majority (86%) of integron-positive isolates were multi-drug 
resistant and exhibited higher resistance rates to antimicrobial agents when compared to integron negative 
strains. Random Amplified Polymorphism DNA (RAPD) analysis of integron positive strains shows clonal 
relationships among isolates with similar resistance phenotypes. These results confirm integrons as possibly 





To date, bacterial evolution has been shaped by the high plasticity of bacterial genomes, and this 
has led to their adaptations to most ecosystems (Stalder et al., 2012).  Antimicrobial agents are 
considered as one of the most significant contributors to modern medicine, having the ability to 
kill or inhibit the growth of a plethora of microorganisms (Gungchao et al., 2013). The extensive 
and uncontrolled use of antimicrobial agents in veterinary medicine, agriculture and for human use 
has led to the emerging rise of resistance to new and commonly used antimicrobial agents. This 
phenomenon is proof that bacteria have the ability to exchange and rearrange genomic sequences 
to gain new traits such as resistance to these agents (Stalder et al., 2012). Therefore, microbial 
mediated infections still remain as one of the greatest public health concerns in the 21st century, 
due to complications experienced in the treatment of infections (Yang et al., 2009;Gungchao et 
al., 2013).  Resistance to antimicrobial agents may arise due to mutations in the bacterial 
chromosome, or through the horizontal transfer of mobile genetic elements (MGEs) such as 
plasmids, transposons and integrons (Koczura et al., 2012). However, horizontal gene transfer 
(HGT) events, which allow for the loss and acquisition of functional modules is the preferred 
method for the transfer of antibiotic resistance genes (ARGs) as opposed to random mutational 
events (Stalder et al., 2012).  Integrons are one of the main types of MGEs currently known to be 
involved in the acquisition and spread of ARGs amongst gram-negative bacteria (Koczura et al., 
2012).  
A functional integron comprises of three key elements namely: an integrase gene (intl), which 
encodes an integrase; a recombination site (attl); and a promoter gene (Pc).  Characterized by the 
presence of invariant RHRY amino acids, integrase, belongs to the tyrosine-recombinase family, 
and is responsible for mediating the recombination between the attl site and a secondary target 
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called the attC site (Gungchao et al., 2013).  These recombination sites are generally associated 
with a single open reading frame, which can be found in a structure called gene cassette (Stalder 
et al., 2012). Gene cassettes (GCs) are one of the smallest MGEs and can exist in either a circular 
or linear form.  They are not always found in integrons, but once integrated, they become part of 
the integron (Fluit and Schmitz, 1999).  GCs encode ARGs, and to date, more than one hundred 
different antibiotic resistance gene cassettes having unique attC sites have been characterized 
(Gungchao et al., 2013). According to Mazel (2006), an integron itself is not movable, but GCs 
within integrons can be mobilized to another integron or another site within the genome.  There 
are two major groups of integrons: chromosomal and mobile integrons, with the latter being found 
on MGEs that promote their dissemination amongst bacteria (Stalder et al., 2012).  Studies by 
Skurnik et al. (2005), demonstrated that mobile integrons are most prevalent in bacterial 
communities who are subjected to direct or indirect antibiotic pressure in clinical, agricultural and 
environmental settings.  In addition, several classes of integrons have been characterized based on 
the divergence in their intl sequences. Classes 1, 2 and 3 integrons are most commonly screened 
for, while class 4 is rare and is termed a ‘super integron’ (Gungchao et al., 2013).  Class 1 integrons 
have been reported in a number of gram-negative organisms, including E. coli, Aeromonas, 
Shigella and Serratia spp., and have therefore been studied extensively.  They have been detected 
in 22 to 77% of clinical isolates obtained from human and animal sources (Gungchao et al., 
2013;Koczura et al., 2012;Stalder et al., 2012). Class 2 integrons contain a defective integrase 
gene and is considered to be less prevalent when compared to the widely distributed class 1 
integron. It is most commonly found in E. coli, Salmonella enterica and Acinetobacter baumanii 
(Ahmed et al., 2005). Class 3 intergrons are the least common and was previously detected in 




Wastewater treatment plants (WWTPs) are the interface between human waste and the aquatic and 
soil environments. The convergence of gut-associated bacteria such as E. coli, antibiotic residues 
and a rich diversity of microbial consortium suggest that WWTPs provide a favorable environment 
for the transfer of MGEs in microbial communities (Rizzo et al., 2013). Reports by Rizzo et al. 
(2013) show that on average, WWTPs discharge approximately 109 – 1012 colony forming units 
per day and of this, around 109 - 1010 are resistant. However, WWTPs are ineffective in completely 
removing ARB in final effluent. Studies by Ferreria da Silva et al. (2006) showed that the total 
number of resistant E. coli isolates recovered from wastewater increased by 10.30% after tertiary 
wastewater treatment, while Plaza et al. (2013) reported that 90% of E.coli isolates recovered from 
WWTPs were resistant to at least one antibiotic. In addition, approximately 30% - 60% of E. coli 
isolates have been reported to contain class 1 integrons (Moura et al., 2007; Zhang et al., 2009a). 
The current study therefore evaluated the antimicrobial resistance patterns of integron bearing 
strains of E. coli isolated from treated wastewater effluent and receiving surface waters and 
identified the gene cassettes harbored by these isolates. In addition, the ability of integrons to be 
transferred via conjugation was evaluated while the genotypic relationship among multi-drug 









3.2 Materials and Methods 
  
3.2.1 E. coli isolates and antibiotic susceptibility testing 
A total of 200 E. coli isolates previously recovered from the treated effluent of two WWTPs and 
the receiving surface water were characterized in this study. Presumptive isolates obtained 
following membrane filtration and plating on selective chromogenic media were biochemically 
identified via iMViC tests, and confirmed via PCR amplification of the mdh gene. Confirmed 
isolates were grown for 24 h in nutrient broth, standardized to a 0.5 McFarland standard according 
to CLSI guidelines (CLSI, 2013), swabbed onto Mueller Hinton agar and thereafter incubated at 
37 °C for 24 h. Determination of the antibiotic resistance profile of each isolate was done using 
the Kirby-Bauer disc diffusion assay using the following antibiotics (µg per disc): Penicillins: 
ampicillin (10), amoxicillin (10); Cephems: cefazolin (30), cephalothin (30), ceftazidime (30); 
Tetracyclines: tetracycline (30), doxycycline (10); Phenicols: chloramphenicol (30); 
Aminoglycosides: amikacin (30), gentamicin (10); Quinolones: nalidixic acid (30); 
Fluoroquinolones: norfloxacin (10), ciprofloxacin (5);  Fosfomycin: fosfomycin (200) and 
Trimethoprim (10). 
 
3.2.2 Identification of integrase genes 
A multiplex PCR procedure was used to detect the presence of classes 1, 2 and 3 integrase genes 
in all confirmed isolates (Dillon et al., 2005). DNA was extracted from the isolates using the 
boiling method and used as template in the PCR assay (Bai et al., 2010). The 50 µl PCR assay 
mixture contained 2 µl of DNA, 1 µl of each primer (Table 3.1), 0.2 µl of Taq DNA Polymerase, 
10 µl of 1 mM dNTP, 3 µl MgCl2, 5 µl of 10 × reaction buffer and 23.8 µl of RNAse free water.  
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Amplification of target genes was performed in a T100 Thermal Cycler (Biorad, USA) under the 
following conditions: Initial denaturation at 94 ºC for 5 min, 30 cycles of denaturation at 94 ºC for 
1 min, annealing at 59 ºC for 1 min, elongation at 72 ºC for 1 min and a final elongation step at 72 
ºC for 8 min. Amplified DNA was resolved by electrophoresis on a 1.5 % agarose gel (Seakem), 
and products visualized after staining of gel with ethidium bromide (0.5 µg/ml) using the 
Chemigenius Bioimaging System (Syngiene, England). Representative bands of positive 
amplicons were excised, sequenced (Inqaba Biotech Pty.) and compared against GenBank 
database by using Basic Local Alignment Search Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
  
3.2.3 Identification of gene cassette arrays 
Primers 3CS and 5CS were used for the detection of gene cassette arrays within integron positive 
isolates (Table 3.1). DNA was extracted using the boiling method and used as a template in the 
PCR reaction (Bai et al., 2010). The PCR assay consisted of the following components: 0.75 µl 
Long PCR Enzyme Mix with MgCl2 (ThermoFisher Scientific), 10 µl of 1mM dNTP, 5 µl of 10 
× reaction buffer, 5 µl of each primer, 3 µl of DNA and 21.25 µl of RNAse free water.  
Amplification of target genes was performed in a T100 Thermal Cycler (Biorad,USA) under the 
following conditions: Initial denaturation at 94 ºC for 2 min, followed by 30 cycles of denaturation 
at 94 ºC for 20 s, annealing at 57 ºC for 30 s and elongation at 68 ºC for 90 s.  A final elongation 
step was done at 68 ºC for 10 min.  Amplified DNA was resolved on a 1.5% agarose gel (Seakem) 




3.2.4 Restriction Fragment Length Polymorphism (RFLP) 
Isolates showing positive amplification for gene cassettes were further characterized by RFLP 
analysis using the restriction enzymes HinfI and RsaI (ThermoFisher Scientific).  Each reaction 
mixture contained 15 µl amplification product and 0.5 µl (5 U) restriction enzyme. Both mixtures 
were incubated for 24 h at 37 ºC.  The restricted fragments were resolved on a 1.5 % agarose gel, 
stained with ethidium bromide (0.5 µg/ml) and visualized. The different RFLP types were 
designated with letters (A-D), and PCR products of amplicons representing different restriction 
patterns were sequenced (Inqaba Biotech Pty.) and compared against the Genbank database using 
the BLAST tool. 
3.2.5 Determination of integrons location 
To determine if identified integrons are plasmid or chromosomally encoded, plasmid and genomic 
DNA was extracted from integron positive isolates using the GeneJet Plasmid MiniPrep Kit 
(Fermentas) and the GeneJet Genomic DNA Purification Kit (Fermentas), respectively. Extracted 
DNA was used as a template in a PCR assay to determine the presence of class 1, 2 and 3 integrase 
genes as previously described.  The location of the identified integron was noted.   
3.2.6 Conjugation 
Ten isolates with plasmid encoded integrons were chosen at random and selected as donor strains 
in conjugation experiments. Donor (n=10) and recipient cells were grown seperately in Luria 
Bertani (LB) broth (Merck, USA) for 18 h. Each culture was then serially diluted and plated onto 
LB agar and incubated at 37 °C for 18 h. After incubation, the number of colonies were counted 
and expressed as CFU/ml. Donor and recipient cells were mixed (2:3) and incubated for 18 h.  
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Threafter, cultures were spread onto LB agar containing nalidixic acid (25 µg/ml) and 
trimethoprim (15 µg/ml) to select for transconjugants. The frequency of transfer was calculated as 
shown in equation 1, and all transconjugants were isolated and screened for the presence of 
integrons as previously described.  E. coli CSH56 which has a natural resistance to nalidixic acid 
was used as the recipient strain.  
Frequency of transfer = 𝑛𝑜 𝑜𝑓 𝑡𝑟𝑎𝑛𝑠𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑛𝑡𝑠/𝑚𝑙
𝑛𝑜 𝑜𝑓 𝑑𝑜𝑛𝑜𝑟 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙
 
 
3.2.7 Random Amplified Polymorphism DNA (RAPD) analysis 
All integron positive isolates were subjected to RAPD analysis. Each PCR mixture (50 μl) 
contained 2.5 μl 10 × reaction buffer, 6 μl MgCl2, 10 μl dNTP, 2 μl of the arbitrary primer 1247 
(Table 3.1), 0.5 μl Taq polymerase, 2 μl DNA and 23 μl RNAse free water. Amplification was 
performed under the following conditions: 2 cycles of 94°C for 30 s, 42°C for 7 s and 72°C for 70 
s, 38 cycles of: 94°C for 1 s, 42°C for 7 s and 72°C for 70 s. A final elongation step was done at 
72°C for 5 min (Salehi et al., 2008).  The PCR products were analysed by electrophoresis on a 
1.5% agarose gel (Seakem), stained with ethidium bromide (0.5 µg/ml), and visualized. 
Photographs of RAPD-PCR patterns were taken using the Chemigenius Bioimaging System 
(Syngiene). Conversion, normalization and further analysis of RAPD patterns were done using the 
Bionumerics 6 software (Applied Maths). The dendogram was drawn by using the unweighted 




Table 3.1: Primer sequences used in this study 
 
3.3 Results 
3.3.1 Antibiotic resistance profiling of E. coli isolates 
The antibiotic resistance pattern(s) of the isolates against the 15 antibiotics are illustrated in 
Figures 3.1 and 3.2. All the 200 E. coli isolates tested were susceptible to amikacin and cefazolin. 
The highest resistance was observed towards trimethoprim (69%), followed by tetracycline (56%), 
ampicillin (52.5%), amoxycillin (40%) and doxycycline (31%). Furthermore, 27%, 21.5%, 20.5%, 
18% and 16.5% of the isolates were resistant towards nalidixic acid, ciprofloxacin, norfloxacin, 
chloramphenicol and cephalothin, respectively, while only 3.5% of the isolates exhibited 
resistance towards gentamicin and fosfomycin, and 7.5% of the isolates were resistant to 
ceftazidime. Five percent of isolates were resistant to 8 antibiotics (Figure 3.1 A), while 9% 
showed resistance to 7 antibiotics (Figure 3.1 B). A large portion (14.5%, 15%, and 39%) of 
isolates were resistant to 6, 5, and 4 antibiotics as seen in Figure 3.1 C and D, and Figure 3.2 E 
respectively. Six percent of E. coli isolates exhibited resistance towards 3 antibiotics (Figure 3.2 




    
Int1-F CAGTGGACATAAGCCTGTTC 160 Dillon et al., 2005 
Int1-R CCCGAGGCATAGACTGTA  
Int2-F CACGGATATGCGACAAAAAGGT 788 Dillon et al., 2005 
Int2-R GTAGCAAACGAGTGACGAAATG  
Int3-F GCCTCCGGCAGCGACTTTCAG 979 Dillon et al., 2005 
Int3-R ACGGATCTGCCAAACCTGACT  
5CS GGCATCCAAGCAGCAAG Variable  Meervenne et al., 
2013 3CS AAGCAGACTTGACCTGA  
1274 AAGAGCCCG Variable Salehi et al., 2008 
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F) while 11% (Figure 3.2 G) and 10.5% (Figure 2 H) of isolates were resistant to 2 and 1 



























































































  A: Eight Drug Patterns 
 
  
  B: Seven Drug Patterns 
 
 
 C: Six Drug Patterns 
 
 
  D: Five Drug Patterns 
 
Figure 3.1: Resistance spectra of E. coli isolates having eight (A), seven (B), six (C) and five (D) drug 
patterns. Amp: Ampicillin; Tet: Tetracycline; Chl: Chloramphenicol; Amo: Amoxycillin; Nal: 
Nalidixic Acid; Nor: Norfloxacin; Cip: Ciprofloxacin; Tri: Trimethoprim; Cep: Cephalothin; Dox: 






































































  E: Four Drug Patterns 
 
                   G: Two Drug Patterns 
 
   
   F: Three Drug Patterns 
 
                  
                    H: One Drug Pattern 
         
Figure 3.2: Resistance spectra of E. coli isolates having four (E), three (F), two (G) and one (H) drug 
pattern/s. Amp: Ampic llin; Tet: Tetracyclin ; Chl: Chloramphenicol; Amo: Amoxycillin; Nal: 
Nalidixic acid; Nor: Norfloxacin; Cip: Ciprofloxacin; Tri: Trimethoprim; Cep: Cephalothin; Dox: 
Doxycycline; Gen: Gentamicin; Cef: Ceftazidime; Fos: Fosfomycin 
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Of the 200 E. coli isolates analysed for the presence of integrons by PCR, 101 isolates were found 
to contain integrons. Class 1 integrons were detected in 50.5% of the isolates while class 2 was 
found in only 1%. One isolate carried both class 1 and class 2. PCR amplification using the 3CS 
and 5CS primer sets to detect gene cassette arrays revealed amplicon sizes ranging between 100 
and 1900 bp.  RFLP analysis of these fragments with the restriction enzymes HinfI and RsaI 
revealed four different RFLP types (Table 3.2). The identity of these cassettes determined via 
sequence analysis showed the presence of 3 gene cassettes, encoding genes dfrA17, dfrA12-aadA2 
and dfrA12-aadA1. Majority (76/101) of the isolates (75.24%) harbored dfrA17 which is associated 
with trimethoprim resistance, whilst 21.78% and 1.98% harbored dfrA12-aadA2 and dfrA12-
aadA1 respectively, which is associated with trimethoprim and streptomycin resistance.  Whilst 
streptomycin resistance/susceptibility was not evaluated in this study, all isolates harboring these 
cassettes were resistant to trimethoprim. PCR analysis showed that all detected integrons were 
located on both the plasmid and chromosome.  
Conjugation experiments yielded a frequency of transfer of 9.4 x 106.  Amongst the integron 
positive E. coli isolates, 3.96% were resistant to 8 antibiotics, 9.90% to 7 antibiotics and 18.81% 
were resistant to 6 antibiotics. Resistance to 5, 4, 3 and 2 antibiotics was observed in 11.88%, 
39.60%, 11.88% and 3.96% of the isolates.  Trimethoprim resistance was not observed in integron 
negative strains while doxycycline resistance was not observed in integron positive strains. Eighty 
six percent of integron positive isolates were resistant to 3 or more classes of antibiotics and were 
therefore considered to be multi-drug resistant. Majority (30.69% and 20.70%) of integron bearing, 
drug-resistant strains were isolated from the discharge and before chlorination points of the 
wastewater treatment process while 19.80% of strains were isolated from both the upstream and 
downstream points of the receiving river sources. Figure 3.3 shows the gel image depicting the 
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presence of intI in all transconjugants (n=10), indicating that tested isolates are capable of 


















Table 3.2: Antibiotic resistance phenotypes, gene cassette arrays and integron locations of 





Resistant Phenotype intI 
gene 
Gene cassettes: 





1 Amp,Tet,Amo, Tri 1 1650 – 1900 dfrA17 C, P 
2 Tet, Amo, Nal, Nor, Tri, Chl 1 1650 – 1900 dfrA17 C, P 
3 Amp, Tet, Cep, Amo, Tri, Cef 1 1650 – 1900 dfrA17 C, P 
4 Tet, Gen, Tri, Chl 1 1650 – 1900 dfrA12-aadA2 C, P 
5 Amp, Tet, Amo, Nal, Tri, Nor, Cip 1 1650 – 1750 dfrA17 C, P 
6 Amp, Tet, Amo Nal, Tri, Nor, Chl, Cip 1 1650 – 1900 dfrA17 C, P 
7 Amp, Nal, Tri, Nor 1 1650 – 1900 dfrA12-aadA1 C, P 
8 Amp, Amo, Tri 1 2000 dfrA12-aadA1 C, P 
9 Tet, Amo, Nal, Nor, Tri, Chl 1 1650 – 1900 dfrA17 C, P 
10 Tet, Amo, Tri, Cep 1 100 dfrA17 C, P 
11 Amp, Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
12 Amp, Nal, Tri, Nor 1 800 dfrA17 C, P 
13 Amp, Tet, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA12-aadA2 C, P 
14 Amp, Tet, Amo, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
15 Amp, Tet, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
16 Amp, Amo, Tri, Fos 1 1650 – 1900 dfrA17 C, P 
17 Amp, Tet, Amo, Nal, Tri, Nor, Chl 1 2000 dfrA12-aadA2 C, P 
18 Amo, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
19 Amp, Tet, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
20 Tri, Cef, Chl, Fos 1 1650 – 1900 dfrA17 C, P 
21 Amp, Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
22 Tri, Cef, Chl, Fos 1 2000 dfrA17 C, P 
23 Amp, Tet, Amo, Tri 1 1650 – 1900 dfrA12-aadA2 C, P 
24 Amp, Amo, Nal, Tri 1 1650 – 1750 dfrA17 C, P 
25 Tet, Amo, Tri, Cep 1 1650 – 1900 dfrA17 C, P 
26 Tet, Tri, Chl 1 800  dfrA17 C, P 
27 Amp, Amo, Tri 1,2 1650 – 1900 dfrA17 C, P 
28 Amp, Tet, Amo, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA17 C, P 
29 Amp, Tet, Amo Nal, Tri, Nor, Chl, Cip 1 1650 – 1900 dfrA17 C, P 
30 Tet, Amo, Nal, Nor, Tri, Chl 1 2000 dfrA17 C, P 
31 Amp, Tet, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA17 C, P 
32 Amp, Tet, Amo, Tri, Cep 1 1650 – 1900 dfrA12-aadA2 C, P 
33 Amp, Tet, Amo, Nal, Tri, Nor 1 1650 – 1900 dfrA12-aadA2 C, P 
34 Amp, Tet, Cep, Amo, Tri, Cef 1 1650 – 1900 dfrA17 C, P 
35 Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA12-aadA2 C, P 
36 Tet, Tri 1,2 2000 dfrA12-aadA2 C, P 
37 Amp, Tet, Tri 1 1650 – 1900 dfrA12-aadA2 C, P 
38 Amp, Amo, Tri, Fos 1 1650 – 1900 dfrA17 C, P 
39 Amp, Tet, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
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40 Amp, Tet, Tri, Cef 1 1650 – 1900 dfrA17 C, P 
41 Tet, Gen, Tri, Chl 1 1650 – 1900 dfrA17 C, P 
42 Amp, Tet, Amo, Nal, Tri, Nor, Chl 1 1650 – 1900 dfrA17 C, P 
43 Amp, Amo, Tri 1 1650 – 1900 dfrA17 C, P 
44 Tet, Tri, Cep, Chl 1 1650 – 1900 dfrA17 C, P 
45 Amp, Amo, Tri 1 1650 – 1900 dfrA17 C, P 
46 Amp, Tet, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA17 C, P 
47 Tet, Tri, Chl 1 2000 dfrA17 C, P 
48 Amo, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
49 Tet, Amo, Tri, Cep 1 1650 – 1900 dfrA17 C, P 
50 Amp, Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA12-aadA2 C, P 
51 Tet, Tri, Cep, Chl 1 1650 – 1900 dfrA12-aadA2 C, P 
52 Amp, Tet, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA12-aadA2 C, P 
53 Amp, Nal, Tri, Nor 1 100 dfrA17 C, P 
54 Amp, Tet, Tri, Cef 1 1650 – 1900 dfrA17 C, P 
55 Amp, Tet, Amo, Nal, Tri, Nor, Chl 1 1650 – 1900 dfrA17 C, P 
56 Amp, Tet, Cep, Amo, Tri, Cef 1 1650 – 1900 dfrA12-aadA2 C, P 
57 Tet, Gen, Tri, Chl 1 2000 dfrA17 C, P 
58 Amp, Tet, Amo, Tri 1 1650 – 1900 dfrA17 C, P 
59 Tet, Tri, Cep, Chl 1 1650 – 1900 dfrA12-aadA2 C, P 
60 Amp, Tet, Tri 1 1650 – 1900 dfrA17 C, P 
61 Amp, Tet, Amo, Tri 1 1650 – 1900 dfrA12-aadA2 C, P 
62 Tet, Tri, Chl 1 1650 – 1900 dfrA17 C, P 
63 Amp, Tet, Amo Nal, Tri, Nor, Chl, Cip 1 1650 – 1900 dfrA17 C, P 
64 Amp, Nal, Tri, Nor 1 2000 dfrA17 C, P 
65 Amp, Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
66 Amp, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
67 Tet, Amo, Nal, Nor, Tri, Chl 1 1650 – 1900 dfrA12-aadA2 C, P 
68 Amp, Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
69 Tet, Tri, Cep, Chl 1 1650 – 1900 dfrA17 C, P 
70 Amp, Tet, Amo, Nal, Tri, Nor, Chl 1 1650 – 1900 dfrA12-aadA2 C, P 
71 Amp, Tet, Amo, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA17 C, P 
72 Amp, Tet, Amo, Tri, Cep 1 1650 – 1900 dfrA17 C, P 
73 Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
74 Amo, Nal, Tri, Nor 1 800 dfrA17 C, P 
75 Amp, Tet, Nal, Tri, Nor, Cip 1 2000 dfrA12-aadA2 C, P 
76 Tet, Tri, Chl 1 1650 – 1900 dfrA17 C, P 
77 Amp, Amo, Tri, Fos 1 1650 – 1900 dfrA17 C, P 
78 Tri, Cef, Chl, Fos 1 1650 – 1900 dfrA17 C, P 
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Table 3.2 continued… 
 
 
Amp: Ampicilin; Tet: Tetracycline; Chl: Chloramphenicol; Amo: Amoxycillin; Nal: Nalidixic acid; Nor: Norfloxacin; Cip: 
Ciprofloxacin; Tri: Trimethoprim; Tet: Tetracycline; Gen: Gentamicin; Fos: Fosfomycin; Cef: Ceftadizime; Cep: 















74 Amo, Nal, Tri, Nor 1 800 dfrA17 C, P 
75 Amp, Tet, Nal, Tri, Nor, Cip 1 2000 dfrA12-aadA2 C, P 
76 Tet, Tri, Chl 1 1650 – 1900 dfrA17 C, P 
77 Amp, Amo, Tri, Fos 1 1650 – 1900 dfrA17 C, P 
78 Tri, Cef, Chl, Fos 1 1650 – 1900 dfrA17 C, P 
79 Tet, Tri, Cep, Chl 1 1650 – 1900 dfrA17 C, P 
80 Amo, Nal, Tri, Nor 1 1650 – 1900 dfrA12-aadA2 C, P 
81 Amp, Tet, Amo, Nal, Tri, Nor 1 1650 – 1900 dfrA12-aadA2 C, P 
82 Amp, Tet, Nal, Tri, Nor 1 1650 – 1900 dfrA17 C, P 
83 Amp, Tet, Amo, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA17 C, P 
84 Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA12-aadA2 C, P 
85 Amp, Tet, Nal, Tri, Nor 1 1650 – 1750 dfrA17 C, P 
86 Amp, Tet, Amo Nal, Tri, Nor, Chl, Cip 1 1650 – 1900 dfrA17 C, P 
87 Amp, Tet, Tri, Cef 1 1650 – 1900 dfrA17 C, P 
88 Amp, Tet, Cep, Amo, Tri, Cef 1 1650 – 1900 dfrA17 C, P 
89 Tet, Tri 1 1650 – 1900 dfrA17 C, P 
90 Tet, Tri 1 1650 – 1900 dfrA17 C, P 
91 Amp, Tet, Amo, Nal, Tri, Nor, Cip 1 1650 – 1900 dfrA12-aadA2 C, P 
92 Tri, Cef, Chl, Fos 1 1650 – 1900 dfrA17 C, P 
93 Tri, Cef, Chl, Fos 1 1650 – 1900 dfrA17 C, P 
94 Tet, Gen, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
95 Amp, Tet, Tri 1 1650 – 1900 dfrA17 C, P 
96 Amp, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
97 Tri, Cef, Chl, Fos 1 1650 – 1900 dfrA17 C, P 
98 Amp, Amo, Nal, Tri 1 1650 – 1900 dfrA17 C, P 
99 Amp, Tet, Amo, Tri, Cep 1 2000 dfrA12-aadA2 C, P 
100 Amp, Tet, Tri, Cef 1 1650 – 1900 dfrA17 C, P 




Figure 3.3: Agarose gel showing the presence of class 1 integrons in positive 
transconjugants (n=10) 
Where: Lane 1: Molecular weight marker; Lanes 2-10: Amplification of class 1 integron (160bp) in positive transconjugants 
 
3.3.3 RAPD analysis of integron positive E. coli isolates 
Analysis of RAPD-PCR patterns obtained with primer 1247 for all integron bearing isolates 
resulted in the UPGMA dendogram depicted in Figure 4. The dendogram indicates the presence 
of 7 clusters. Cluster I comprised of 7 isolates, with majority of isolates having similar resistance 
phenotypes. Majority of the isolates in cluster I (85.71%) were resistant to the penicillin and 
tetracycline class of antibiotics whilst no isolates showed resistance to fosfomycin.  Cluster II 
comprised a large portion of the total number of isolates tested with 31.68% (31/101) of tested 
isolates being grouped into this cluster.  Similarities to cluster I was observed in which a majority 
of isolates were resistant to the penicillin (ampicillin and amoxicillin) and tetracycline 
(tetracycline) class of antibiotics. However, the frequency of tetracycline resistance was lower in 
isolates belonging to cluster II when compared to those in cluster I.  In addition, 4 isolates (12.50%) 
showed resistance to fosfomycin, which is a phenotypic trait not observed in isolates belonging to 
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isolates. Once again, resistance to tetracycline was prevalent among the isolates in this cluster 
followed by resistance to ampicillin (59.46%) and amoxicillin (54.05%). However, isolates in 
cluster III showed an increased resistance to cephalothin (18.92%) and ciprofloxacin (18.92%), 
and a decrease in resistance to the penicillin class of antibiotics when compared to clusters I and 
II. Resistance to fosfomycin was not observed in this cluster. Cluster IV contained 6 isolates, all 
of which are susceptible to ciprofloxacin and gentamicin. Fifty percent of isolates in this cluster 
exhibited resistance towards ampicillin, amoxicillin, tetracycline, norfloxacin and nalidixic acid. 
All E. coli isolates in cluster V (n=7) showed resistance to tetracycline and susceptibility towards 
fosfomycin. Cluster VI comprises of 9 isolates, all of which show susceptibility to cephalothin and 
ciprofloxacin. The highest resistance was observed towards tetracycline (55.56%) and the 
penicillin class of antibiotics (ampicillin: 66.67%; amoxicillin: 55.56%). In addition a decrease in 
resistance towards norfloxacin (11.11%), which belongs to the class quinolones was noted in this 
cluster when compared to previously defined clusters. All isolates belonging to cluster VII (n=3) 
showed susceptibility towards gentamicin (aminoglycosides), chloramphenicol (phenicols), 
fosfomycin (fosfomycins) and all tested antibiotics belonging to the quinolone class (norfloxacin, 
ciprofloxacin and nalidixic acid). Tetracycline resistance (100%) was observed in all isolates 


































































































































































































































Figure 3.4: UPGMA dendogram derived from a comparison of RAPD patterns of E. coli 





Integrons play a major role in the dissemination of antibiotic resistance genes in the environment. 
The detection frequency of integrons (50.5%) in the present study (Table 3.2) is much higher than 
reported values for E. coli isolates from surface water studies in France (11%) (Laroche et al., 
2009), and the Czech Republic (29.6%) (Dolejska et al., 2009), and higher than values obtained 
using clinical isolates (Vinue et al., 2010).  This may suggest that a stronger selective pressure 
exists in the WWTPs and respective receiving surface waters chosen for this study.  The results 
obtained in this study is consistent with previous studies by Chen et al. (2010) in which only 
classes 1 and 2 integrons were detected. The high prevalence of class 1 integrons over class 2 
integrons obtained in this study is also consistent with studies by Han et al. (2012). The results 
demonstrate that class 1 integrons are more prevalent as antibiotic resistant E. coli strains in the 
Durban area. Class 3 integrons are considered rare even in clinical isolates and were not detected 
in this study.  So far, only a few class 3 integrons have been studied in detail (Correia et al., 2003; 
Lu et al., 2010). 
The prevalence of gene cassettes observed in this study is higher than that obtained in similar 
studies (Lu et al., 2010).  However, the identity of the gene cassettes in the present study was 
similar to that reported by Lu et al. (2010) and Sanchez et al. (2002) in which resistance to 
trimethoprim and aminoglycosides were widespread among isolates harboring class 1 integrons.  
Results from this study also corroborate previous reports by Povilonis et al. (2010) and Lu et al. 
(2010) implicating dihydrofolate reductase genes (dfrA12, dfrA1 and dfrA17) as the most prevalent 
genes found in integron positive isolates. This was often accompanied by aadA1 or aadA2 which 
confers resistance to aminoglycosides (Lu et al., 2010). These two types belong to the most 
common integron types found in E. coli (van Meervenne et al., 2013). However, not all isolates 
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which harbored the aadA1 cassettes in this study exhibited phenotypic resistance towards 
aminoglycosides. There were no novel gene cassette arrangements or gene cassettes found in the 
E. coli isolates in this study when compared to previous studies.  
In this study, high resistance rates of E. coli to tetracycline, ampicillin and amoxicillin was 
observed. This most likely arose from the long term and widespread use of these antimicrobials 
for the treatment of various diseases in clinical and agricultural settings in South Africa.  According 
to Mellon et al. (2011), the most extensively sold antibiotics in South Africa include: tylosin, 
tetracycline, sulfonamides and penicillins.  In addition, the application of these drugs in food and 
animals in particular may lead to a selection of resistant strains of bacteria, which could lead to 
treatment problems in infected humans and animals. The highest resistance amongst integron 
positive isolates was observed towards sulfonamides, tetracyclines, penicillins and phenicols.  
Integron positive strains were more resistant to these classes of antibiotics when compared to 
integron negative strains.  The resistance to trimethoprim observed in this study can be attributed 
to the presence of integrons while resistance to tetracycline and ampicillin could be due to the 
association of mobile integrons with other MGEs such as plasmids and transposons (White et al., 
2001; van Meervenne et al., 2013). 
According to Vo et al. (2006), the location of antimicrobial resistance genes in the bacterial 
chromosome contributes to clonal spread of resistance genes on the conjugative plasmid, which 
promotes horizontal transfer. Hsu et al. (2006) demonstrated that class 1 integrons were located 
on conjugative plasmids, while others reported integrons to be located mainly on the chromosome 
(Vo et al., 2006).  In the current study, integrons were found on both the chromosome and plasmid 
in all isolates, indicating that there were both vertical and horizontal transfers of the resistance 
gene among these isolates. Previous studies on the location of integrons have also revealed the 
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presence of 70.7% of class 1 integrons on both the plasmid and chromosome (Lu et al., 2010).  
The current study also demonstrated that plasmid encoded class 1 integrons could be transferred 
via conjugation to recipient strains, similar to the observations in previous reports (Zhang et al., 
2009). The transfer of integrons via conjugation enables resistance determinants on gene cassettes 
to be transferred to strains devoid of such traits, thus contributing to the dissemination of antibiotic 
resistance genes (ARGs) in bacteria.  It can be said that the environment in a WWTP could 
facilitate HGT as they combine several favourable factors namely: a high cell density sustained by 
a nutrient rich environment, and a recurrent contamination with both antibiotics and antibiotic 
resistant bacteria (ARB) (Rizzo et al., 2013). 
The RAPD technique accurately differentiates strains of E. coli by means of the number and 
position of the amplified DNA fragments.  Polymorphism is then observed and rated on the 
presence or absence of a DNA fragment and relates sequence variation due to nucleotide insertion, 
deletion or substitution (McGregor et al., 2000). The greater the differences in the individual 
patterns, the more unrelated the strains are from one another (Fei et al., 2003).   This technique 
was used to confirm the phenotypic and genotypic identities of integron bearing, E. coli strains 
and to determine if these strains shared any clonal relationships. All isolates with similar banding 
patterns were grouped into a single cluster, resulting in the presence of 7 distinct clusters as shown 
by the UPGMA dendogram (Figure 3.4). All clusters contained many sub-clusters, indicating that 
there is considerable polymorphism amongst the strains in each group. However, all strains 
containing similar resistant phenotypes appear to be genetically related. This is confirmed by the 
presence of many roots within the tree, which not only indicate a relationship between strains in 
the same cluster but show a common link between E. coli strains in all clusters. It can be assumed 
that this close relationship may be due to the presence of integrons, which have been shown to 
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have the ability to move between strains and confer resistance to antibiotics. 
3.5 Conclusion 
In summary, the present study characterized and compared antibiotic resistant E. coli isolates 
obtained from treated wastewater effluent and receiving aquatic milieu. The presence of integrons 
was also determined and the impact of their presence within antibiotic resistant isolates was 
evaluated. In addition, the ability to transfer plasmids encoding resistance determinants via 
conjugation was evaluated.  The evidence suggests that WWTPs are potential hotspots for ARB 
and could possibly promote the dissemination of ARGs amongst bacteria due to the unique 
selective pressures that exist within this environment. The clonal relationships seen between 
antimicrobial resistant, integron bearing strains highlights the fact that isolates exhibiting 
resistance to certain classes of antibiotics are most often related. This may be due to a common 
ancestor or may be attributed to the presence of MGEs, which transfer resistance genes found in 
gene cassettes. The RAPD technique is therefore useful in characterizing isolates, which may have 
experienced genomic changes before or after resistance has developed. The current study is in 
agreement with previous reports by Gallert et al. (2005), Ferreira daSilva et al. (2006), Goñi-Urriza 
et al. (2000), Baquero et al. (2008), Martínez (2009), and Servais and Passerat (2009) on 
antimicrobial resistance in WWTPs, which have all indicated that WWTPs are among the leading 
reservoirs of ARB and ARGs in the environment. This calls for more stringent monitoring of 
antimicrobial use or the search for alternate treatment options in an attempt to prevent the spread 






GENERAL DISCUSSION AND CONCLUSION 
 
4.1 Research in perspective 
Water remains as an essential resource needed for everyday activities. Usafe and insufficient 
drinking water, and inadequate sanitation are frequently identified as one of the principal causes 
of water-related diseases (DWAF, 2013). Unrelenting urbanization as a result of increased 
population also places strain on already stressed water supplies (Ashbolt, 2004). Inadequately 
treated effluent from wastewater treatment plants (WWTPs) are largely responsible for the high 
microbial loads found in receiving surface waters. These microbial populations are resistant to 
commonly used antibiotics and have the potential to cause disease (Stalder et al., 2012). In 
addition, they have the ability to transfer resistant determinants, which pose challenges to the 
treatment of bacterial infections in clinical settings.  
 
Bacterial analysis of the treated effluent and receiving surface water samples from the Northern 
wastewater treatment plant (NWWTP) and the New Germany treatment works (NGTWs) as 
presented in chapter two, indicated variability in E. coli populations obtained from all sampling 
points. It can be deduced that the larger of the plants, NWWTP was inefficient in reducing E. coli 
populations for 3 out of the 6 months of sampling. Treatment efficiency rates of 62.82%, 25.00% 
and 19.25%, were recorded for the months of May, June and July respectively. The higher 
microbial loads obtained at the DP during March, April and August at NWWTP may be attributed 
to the upgrade of plant infrastructure going on at the time. However, poorly maintained outfall 
pipes seen at the plant were not being upgraded and this may be one of the major contributing 
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factors to the increased bacterial load. The discharge of waste by informal settlement dwellers into 
the surface waters did not seem to impact the microbial load obtained at the US and DS points of 
the uMgeni River as E. coli populations at these points were relatively low when compared to the 
DP which is directly under the influence of the wastewater treatment plant. The low populations 
obtained downstream of the uMgeni River receiving effluent from the NWWTP may be due to the 
dilution effect of “clean” water flowing from the US point. In contrast, the NGTWs appeared to 
be efficient, having the ability to reduce E. coli populations by over 93% for 4 out of the 6 months 
of sampling. This efficiency may be attributed to the smaller operating capacity of the plant as well 
as the influx of chemicals and dyes from nearby industries, which were suspected to have 
inhibitory effects on the E. coli populations. However, although both plants displayed the ability 
to treat wastewater, this was not to acceptable standards as stipulated by the Department of Water 
Affairs, which requires 0 CFU/ml for E. coli in water used for domestic purposes.  Results from 
this study therefore highlight the ineffectiveness of WWTPs in question.  In addition, it 
demonstrates the ability of certain strains of E. coli to survive tertiary treatment (chlorination) and 
pollute receiving surface waters. 
 
The physico-chemical profile of any water sample is easily affected by the wastewater treatment 
process. The amount of dissolved oxygen is easily affected by the temperature of the water during 
the treatment process, while the biochemical oxygen demand (BOD) and chemical oxygen demand 
(COD) is affected by the influx of organic waste, as well as failing septic systems. This study 
showed that although the NWWTP was not as efficient in reducing the E. coli loads compared to 
NGTWs, it was efficient in reducing majority of the physico-chemical parameters tested. BOD 
and COD concentrations for the NWWTP showed that this plant is not the only source of pollution 
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of receiving surface waters, but that the NGTWs definitely is a major contributor to the bacterial 
pollution of the Aller River.  This is evident by an increase in COD, TDS, nitrate and phosphate 
levels at the DP of the NGTWs after the treatment process.  Elevated concentrations of any of 
these parameters has been shown to alter the normal biological functioning of ecosystems, which 
not only affects freshwater life, but human populations too (DWAF, 1996).  The physico-chemical 
profile of the water samples studied, discourages the use of this water for domestic purposes based 
on the South African water quality guidelines for domestic use (DWAF, 1996). 
 
The virulence gene and antimicrobial resistance profile of E. coli isolates were also investigated 
and reported in chapter two and provide further insight into the potentially harmful nature of E. 
coli isolates being discharged into surface waters as a result of improperly treated wastewater 
effluent. Determination of the presence of stx1, stx2, hly, eaeA and fliC genes revealed that the 
frequency of these genes in E. coli isolates detected in the current study were lower than that of 
previous studies. No definite conclusions could be drawn without further research. However, it 
should be noted that 14% of tested isolates contained the eaeA gene in conjunction with either stx1 
or stx2, which is characteristic of E. coli having the ability to cause hemorrhagic colitis. In addition, 
this study showed that certain isolates (18%) are now resistant to drugs (chloramphenicol), which 
is worrisome as these drugs are only reserved for life threatening situations. In 2014, the World 
Health Organization (WHO) named E. coli as an organism of interest due to the rise of resistance 
towards fluoroquinolones (WHO, 2014). As presented in chapter two, the E. coli isolates exhibited 
20.5% and 21.5% resistance towards norfloxacin and ciprofloxacin respectively, which are 
antibiotics belonging to fluroquinolone class of antibiotics. Trends of resistance observed towards 
gentamicin and the β-lactam group of antimicrobial agents were similar to that of Ram et al. (2008) 
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and Luczkiewicz et al. (2010), while an increase in resistance towards the β-lactam group was 
observed when compared to previous studies conducted in the Durban area in 2009 (Olaniran et 
al., 2009).  Rizzo et al. (2013) has indicated that WWTPs are one of the main sources of antibiotics, 
antibiotic resistance genes (ARGs) and antibiotic resistant bacteria (ARB) into the environment.  
 
Resistance to antimicrobial agents has been attributed to the spread of mobile genetic elements 
(MGEs) which confer resistance to other organisms (Olaniran et al., 2009;WHO, 2014). MGEs 
play an important role in the dissemination of ARGs in the environment through the mobilization 
of gene cassettes by horizontal gene transfer (HGT).  The frequency of integrons in the current 
study (50.5%) is much higher than reported values from previous surface water studies in France 
(11%) and the Czech Republic (29.6%) (Dolejska et al., 2009; Laroche et al., 2009). To the best 
of our knowledge, no study has been undertaken to determine the presence of integrons within E. 
coli isolates obtained from effluents of WWTPs and receiving surface waters in Durban, South 
Africa.  The detection of class 1 and 2 integrons were consistent with previously reported studies 
as the presence of class 3 integrons in E. coli is rare.  The presence of the dfrA17/dfrA12 and aadA2 
gene cassettes through RFLP sequence analysis were also consistent with previous reports 
(Sanchez et al., 2002;Lu et al., 2010). The presence of these specific cassettes corresponded to the 
phenotypic characteristics displayed by isolates harboring class 1 integrons, in which both 
resistance to trimethoprim and aminoglygosides were noted.  
 
As the mobilization of integrons via conjugation allows for resistance determinants on gene 
cassettes to be transferred, conjugation experiments involving integron positive strains were 
carried out as mentioned in chapter three.  It was observed that all integron-bearing isolates 
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contained integrons on both the plasmid and chromosome, indicating that horizontal and vertical 
transfers of resistance genes between strains did exist. Additionally, these plasmids could be 
transferred to isolates devoid of integrons, emphasizing the fact that the rise in antimicrobial 
resistance may be due to the transfer of resistance genes to non-resistant strains. A review by Rizzo 
et al. (2013) suggests that WWTPs provide a favourable environment for the facilitation of HGT 
due to the nutrient rich environment and a recurrent contamination of antibiotics.  Further analysis 
of integron bearing isolates using the RAPD-PCR technique indicated that isolates having similar 
resistance patterns could be grouped together, indicating a common linkage.  Linkages (roots), 
which can be seen in the UPGMA dendogram presented in chapter three indicates a relationship 
between all strains and possibly a common ancestor. It can also be speculated that this relationship 
involves the transfer of integrons. 
 
The overall findings of this study emphasizes the need for constant evaluation and monitoring of 
WWTPs by the relevant authorities, to ensure that plants are efficient and comply with the set 
guidelines.  This will in-turn ensure better public health and safety.  This study indicates that 
WWTPs are indeed hotspots for antibiotic resistance, and that the inefficiency of WWTPs resulted 
in the discharge of potentially pathogenic and multi-drug resistant bacteria into surface waters used 
for domestic purposes. In addition, these bacteria had the ability to transfer resistance determinants 







4.2 Potential for future development of the study 
The epidemiological importance of pathogenic E. coli continues to be of public health concern 
(EFSA, 2011; Dadie et al., 2014).  Although all E. coli strains are potentially virulent, only some 
have acquired virulence factors and are responsible for the recent outbreaks of digestive and extra 
–intestinal infections as observed in Germany in 2011 and the USA in 2014 (Dadie et al., 2014).  
According to Dadie et al. (2014), one of the alternatives for the control of such infections involves 
epidemiological surveillance, which itself would be based on spatio-temporal documentation of 
phenotypic and molecular determinants of pathotypes.  The data generated would be useful in 
implementing outbreak prevention models, to reveal the diversity of E. coli strains, risk factors, 
and also provide traceability and evolutionary history of pathotypes (Dadie et al., 2014).  
Therefore, future work on these E. coli isolates would involve the differentiation of isolates into 
pathotypes based on the PCR detection of virulence genes, which are specific to each pathotype. 
It is also proposed that the sample size be increased so as to maximize the chances of detecting the 
desired pathotypes.  Pathotypes to be investigated would include: enterohemorrhagic E. coli 
(EHEC), enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), enteropathogenic E. coli 
(EPEC), enteroaggregative E. coli (EAEC), diffusely adherent E. coli (DAEC) and uropathogenic 
E. coli (UPEC). Uropathogenic E. coli (UPEC) is responsible for over 90% of urinary tract 
infections (UTIs). Cytotoxic necrotozing factor type 1 (CNF-1) is a bacterial toxin, which is found 
in certain UPEC and diarrheagenic strains of E. coli and which is known to target the Rho family 
of small GTP-binding proteins (Mills et al., 2000).  Reports by Mills et al. (2000) show that this 
toxin has a number of effects on mammalian tissue, some of which include: necrosis of skin with 
intradermal inoculation of E. coli lysates containing the toxin; enlargement and multinucleation of 
tissue culture cells after treatment with crude toxin preparations; actin stress fiber formation after 
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exposure to CNF-1; phagocytic activity in human Hep-2 epithelial cells and impairment of cell 
repair in human bladder cells.  Although the effects of CNF-1 have been investigated, the exact 
role of CNF-1 in the pathogenesis of UTIs remain unknown.  It is therefore important that the 
contribution of CNF-1 to uropathogenesis be investigated so as to add to the pool of existing 
knowledge.  Thus far, no work has been done in the Durban area involving UPEC strains obtained 
from wastewater and the effect of resulting toxins on human cell lines from relevant physiological 
sites.  It would be of interest that future work involve determining the effect of CNF-1 on human 
bladder, ureter and kidney cell lines. All cell lines would be treated with CNF-1 and the 
intoxication phenotype would be determined using specific assays and immunofluorescence 
microscopy.  Intoxication phenotypes to be evaluated include cytotoxicity, actin fiber formation, 
Rho modification and multi-nucleation (Mills et al., 2000). The relationship between virulent 
clones of E. coli and their phylogenetic groups can also be established, therefore, molecular 
serotyping (by PCR-RFLP detection of the operon O rfb gene) and differentiation into distinct 
phylogenetic groups could also provide valuable insight into the study, as data on the molecular 
characteristics of pathogenic E. coli isolated from wastewater in South Africa is rare.  
 
Virulent strains of E. coli may also possess other traits, which make infections mediated by them 
difficult to treat. Pathogens carrying Extended-Spectrum-β-Lactamases (ESBLs) are one of the 
main challenges to antibiotic therapy (Zarfel et al., 2013).  ESBLs are defined as enzymes, which 
have the ability to hydrolyze penicillins, aztreonam and 1st, 2nd, and 3rd generation cephalosporins.  
They are mainly found in the family Enterobacteriaceae, in particular E. coli and Klebsiella (Zarfel 
et al., 2013). Till now, over 200 different ESBL genes encoding β-lactamases have been identified. 
According to Zarfel et al. (2013), these genes are genetically diverse and highly mobile, due to 
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their presence on MGEs. In addition, HGT is said to play an important role in spreading resistance 
to different strains. Not only has ESBL-producing bacteria been found in wastewater, but, the 
distribution of ESBL genes in non-human reservoirs is said to be significantly different (Zarfel et 
al., 2013). Since the concepts of antibiotic resistance, virulence genes, MGEs and HGT has already 
been explored, it would be interesting to establish if any relationships exist between ESBL 
producing E. coli within this group.  Analysis of environmental samples of E. coli in this regard is 
important to understand how antibiotic resistance is transferred to humans (Zarfel et al., 2013).   
 
Antibiotic resistant bacteria and associated resistance determinants have become an important 
environmental contamination issue. Information on the prevalence of ARB which are potentially 
pathogenic, could serve as a basis for proper selection of optimal wastewater treatment processes 
as it has been established that WWTPs and receiving surface waters are reservoirs for ARGs and 
ARB (Titilawo et al., 2015). Genes encoding resistance towards aminoglycosides, sulfonamides, 
tetracyclines and β-lactams have been frequently detected in bacterial isolates from wastewater 
(Lee et al., 1998; Lin and Biyela, 2005; Park et al., 2003; Schwartz et al., 2003; Mukherjee and 
Chakraborty, 2006; Poppe et al., 2006).  Numerous waterborne outbreaks have been attributed to 
multi-drug resistant E. coli worldwide, and the high prevalence of multi-drug resistance warrants 
a need for antibiotic surveillance and the planning of active interventions to reduce drug resistance 
worldwide (Olayinka et al., 2004; Titilawo et al., 2015). It is then proposed that future work 
involve the testing of a broader range of antibiotics using the Kirby-Bauer disc diffusion assay. 
Isolates will be exposed to a panel of antibiotics not previously tested, which include: 
streptomycin, kanamycin, neomycin, cefepime, meropenem, imipenem, gatilofloxacin, 
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sulfamethoxazole and nitrofurantoin.  In addition, isolates will be screened for the presence of 19 
ARGs belonging to 5 classes of antibiotics. 
 
According to Yu et al. (2010), resistance to the aminoglycosides class of antibiotics is becoming 
a serious clinical problem.  Gram-negative rods such as E. coli produce many aminoglycoside-
modifying enzymes such as phosphotransferases, nucleotidyltransferases and acetyltransferases 
(Bercot et al., 2011). In addition, plasmid-mediated 16S rRNA methylases identified in members 
of the family Enterobacteriaceae have been shown to confer high levels of resistance to 
aminoglycosides (Bercot et al., 2011). These methylases have now emerged as unique mechanisms 
for high-level resistance to arbekacin, amikacin, tobramycin and gentamicin, which has become 
quite problematic in clinical settings (Yu et al., 2010). To date, six plasmid-encoded methylases 
(ArmA, RmtA, RmtB, RmtC, RmtD and NpmA) have been identified in gram-negative bacilli, 
and many of these have been identified specifically in E. coli (Yu et al., 2010; Bercot et al., 2011). 
In addition to this, recent studies have shown that 16S rRNA methylase genes are most commonly 
detected in ESBL producing isolates which harbor a gene encoding a carbapenemase NDM-1, 
which further exacerbates the issue of multi-drug resistance.  There is clearly an emerging spread 
of 16S rRNA methylase producers and epidemiological data regarding 16S rRNA methylase 
production in E. coli isolates in South Africa is lacking.  Future work on these E. coli isolates from 
wastewater would involve the identification of carbapenemase NDM-1, screening of the isolates 
for methylase genes via PCR, as well as conjugation experiments to determine if aminoglycoside 
resistance is transferable in 16S rRNA methylase bearing plasmids.  The relationship between the 
ESBL producing isolates, isolates harboring carpapenemase NDM-1 and methylase producers will 
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APPENDIX I: MICROBIAL ANALYSIS 
 
A: Northern Wastewater Treatment Plant 
 















Table 2: CFU/ml obtained across all sampling points in April 
NWWTP: April 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - 320 6.4 108 2.16 40 0.80 3 0.06 
BC 2 - - Tmtc - 340 6.8 115 2.30 44 0.88 6 0.12 
DP 1 Tmtc - Tmtc - Tmtc - 348 6.96 168 3.36 79 1.58 
DP 2 Tmtc - Tmtc - Tmtc - 232 4.64 153 3.06 80 1.60 
US 1 - - - - 22 0.44 8 0.16 1 0.02 0 0 
US 2 - - - - 35 0.70 4 0.08 0 0 10 0.20 
DS 1 - - - - 580 11.60 103 2.06 12 0.24 0 0 
DS 2 - - - - 512 10.24 96 1.92 15 0.3 3 0.06 
NWWTP: March 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - 212 4.24 30 0.60 6 0.12 2 0.04 
BC 2 - - Tmtc - 272 5.44 23 0.46 4 0.08 0 0 
DP 1 Tmtc - 528 10.56 312 6.24 - - - - - - 
DP 2 Tmtc - 1040 20.80 720 14.40 - - - - - - 
US 1 - - - - 19 0.38 8 0.16 4 0.08 1 0.02 
US 2 - - - - 4 0.08 10 0.20 1 0.02 2 0.04 
DS 1 - - - - 40 0.80 1 0.02 1 0.02 0 0 
DS 2 - - - - 30 0.60 4 0.08 0 0 2 0.04 
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 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc Tmtc Tmtc - Tmtc - 132 2.64 35 0.7 
BC 2 - - Tmtc Tmtc Tmtc - Tmtc - 180 3.6 29 0.58 
DP 1 - - Tmtc Tmtc Tmtc Tmtc Tmtc - 48 0.96 38 0.76 
DP 2 Tmtc - Tmtc Tmtc Tmtc Tmtc Tmtc - 68 1.36 40 0.8 
US 1 Tmtc - - - 39 0.78 11.00 0.22 4.0 0.08 2 0.04 
US 2 - - - - 37 0.74 8.00 0.16 5.0 0.10 1.08.08 0.02 
DS 1 - - - - 30 0.60 5.00 0.10 0 0 0 0 
DS 2 - - - - 34 0.68 5.00 0.10 0 0 0 0 
NWWTP: June 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc Tmtc Tmtc - 80 1.6 13 0.26 12 0.24 
BC 2 - - Tmtc Tmtc Tmtc - 100 2 17 0.34 9 0.18 
DP 1 - - Tmtc Tmtc Tmtc Tmtc 67 1.34 10 0.2 5 0.1 
DP 2 - - Tmtc Tmtc Tmtc Tmtc 68 1.36 16 0.32 4 0.08 
US 1 - - - - Tmtc - 13 0.26 2 0.04 0 0 
US 2 - - - - Tmtc - 10 0.2 6 0.12 1 0.02 
DS 1 - - - - Tmtc - 17 0.34 12 0.24 5 0.1 
DS 2 - - - - Tmtc - 10 0.2 8 0.16 11 0.22 
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Table 6: CFU/ml obtained across all sampling points in August
NWWTP: July 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - Tmtc - 75 1.5 7 0.14 0 0 
BC 2 - - Tmtc - Tmtc - 69 1.38 5 0.1 0 0 
DP 1 6 0.12 3 0.06 0 0 0 0 0 0 0 0 
DP 2 8 0.16 1 0.02 0 0 0 0 0 0 0 0 
US 1 - - - - 22 0.44 5 0.1 1 0.02 0 0 
US 2 - - - - 19 0.38 3 0.06 0 0 0 0 
DS 1 3 0.06 1 0.02 0 0 0 0 0 0 0 0 
DS 2 4 0.08 0 0 0 0 0 0 0 0 0 0 
NWWTP: August 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc Tmtc Tmtc - 248 4.96 190 3.80 79 1.58 
BC 2 - - Tmtc Tmtc Tmtc - 245 4.9 185 3.70 86 1.72 
DP 1 - - Tmtc    Tmtc Tmtc - 264 5.28 189 3.78 112 2.24 
DP 2 - - Tmtc Tmtc Tmtc - 265 5.3 193 3.86 99 1.98 
US 1 - - - - 36 - 9 0.18 6 0.12 1 0.02 
US 2 - - - - 41 - 12 0.24 3 0.06 2 0.04 
DS 1 - - - - 10 - 2 0.04 0 0 0 0 







Table 7:  Average CFU/ml for March 
 
Average cfu/ml x 103 : March 
Sample Point Value 1 Value 2 Avg Std dev 
BC 0.424 0.544 0.484 0.85 
DP 0.624 1.44 1.032 5.77 
US 0.038 0.038 0.038 0.21 
DS 0.08 0.06 0.07 0.14 
 
Table 8:  Average CFU/ml for April 
 
Average cfu/ml x 103 : April 
Sample Point Value 1 Value 2 Avg Std dev 
BC 2.16 2.3 2.23 2.27 
DP 6.96 4.64 5.8 3.41 
US 0.16 0.08 0.12 1.08 
DS 2.06 1.92 1.99 0.10 
 
Table 9:  Average CFU/ml for May 
 
Average cfu/ml x 103 : May 
Sample Point Value 1 Value 2 Avg Std dev 
BC 26.4 36 31.2 5.54 
DP 9.6 13.6 11.6 2.31 
US 0.8 1 0.9 0.12 
DS 1 1 1 0.00 
 
 
Table 10:  Average CFU/ml for June 
 
Average cfu/ml x 103 : June 
Sample Point Value 1 Value 2 Avg Std dev 
BC 1.6 2 1.8 0.23 
DP 1.34 1.36 1.35 0.01 
US 0.26 0.2 0.23 0.03 




Table 11:  Average CFU/ml for July 
 
Average cfu/ml x 103 : July 
Sample Point Value 1 Value 2 Avg Std dev 
BC 3.28 3.16 3.22 0.07 
DP 2.64 2.56 2.6 0.05 
US 0.7 0.6 0.65 0.06 
DS 0.52 0.6 0.56 0.05 
 
 
Table 12:  Average CFU/ml for August 
 
Average cfu/ml x 103 : August 
Sample Point Value 1 Value 2 Avg Std dev 
BC 4.96 245 4.93 0.08 
DP 5.28 265 5.27 0.40 
US 0.08 12 0.21 0.08 
DS 0.04 1 0.03 0.06 
 159 
B: New Germany Treatment Works 
 






























 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - 260 5.2 64 1.28 7 0.14 1 0.02 
BC 2 - - Tmtc - - - 56 1.12 4 0.08 1 0.02 
DP 1 6 0.12 3 0.06 6 0.12 0 0 0 0 - - 
DP 2 11 0.22 3 0.06 0 0 0 0 0 0 - - 
US 1 - - - - 184 3.68 8 34 1 0.02 0 0 
US 2 - - - - 232 4.6 10 17 3 0.06 1 0.02 
DS 1 - - - - 0 0 0 0 0 0 0 0 
DS 2 - - - - 0 0 0 0 0 0 0 0 
NGTW: April 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - 48 0.96 11 0.22 1 0.02 0 0 0 0 
BC 2 - - 50 1 7 0.14 0 0 0 0 0 0 
DP 1 - - 0 0 0 0 0 0 - - - - 
DP 2 - - 1 0.02 0 0 3 0.06 - - - - 
US 1 - - - - 360 7.2 33 0.66 3 0.06 0 0 
US 2 - - - - 400 8 31 0.62 4 0.08 0 0 
DS 1 - - - - 0 0 0 0 0 0 2 0.04 
DS 2 - - - - 0 0 0 0 0 0 0 0 
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 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - Tmtc - 350 7 270 5.4 106 2.12 
BC 2 - - Tmtc - Tmtc - 325 6.5 258 5.16 123 2.46 
DP 1 - - Tmtc - Tmtc - Tmtc - 156 3.12 96 1.92 
DP 2 - - Tmtc - Tmtc - Tmtc - 140 2.8 80 1.60 
US 1 - - - - 19 0.38 7 0.14 2 0.04 0 0 
US 2 - - - - 15 0.30 7 0.14 0 0 0 0 
DS 1 - - - - Tmtc - Tmtc - 330 6.6 279 5.58 
DS 2 - - - - Tmtc - Tmtc - 300 6 280 5.60 
NGTW: June 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - Tmtc - 140 2.8 13 0.26 3 0.06 
BC 2 - - Tmtc - Tmtc - 100 2 18 0.36 5 0.1 
DP 1 - - Tmtc - Tmtc - 100 2 16 0.32 6 0.12 
DP 2 - - Tmtc - Tmtc - 120 2.4 11 0.22 8 0.16 
US 1 - - - - Tmtc - 10 0.2 8 0.16 2 0.04 
US 2 - - - - Tmtc - 16 0.32 9 0.18 3 0.06 
DS 1 - - - - Tmtc - 60 1.2 18 0.36 2 0.04 
DS 2 - - - - tmtc - 54 1.08 16 0.32 3 0.06 
 161 
 














Table 6: CFU/ml obtained across all sampling points in August 
 
NGTW: July 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - Tmtc - 75 1.5 7 0.14 0 0 
BC 2 - - Tmtc - Tmtc - 69 1.38 5 0.10 0 0 
DP 1 6 0.12 3 0.06 0 0 0 0 0 0 0 0 
DP 2 8 0.16 1 0.02 0 0 0 0 0 0 0 0 
US 1 - - - - 22 0.44 5 0.1 1 0.02 0 0 
US 2 - - - - 19 0.38 3 0.06 0 0 0 0 
DS 1 3 0.06 1 0.02 0 0 0 0 0 0 0 0 
DS 2 4 0.08 0 0 0 0 0 0 0 0 0 0 
NWWTP: August 
 1 × 100 1 × 101 1 × 102 1 × 103 1 × 104 1 × 105 
` 1 10 100 1000 10000 100000 
 Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml Count CFU/ml 
BC 1 - - Tmtc - 51 1.02 9 0.18 4 0.08 0 0 
BC 2 - - Tmtc - 59 1.18 7 0.14 3 0.06 1 0.02 
DP 1 - - 2 0.04 0 0 0 0 0 0 0 0 
DP 2 - - 1 0.02 0 0 0 0 0 0 0 0 
US 1 - - - - 216 4.32 133 2.66 126 2.52 50 1 
US 2 - - - - 220 4.4 131 2.62 118 2.36 46 0.92 
DS 1 - - - - 29 0.58 15 0.3 4 0.08 1 0.02 








Table 7:  Average CFU/ml for March 
 
Average cfu/ml x 103 : March 
Sample Point Value 1 Value 2 Avg Std dev 
BC 0.52 1.12 0.82 0.53 
DP 0.012 0 0.006 0.24 
US 0.36 0.46 0.41 0.24 
DS 0 0 0 0.00 
Table 8:  Average CFU/ml for April 
 
Average cfu/ml x 103 : March 
Sample Point Value 1 Value 2 Avg Std dev 
BC 0.02 0 0.01 1.50 
DP 0 3 1.5 1.32 
US 0.66 0.62 0.64 0.37 
DS 0 0 0 0.00 
 
Table 9:  Average CFU/ml for May 
 
Average cfu/ml x 103 : May 
Sample Point Value 1 Value 2 Avg Std dev 
BC 7 6.5 6.75 0.29 
DP 0.312 0.28 0.296 0.02 
US 0.14 0.14 0.14 0.00 






















Table 10:  Average CFU/ml for June 
 
Average cfu/ml x 103 : June 
Sample Point Value 1 Value 2 Avg Std dev 
BC 2 2.8 2.4 0.46 
DP 2.4 2 2.2 0.23 
US 0.2 0.32 0.26 0.07 
DS 1.2 1.08 1.14 0.07 
 
Table 11:  Average CFU/ml for July 
 
Average cfu/ml x 103 : July 
Sample Point Value 1 Value 2 Avg Std dev 
BC 1.5 1.38 1.44 0.07 
DP 0.0006 0.0002 0.0004 0.00 
US 0.1 0.06 0.08 0.02 
DS 0.0002 0 0.0001 0.00 
 
Table 12:  Average CFU/ml for August 
 
Average cfu/ml x 103 : August 
Sample Point Value 1 Value 2 Avg Std dev 
BC 0.18 0.14 0.16 0.04 
DP 0 0 0 0.00 
US 2.66 2.62 2.64 0.10 






APPENDIX II: PHYSICOCHEMICAL ANALYSIS 
 
A: Northern Wastewater Treatment Plant 
 
Table 1: Temperature values obtained over the six month period 
 
Temperature °C 





 BC 26.00 26.00 26.00 26.00 0.00 
DP 25.00 25.00 25.00 25.00 0.00 
US 26.00 26.00 26.00 26.00 0.00 





BC 22.00 22.00 22.00 22.00 0.00 
DP 22.00 22.00 22.00 22.00 0.00 
US 21.00 21.00 21.00 21.00 0.00 





BC 22.00 22.00 21.80 21.93 0.12 
DP 21.00 21.00 21.00 21.00 0.00 
US 21.00 21.00 21.00 21.00 0.00 





BC 13.50 13.50 13.50 13.50 0.00 
DP 13.00 12.50 12.50 12.67 0.29 
US 13.00 13.00 13.00 13.00 0.00 





BC 14.80 14.80 14.80 14.80 0.00 
DP 15.50 15.20 15.20 15.30 0.17 
US 15.00 15.00 14.80 14.93 0.12 






 BC 21.00 21.00 21.00 21.00 0.00 
DP 19.00 19.00 19.00 19.00 0.00 
US 20.00 20.00 20.00 20.00 0.00 












Table 2: Salinity of water samples obtained over the six month period 
 
Salinity % 





 BC 0.41 0.41 0.41 0.41 0 
DP 0.44 0.44 0.44 0.44 0 
US 0.37 0.37 0.37 0.37 0 





BC 0.38 0.38 0.38 0.38 0 
DP 0.44 0.44 0.45 0.44 0.01 
US 0.49 0.49 0.49 0.49 0 





BC 0.42 0.42 0.42 0.42 0 
DP 0.48 0.48 0.48 0.48 0 
US 1.07 1.08 1.08 1.08 0.01 





BC 0.34 0.34 0.34 0.34 0 
DP 0.37 0.37 0.37 0.37 0 
US 0.53 0.54 0.54 0.54 0 





BC 0.34 0.34 0.35 0.34 0.01 
DP 0.42 0.42 0.42 0.42 0 
US 0.71 0.72 0.72 0.72 0 






 BC 0.37 0.37 0.37 0.37 0 
DP 0.41 0.41 0.41 0.41 0 
US 0.44 0.44 0.44 0.44 0 
















Table 3: Conductivity of water samples over the six month period 
 
Conductivity(µS/cm) 





 BC 839 840 840 839.67 0.58 
DP 889 888 887 888 1 
US 755 758 760 757.67 2.52 





BC 785 781 784 783.33 2.08 
DP 902 903 906 903.67 2.08 
US 1001 996 996 997.67 2.89 





BC 853 853 853 853 0 
DP 966 966 966 966 0 
US 2116 2115 2116 2115.67 0.58 





BC 702 703 704 703 1 
DP 759 755 758 757.33 2.08 
US 1080 1083 1084 1082.33 2.08 





BC 718 725 731 724.67 6.51 
DP 851 849 849 849.67 1.15 
US 1424 1430 1432 1428.67 4.16 






 BC 753 752 759 754.67 3.79 
DP 841 840 839 840 1 
US 903 898 896 899 3.61 
















Table 4: Resistivity of the water samples over the six month period 
 
Resistivity (Ὠ.cm) 





 BC 1192.00 1191.00 1190.00 1191.00 1.00 
DP 1125.00 1126.00 1127.00 1126.00 1.00 
US 1320.00 1316.00 1325.00 1320.33 4.51 





BC 1275.00 1280.00 1275.00 1276.67 2.89 
DP 1108.00 1108.00 1104.00 1106.67 2.31 
US 1004.00 1004.00 1004.00 1004.00 0.00 





BC 1173.00 1173.00 1173.00 1173.00 0.00 
DP 1037.00 1035.00 1036.00 1036.00 1.00 
US 473.00 473.00 473.00 473.00 0.00 





BC 1426.00 1423.00 1421.00 1423.33 2.52 
DP 1318.00 1324.00 1319.00 1320.33 3.21 
US 926.00 923.00 923.00 924.00 1.73 





BC 1368.00 1365.00 1379.00 1370.67 7.37 
DP 1176.00 1178.00 1177.00 1177.00 1.00 
US 702.00 699.00 699.00 700.00 1.73 






 BC 1327.00 1314.00 1317.00 1319.33 6.81 
DP 1189.00 1190.00 1192.00 1190.33 1.53 
US 1107.00 1114.00 1116.00 1112.33 4.73 
















Table 5: TDS concentrations over the six month period 
 
Total Dissolved Solids mg/L 





 BC 411 411 412 411.33 0.58 
DP 436 436 436 436 0 
US 370 371 369 370 1 





BC 384 382 383 383 1 
DP 443 444 445 444 1 
US 493 490 490 491 1.73 





BC 418 418 418 418 0 
DP 475 475 475 475 0 
US 1063 1069 1069 1067 3.46 





BC 342 343 343 342.67 0.58 
DP 366 369 370 368.33 2.08 
US 535 533 535 534.33 1.15 





BC 340 351 354 348.33 7.37 
DP 417 416 416 416.33 0.58 
US 705 712 713 710 4.36 






 BC 368 372 371 370.33 2.08 
DP 412 412 411 411.67 0.58 
US 443 441 440 441.33 1.53 












Table 6: Turbidity of the water samples over the six month period 
 
Turbidity (NTU) 























 BC 8.08 8.12 7.53 7.91 0.33 8.08 8.12 7.53 7.91 0.33 7.91 0.33 
DP 37.40 16.60 16.20 23.40 12.13 37.40 16.60 16.20 23.40 12.13 23.40 12.13 
US 17.10 16.40 16.50 16.67 0.38 17.10 16.40 16.50 16.67 0.38 16.67 0.38 





 BC 56.60 56.60 56.40 56.53 0.12 51.50 51.50 51.30 51.43 0.12 53.98 2.94 
DP 76.60 76.60 76.10 76.43 0.29 65.40 65.40 65.90 65.60 0.26 71.02 6.25 
US 19.70 19.70 19.70 19.70 0.00 17.00 17.00 17.00 17.00 0.00 18.35 1.56 




 BC 19.60 19.60 19.60 19.60 0.00 25.90 20.10  19.10 21.70 3.67 20.65 1.21 
DP 14.10 14.10 14.00 14.07 0.06 14.40 14.30 14.40 14.37 0.06 14.22 0.17 
US 12.80 12.80 12.80 12.80 0.00 14.70 14.30 14.10 14.37 0.31 13.58 0.90 





 BC 7.37 7.37 7.37 7.37 0.00 7.23 7.24 7.24 7.24 0.01 7.30 0.08 
DP 7.34 7.35 7.35 7.35 0.00 7.23 7.24 7.25 7.24 0.01 7.29 0.06 
US 7.64 7.65 7.65 7.65 0.01 7.54 7.50 7.53 7.54 0.01 7.59 0.06 





 BC 9.28 9.22 9.20 9.23 0.04 4.04 3.95 3.96 3.98 0.05 6.61 3.03 
DP 8.29 8.29 8.29 8.29 0.00 4.85 5.01 4.93 4.93 0.08 6.61 1.94 
US 9.91 9.91 9.91 9.91 0.00 4.69 4.61 4.68 4.66 0.04 7.29 3.03 







 BC 56.70 56.00 56.40 56.37 0.35 56.70 56.00 56.40 56.37 0.35 56.37 0.35 
DP 68.70 67.90 69.00 68.53 0.57 68.70 67.90 69.00 68.53 0.57 68.53 0.57 
US 28.70 28.70 28.80 28.73 0.06 28.70 28.70 28.80 28.73 0.06 28.73 0.06 
DS 20.70 20.80 20.80 20.77 0.06 20.70 20.80 20.80 20.77 0.06 20.77 0.06 
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Table 7: pH of the water samples over the six month period 
 
 
Point Replicate 1 Replicate 2 Replicate 3 Average Std Dev Replicate 1 Replicate 2Replicate 3 Average Std Dev Final Ave Std dev
BC 7.15 7.05 7.12 7.11 0.05 7.15 7.05 7.12 7.11 0.05 7.11 0.05
DP 7.31 7.44 7.34 7.36 0.07 7.31 7.44 7.34 7.36 0.07 7.36 0.07
US 7.29 7.15 7.31 7.25 0.09 7.29 7.15 7.31 7.25 0.09 7.25 0.09
DS 7.23 7.30 7.19 7.24 0.06 7.23 7.30 7.19 7.24 0.06 7.24 0.06
BC 7.70 7.60 7.70 7.67 0.05 7.12 7.11 7.03 7.09 0.04 7.38 0.33
DP 7.50 7.30 7.40 7.40 0.10 7.13 7.05 7.02 7.04 0.02 7.22 0.21
US 7.50 7.30 7.50 7.43 0.12 7.16 7.13 7.14 7.14 0.01 7.29 0.17
DS 7.70 7.60 7.60 7.63 0.06 7.16 7.16 7.15 7.16 0.01 7.40 0.28
BC 7.05 7.07 7.11 7.08 0.03 7.18 6.93 6.76 6.96 0.21 20.65 1.21
DP 7.26 7.29 7.28 7.28 0.02 6.97 6.80 6.75 6.84 0.12 14.22 0.17
US 6.88 6.95 6.91 6.91 0.04 6.79 6.77 6.92 6.83 0.08 13.58 0.90
DS 7.15 7.10 7.13 7.13 0.03 6.69 6.51 6.50 6.57 0.11 13.58 0.79
BC 7.37 7.37 7.37 7.37 0.00 7.23 7.24 7.24 7.24 0.01 7.30 0.08
DP 7.34 7.35 7.35 7.35 0.01 7.23 7.24 7.25 7.24 0.01 7.29 0.06
US 7.64 7.65 7.65 7.65 0.01 7.54 7.54 7.53 7.54 0.01 7.59 0.06
DS 7.84 7.85 7.84 7.84 0.01 7.74 7.75 7.76 7.75 0.02 7.80 0.05
BC 7.47 7.49 7.48 7.48 0.01 6.92 7.00 6.85 6.92 0.08 7.20 0.32
DP 7.70 7.70 7.70 7.70 0.00 6.26 6.37 6.28 6.30 0.06 7.00 0.81
US 7.54 7.55 7.54 7.54 0.01 6.40 6.37 6.38 6.38 0.02 6.96 0.67
DS 7.85 7.88 7.87 7.87 0.02 6.05 5.90 6.03 5.99 0.08 6.93 1.08
BC 6.73 6.86 6.95 6.85 0.11 6.73 6.86 6.95 6.85 0.11 6.85 0.11
DP 7.05 7.09 7.13 7.09 0.04 7.05 7.09 7.13 7.09 0.04 7.09 0.04
US 7.10 7.11 7.15 7.12 0.03 7.10 7.11 7.15 7.12 0.03 7.12 0.03


























Table 8: COD concentrations obtained over the six month period 
 
 
Replicate 1Replicate 2Replicate 3Average Average 1 Std Dev Replicate 1Replicate 2 Replicate 3 Average Std Dev Average 2 Final Ave Std Dev
BC 1 90.00 80.00 97.00 89.00 8.54 90.00 80.00 97.00 89.00 8.54
BC2 115.00 113.00 114.00 114.00 1.00 115.00 113.00 114.00 114.00 1.00
BC3 112.00 111.00 111.00 111.33 0.58 112.00 111.00 111.00 111.33 0.58
DP 1 <10 <10 <10 < 10 0.00 <10 <10 <10 <10 0.00
DP 2 <10 <10 <10 < 10 0.00 <10 <10 <10 <10 0.00
DP 3 <10 <10 <10 < 10 0.00 <10 <10 <10 <10 0.00
US 1 163.00 169.00 164.00 165.33 3.21 163.00 169.00 164.00 165.33 3.21
US 2 157.00 157.00 156.00 156.67 0.58 157.00 157.00 156.00 156.67 0.58
US 3 161.00 164.00 161.00 162.00 1.73 164.00 161.00 161.00 162.00 1.73
DS 1 112.00 113.00 114.00 113.00 1.00 121.00 113.00 114.00 116.00 4.36
DS 2 309.00 310.00 309.00 309.33 0.58 309.00 310.00 309.00 309.33 0.58
DS 3 152.00 152.00 152.00 152.00 0.00 152.00 152.00 152.00 152.00 0.00
BC 1 126.00 126.00 127.00 126.33 0.58 126.00 126.00 127.00 126.33 0.58
BC2 129.00 129.00 128.00 128.67 0.58 129.00 129.00 128.00 128.67 0.58
BC3 127.00 128.00 131.00 128.67 2.08 127.00 128.00 131.00 128.67 2.08
DP 1 151.00 150.00 150.00 150.33 0.58 151.00 150.00 150.00 150.33 0.58
DP 2 149.00 149.00 145.00 147.67 2.31 149.00 149.00 145.00 147.67 2.31
DP 3 162.00 160.00 160.00 160.67 1.15 162.00 160.00 160.00 160.67 1.15
US 1 309.00 308.00 310.00 309.00 1.00 309.00 313.00 311.00 311.00 2.00
US 2 311.00 310.00 309.00 310.00 1.00 309.00 313.00 311.00 311.00 0.00
US 3 309.00 309.00 308.00 308.67 0.58 309.00 313.00 311.00 311.00 0.00
DS 1 304.00 304.00 304.00 304.00 0.00 304.00 304.00 304.00 304.00 0.00
DS 2 302.00 302.00 302.00 302.00 0.00 302.00 302.00 302.00 302.00 0.00
DS 3 303.00 303.00 303.00 303.00 0.00 303.00 303.00 303.00 303.00 0.00
BC 1 52.00 49.00 50.00 50.33 1.53 92.00 92.00 92.00 92.00 0.00
BC2 37.00 36.00 38.00 37.00 1.00 86.00 85.00 86.00 85.67 0.52
BC3 28.00 27.00 27.00 27.33 0.58 37.00 37.00 37.00 37.00 0.00
DP 1 <10 <10 <10 <10 0.00 < 10 < 10 < 10 <10 0.00
DP 2 <10 <10 <10 <10 0.00 < 10 < 10 < 10 <10 0.00
DP 3 <10 <10 <10 <10 0.00 < 10 < 10 < 10 <10 0.00
US 1 18.00 19.00 18.00 18.33 0.58 79.00 79.00 79.00 79.00 0.00
US 2 20.00 21.00 21.00 20.67 0.58 35.00 35.00 35.00 35.00 0.00
US 3 19.00 20.00 22.00 20.33 1.53 37.00 40.00 40.00 39.00 1.55
DS 1 308.00 310.00 308.00 308.67 1.15 308.00 308.00 308.00 308.00 0.00
DS 2 307.00 309.00 307.00 307.67 1.15 300.00 300.00 300.00 300.00 0.00
























































Table 8 continued… 
 
 
Replicate 1Replicate 2Replicate 3Average Average 1 Std DevReplicate 1Replicate 2Replicate 3Average Std Dev Average 2Final Ave Std Dev
BC 1 110.00 109.00 110.00 109.67 0.58 110.00 109.00 110.00 109.67 0.58
BC2 117.00 117.00 117.00 117.00 0.00 117.00 117.00 117.00 117.00 0.00
BC3 114.00 113.00 113.00 113.33 0.58 114.00 113.00 113.00 113.33 0.58
DP 1 286.00 293.00 292.00 290.33 3.79 286.00 293.00 292.00 290.33 3.79
DP 2 303.00 302.00 303.00 302.67 0.58 303.00 302.00 303.00 302.67 0.58
DP 3 307.00 307.00 307.00 307.00 0.00 307.00 307.00 307.00 307.00 0.00
US 1 107.00 107.00 106.00 106.67 0.58 127.00 114.00 112.00 117.67 8.14
US 2 113.00 113.00 112.00 112.67 0.58 127.00 114.00 112.00 117.67 8.14
US 3 110.00 111.00 111.00 110.67 0.58 127.00 114.00 112.00 117.67 8.14
DS 1 86.00 86.00 86.00 86.00 0.00 88.00 94.00 88.00 90.00 3.46
DS 2 90.00 90.00 90.00 90.00 0.00 88.00 94.00 88.00 90.00 3.46
DS 3 90.00 91.00 90.00 90.33 0.58 88.00 94.00 88.00 90.00 3.46
BC 1 123.00 122.00 123.00 122.67 0.58 123.00 121.00 122.00 122.00 1.00
BC2 117.00 116.00 118.00 117.00 1.00 97.00 108.00 99.00 101.33 5.86
BC3 113.00 114.00 119.00 115.33 3.21 121.00 121.00 121.00 121.00 0.00
DP 1 295.00 295.00 294.00 294.67 0.58 292.00 291.00 291.00 291.33 0.58
DP 2 293.00 293.00 293.00 293.00 0.00 291.00 291.00 291.00 291.00 0.00
DP 3 287.00 288.00 288.00 287.67 0.58 290.00 290.00 289.00 289.67 0.58
US 1 312.00 311.00 312.00 311.67 0.58 312.00 312.00 312.00 312.00 0.00
US 2 312.00 312.00 311.00 311.67 0.58 311.00 311.00 311.00 311.00 0.00
US 3 315.00 314.00 313.00 314.00 1.00 310.00 310.00 310.00 310.00 0.00
DS 1 312.00 313.00 313.00 312.67 0.58 314.00 313.00 312.00 313.00 1.00
DS 2 311.00 312.00 313.00 312.00 1.00 311.00 311.00 310.00 310.67 0.58
DS 3 312.00 313.00 313.00 312.67 0.58 309.00 309.00 310.00 309.33 0.58
BC 1 311.00 310.00 310.00 310.33 0.58 311.00 310.00 310.00 310.33 0.58
BC2 309.00 309.00 310.00 309.33 0.58 309.00 309.00 310.00 309.33 0.58
BC3 311.00 310.00 311.00 310.67 0.58 311.00 310.00 311.00 310.67 0.58
DP 1 183.00 188.00 185.00 185.33 2.52 183.00 188.00 185.00 185.33 2.52
DP 2 181.00 181.00 181.00 181.00 0.00 181.00 181.00 181.00 181.00 0.00
DP 3 184.00 180.00 182.00 182.00 2.00 184.00 180.00 182.00 182.00 2.00
US 1 111.00 110.00 109.00 110.00 1.00 111.00 110.00 109.00 110.00 1.00
US 2 105.00 105.00 106.00 105.33 0.58 105.00 105.00 106.00 105.33 0.58
US 3 99.00 100.00 108.00 102.33 4.93 99.00 100.00 108.00 102.33 4.93
DS 1 307.00 308.00 309.00 308.00 1.00 307.00 308.00 309.00 308.00 1.00
DS 2 313.00 312.00 311.00 312.00 1.00 313.00 312.00 311.00 312.00 1.00































































Table 10: BOD concentrations obtained in April 
 
 
BOD DAY 0 BOD DAY 7
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 7.63 7.63 7.70 7.65 0.04 6.89 6.41 6.03 6.44 0.43 0.67 1.10 1.82 2.49 1.81 0.69 2.23 0.36
NW BC 225 7.36 7.43 7.43 7.41 0.04 6.79 6.45 6.5 6.58 0.18 0.72 0.79 1.36 1.29 1.15 0.31
NW BC 275 7.34 7.50 7.46 7.43 0.08 5.68 5.63 5.42 5.58 0.14 0.92 1.80 2.03 2.22 2.02 0.21
NW BC 300 7.69 7.56 7.63 7.63 0.07 3.51 3.66 3.86 3.68 0.18 1.00 4.18 3.90 3.77 3.95 0.21
NW AC 200 7.80 7.98 7.99 7.92 0.11 4.04 3.96 4 4.00 0.04 0.67 5.61 6.00 5.96 5.86 0.21 5.13 0.18
NW AC 225 8.14 8.20 8.26 8.20 0.06 3.14 3.37 3.58 3.36 0.22 0.72 6.94 6.71 6.50 6.72 0.22
NW AC 275 8.36 8.35 8.37 8.36 0.01 4.96 5.23 4.94 5.04 0.16 0.92 3.70 3.39 3.73 3.61 0.19
NW AC 300 8.09 8.04 8.11 8.08 0.04 3.71 3.62 3.88 3.74 0.13 1.00 4.38 4.42 4.23 4.34 0.10
NW US 60 8.09 8.16 8.15 8.13 0.04 6.2 5.02 6 5.74 0.63 0.20 9.45 15.70 10.75 11.97 3.30 5.62 1.01
NW US 150 8.38 8.36 8.34 8.36 0.02 6.61 6.67 6.44 6.57 0.12 0.50 3.54 3.38 3.80 3.57 0.21
NW US 200 7.97 7.91 7.94 7.94 0.03 5.98 5.8 5.61 5.80 0.19 0.67 2.97 3.15 3.48 3.20 0.26
NW US 300 8.14 8.13 8.11 8.13 0.02 4.66 4.07 4.4 4.38 0.30 1.00 3.48 4.06 3.71 3.75 0.29
NW DS 60 8.16 8.10 8.15 8.14 0.03 5.58 5.57 5.69 5.61 0.07 0.20 12.90 12.65 12.30 12.62 0.30 5.62 0.24
NW DS150 7.90 7.92 7.91 7.91 0.01 5.42 5.52 5.63 5.52 0.11 0.50 4.96 4.80 4.56 4.77 0.20
NW DS 200 7.72 8.02 8.03 7.92 0.18 5.75 5.81 5.8 5.79 0.03 0.67 2.94 3.30 3.33 3.19 0.22
NW DS 300 7.81 7.71 7.80 7.77 0.06 5.99 5.96 5.61 5.85 0.21 1.00 1.82 1.75 2.19 1.92 0.24
CONTROL 8.37 8.32 8.36 8.35 0.03 6.68 6.69 6.79 6.72 0.06 1.00 1.69 1.63 1.57 1.63 0.06
March
BOD DAY 0 BOD DAY 7
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 7.68 7.82 7.71 7.74 0.07 5.86 4.54 4.84 5.08 0.69 0.67 2.72 4.90 4.28 3.97 1.12 3.30 0.97
NW BC 225 8.17 7.31 7.7 7.73 0.43 3.95 4.99 4.3 4.41 0.53 0.72 5.86 3.22 4.72 4.60 1.32
NW BC 275 7.34 7.08 7.29 7.24 0.14 5.5 3.43 4.79 4.57 1.05 0.92 2.00 3.97 2.72 2.89 1.00
NW BC 300 7.87 7.58 7.59 7.68 0.16 6.6 5.58 5.6 5.93 0.58 1.00 1.27 2.00 1.99 1.75 0.42
NW AC 200 7.69 7.45 7.62 7.59 0.12 5.19 5.62 5.01 5.27 0.31 0.67 3.73 2.73 3.90 3.45 0.63 3.44 0.67
NW AC 225 7.36 7.78 7.9 7.68 0.28 4.77 4.21 4.92 4.63 0.37 0.72 3.60 4.96 4.14 4.23 0.69
NW AC 275 7.14 7.61 7.63 7.46 0.28 4.28 4.13 4.78 4.40 0.34 0.92 3.11 3.78 3.10 3.33 0.39
NW AC 300 7.95 7.92 7.95 7.94 0.02 6.28 4.83 4.45 5.19 0.97 1.00 1.67 3.09 3.50 2.75 0.96
NW US 60 8.52 8.53 8.52 8.52 0.01 4.17 4.37 4.49 4.34 0.16 0.20 21.75 20.80 20.15 20.90 0.80 8.49 0.47
NW US 150 8.48 8.5 8.5 8.49 0.01 5.63 5.55 5.83 5.67 0.14 0.50 5.70 5.90 5.34 5.65 0.28
NW US 200 8.51 8.53 8.51 8.52 0.01 5.45 5.96 5.29 5.57 0.35 0.67 4.57 3.84 4.81 4.40 0.51
NW US 300 8.49 8.47 8.48 8.48 0.01 5.54 5.19 5.73 5.49 0.27 1.00 2.95 3.28 2.75 2.99 0.27
NW DS 60 8.31 8.31 8.28 8.30 0.02 5.15 5.14 5.05 5.11 0.06 0.20 15.80 15.85 16.15 15.93 0.19 6.33 0.21
NW DS150 8.05 8.05 7.98 8.03 0.04 5.89 5.97 5.92 5.93 0.04 0.50 4.32 4.16 4.12 4.20 0.11
NW DS 200 7.76 7.74 7.89 7.80 0.08 5.78 5.8 5.43 5.67 0.21 0.67 2.96 2.90 3.67 3.17 0.43
NW DS 300 7.23 7.27 7.45 7.32 0.12 5.24 5.13 5.49 5.29 0.18 1.00 1.99 2.14 1.96 2.03 0.10
CONTROL 8.37 8.32 8.36 8.35 0.03 6.68 6.69 6.79 6.72 0.06 1.00 1.69 1.63 1.57 1.63 0.06
April
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BOD DAY 0 BOD DAY 5
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 6.78 6.75 6.72 6.75 0.03 6.69 6.21 6.22 6.37 0.27 0.67 0.13 0.81 0.75 0.56 0.37 1.03 0.19
NW BC 225 6.78 6.9 6.81 6.83 0.06 5.25 5.18 5.27 5.23 0.05 0.72 2.13 2.39 2.14 2.22 0.15
NW BC 275 6.23 6.28 6.11 6.21 0.09 6.21 6.49 6.36 6.35 0.14 0.92 0.02 -0.23 -0.27 -0.16 0.16
NW BC 300 6.86 6.93 6.98 6.92 0.06 5.35 5.53 5.42 5.43 0.09 1.00 1.51 1.40 1.56 1.49 0.08
NW AC 200 8 8.02 7.99 8.00 0.02 5.45 5.09 5.1 5.21 0.21 0.67 3.81 4.37 4.31 4.16 0.31 3.25 0.17
NW AC 225 7.95 7.94 7.95 7.95 0.01 5.12 5.05 5.02 5.06 0.05 0.72 3.93 4.01 4.07 4.00 0.07
NW AC 275 8.09 8.05 8.07 8.07 0.02 5.42 5.81 5.49 5.57 0.21 0.92 2.90 2.43 2.80 2.71 0.25
NW AC 300 7.94 7.95 7.97 7.95 0.02 5.8 5.78 5.9 5.83 0.06 1.00 2.14 2.17 2.07 2.13 0.05
NW US 60 8.12 8.11 8.09 8.11 0.02 6.25 6.45 6.9 6.53 0.33 0.20 9.35 8.30 5.95 7.87 1.74 4.29 0.79
NW US 150 8.13 8.11 8.14 8.13 0.02 6.14 6.3 6.61 6.35 0.24 0.50 3.98 3.62 3.06 3.55 0.46
NW US 200
NW US 300 8.01 8.02 7.98 8.00 0.02 6.49 6.75 6.4 6.55 0.18 1.00 1.52 1.27 1.58 1.46 0.16
NW DS 60 8.17 8.16 8.15 8.16 0.01 5.61 5.53 5.39 5.51 0.11 0.20 12.80 13.15 13.80 13.25 0.51 5.68 0.30
NW DS150 8.09 8.1 8.15 8.11 0.03 5.99 6.1 6.09 6.06 0.06 0.50 4.20 4.00 4.12 4.11 0.10
NW DS 200 8.14 8.17 8.19 8.17 0.03 5.76 5.4 5.95 5.70 0.28 0.67 3.55 4.13 3.34 3.68 0.41
NW DS 300 8.11 8.14 8.1 8.12 0.02 6.54 6.22 6.49 6.42 0.17 1.00 1.57 1.92 1.61 1.70 0.19
CONTROL 8.13 8.16 8.14 8.14 0.02 7.92 8.03 8.07 8.01 0.08 1.00 0.21 0.13 0.07 0.14 0.07
May
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Average BOD of water samples in May 
 
Final BOD Average: May 
  AVG 1 AVG 2 AVG STD DEV 
NW BC 1.03 1.79 1.41 0.44 
NW DP 3.25 2.82 3.04 0.25 
NW US 4.29 4.75 4.52 0.27 
NW DS 5.68 4.45 5.07 0.71 
BOD DAY 0 BOD DAY 5
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3
NW BC 200 7.65 7.6 7.57 7.61 0.04 5.74 5.89 5.62 5.75 0.12 0.67 2.79 1.79 0.62
NW BC 225 7.3 7.28 7.3 7.29 0.01 6.18 6.2 6.27 6.22 0.04 0.72 1.44
NW BC 275 7.39 7.4 7.39 7.39 0.01 6.05 6.08 6.1 6.08 0.02 0.92 1.44
NW BC 300 7.59 7.6 7.61 7.6 0.01 6.07 6.15 6.11 6.11 0.04 1.00 1.49
NW AC 200 7.99 5.92 2.07 0.67 3.11 5.93 5.91 5.93 5.92 0.01 0.67 3.11 2.82 0.48
NW AC 225 7.97 6.36 1.61 0.75 2.15 6.45 6.3 6.32 6.36 0.07 0.72 2.15
NW AC 275 8.07 5.59 2.48 0.92 2.71 5.57 5.65 5.55 5.59 0.05 0.92 2.71
NW AC 300 8.08 5.86 2.22 1.00 3.33 5.83 5.96 5.78 5.86 0.08 1.00 3.33
NW US 200 8.15 8.15 8.16 8.15 0.01 5.99 6.02 5.93 5.98 0.04 0.20 10.87 4.75 3.80
NW US 225 8.12 8.1 8.09 8.10 0.01 6.37 6.53 6.31 6.40 0.10 0.50 3.40
NW US 275 8.14 8.14 8.14 8.14 0.00 6.42 6.4 6.4 6.41 0.01 2.60
NW US 300 8.17 8.1 8.15 8.14 0.03 5.94 6.08 5.95 5.99 0.07 1.00 2.15
NW DS 60 8.24 8.22 8.22 8.23 0.01 6.07 5.98 6.01 6.02 0.04 0.20 11.03 4.45 5.17
NW DS 200 8.16 8.17 8.17 8.17 0.01 8.09 8 7.98 8.02 0.05 0.67 0.21
NW DS 300 8 8.09 8.11 8.07 0.05 6.04 5.95 5.92 5.97 0.06 1.00 2.10
CONTROL 8.29 8.29 8.22 8.27 0.04 6.81 6.85 6.96 6.87 0.07 1.00 1.39
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BOD DAY 0 BOD DAY 5
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 8.26 8.18 8.24 8.23 0.04 4.4 4.75 4.23 4.46 0.27 0.67 5.76 5.12 5.99 5.62 0.45 3.66 0.30
NW BC 225 8.04 8.09 8.12 8.08 0.04 5.52 5.36 5.22 5.37 0.15 0.72 3.50 3.79 4.03 3.77 0.26
NW BC 275 7.74 7.83 7.73 7.77 0.06 5.05 5.47 5.15 5.22 0.22 0.92 2.92 2.57 2.80 2.76 0.18
NW BC 300 7.79 7.96 7.89 7.88 0.09 5.65 5.22 5.36 5.41 0.22 1.00 2.14 2.74 2.53 2.47 0.30
NW AC 200 8.67 8.64 8.68 8.66 0.02 5.43 5.71 5.43 5.52 0.16 0.67 4.84 4.37 4.85 4.69 0.27 4.08 0.21
NW AC 225 8.56 8.59 8.57 8.57 0.02 5.09 5 5.17 5.09 0.09 0.72 4.82 4.99 4.72 4.84 0.13
NW AC 275 8.63 8.69 8.7 8.67 0.04 5.2 5.36 5.44 5.33 0.12 0.92 3.73 3.62 3.54 3.63 0.09
NW AC 300 8.68 8.66 8.67 8.67 0.01 5.55 5.82 5.17 5.51 0.33 1.00 3.13 2.84 3.50 3.16 0.33
NW US 60 8.6 8.56 8.54 8.57 0.03 4.62 4.62 4.45 4.56 0.10 0.20 19.90 19.70 20.45 20.02 0.39 9.80 0.44
NW US 150 8.48 8.42 8.43 8.44 0.03 5.48 5.92 5.38 5.59 0.29 0.50 6.00 5.00 6.10 5.70 0.61
NW US 200
NW US 300 8.37 8.33 8.26 8.32 0.06 4.93 4.26 4.69 4.63 0.34 1.00 3.44 4.07 3.57 3.69 0.33
NW DS 60 8.47 8.48 8.51 8.49 0.02 5.77 5.66 5.68 5.70 0.06 0.20 13.50 14.10 14.15 13.92 0.36 6.93 0.35
NW DS150 8.5 8.51 8.48 8.50 0.02 5.78 5.8 5.53 5.70 0.15 0.50 5.44 5.42 5.90 5.59 0.27
NW DS 200 8.36 8.37 8.41 8.38 0.03 5.33 5.68 5.17 5.39 0.26 0.67 4.52 4.01 4.84 4.46 0.41
NW DS 300 8.37 8.33 8.36 8.35 0.02 4.22 4.69 4.87 4.59 0.34 1.00 4.15 3.64 3.49 3.76 0.35
CONTROL 8.67 8.58 8.51 8.59 0.08 7.66 7.67 7.59 7.64 0.04 1.00 1.01 0.91 0.92 0.95 0.06
June
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BOD DAY 0 BOD DAY 5
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 8 7.96 7.96 7.97 0.02 4.76 4.77 4.5 4.68 0.15 0.67 4.84 4.76 5.16 4.92 0.21 4.36 0.16
NW BC 225 8.09 8.1 7.9 8.03 0.11 4.33 4.29 4.39 4.34 0.05 0.72 5.22 5.29 4.88 5.13 0.22
NW BC 275 7.78 7.77 7.79 7.78 0.01 3.88 3.85 3.63 3.79 0.14 0.92 4.24 4.26 4.52 4.34 0.16
NW BC 300 7.59 7.59 7.6 7.59 0.01 4.46 4.53 4.59 4.53 0.07 1.00 3.13 3.06 3.01 3.07 0.06
NW AC 200 8.45 8.42 8.44 8.44 0.02 4.45 4.42 4.32 4.40 0.07 0.67 5.97 5.97 6.15 6.03 0.10 4.54 0.12
NW AC 225 8.43 8.41 8.42 8.42 0.01 5.11 5.27 5.35 5.24 0.12 0.72 4.61 4.36 4.26 4.41 0.18
NW AC 275 8.56 8.57 8.57 8.57 0.01 4.69 4.78 4.65 4.71 0.07 0.92 4.21 4.12 4.26 4.20 0.07
NW AC 300 8.69 8.66 8.68 8.68 0.02 5.07 5.32 5.13 5.17 0.13 1.00 3.62 3.34 3.55 3.50 0.15
NW US 200 8.1 8.12 8.14 8.12 0.02 4.72 4.79 4.79 4.77 0.04 0.20 16.90 16.65 16.75 16.77 0.13 9.42 0.15
NW US 225 8.31 8.3 8.32 8.31 0.01 4.45 4.24 4.31 4.33 0.11 0.50 7.72 8.12 8.02 7.95 0.21
NW US 275 8.34 8.34 8.35 4.4 4.33 4.26
NW US 300 8.21 8.16 8.21 8.19 0.03 4.69 4.75 4.56 4.67 0.10 1.00 3.52 3.41 3.65 3.53 0.12
NW DS 200 8.41 8.48 8.48 8.46 0.04 4.6 4.46 4.49 4.52 0.07 0.20 19.05 20.10 19.95 19.70 0.57 10.32 0.42
NW DS 225 8.56 8.57 8.52 8.55 0.03 4.87 4.5 4.79 4.72 0.19 0.50 7.38 8.14 7.46 7.66 0.42
NW DS 275
NW DS 300 8.44 8.48 8.5 8.47 0.03 5.04 4.97 4.6 4.87 0.24 1.00 3.40 3.51 3.90 3.60 0.26
CONTROL 8.42 8.43 8.43 8.43 0.01 8.14 8.13 8.15 8.14 0.01 1.00 0.28 0.30 0.28 0.29 0.01
AVG 1 AVG 2 AVG STD DEV
NW BC 3.66 4.36 4.01 0.41
NW DP 4.08 4.54 4.31 0.26
NW US 9.80 9.42 9.61 0.22
NW DS 6.93 7.74 7.34 0.47
Final BOD Average: June
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BOD DAY 0 BOD DAY 5
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 6.61 6.92 6.8 6.78 0.16 4.07 4.91 4.27 4.42 0.44 0.67 3.79 3.00 3.78 3.52 0.45 1.70 0.38
NW BC 225 6.17 6.68 6.67 6.51 0.29 5.46 5.1 5.2 5.25 0.19 0.72 0.99 2.19 2.04 1.74 0.66
NW BC 275 0.92 0.00 0.00 0.00 0.00 0.00
NW BC 300 6.48 5.74 6.18 6.13 0.37 4.84 4.64 4.31 4.60 0.27 1.00 1.64 1.10 1.87 1.54 0.40
NW AC 200 7.73 7.71 7.66 7.70 0.04 4.76 4.93 4.72 4.80 0.11 0.67 4.43 4.15 4.39 4.32 0.15 3.07 0.19
NW AC 225 7.71 7.13 7.4 7.41 0.29 5.44 5.23 5.1 5.26 0.17 0.72 3.15 2.64 3.19 3.00 0.31
NW AC 275 7.7 7.21 7.35 7.42 0.25 5.46 5.05 5 5.17 0.25 0.92 2.43 2.35 2.55 2.45 0.10
NW AC 300 7.27 7.36 7.42 7.35 0.08 4.92 4.85 4.72 4.83 0.10 1.00 2.35 2.51 2.70 2.52 0.18
NW US 60 8.35 8.45 8.32 8.37 0.07 4.85 4.05 4.96 4.62 0.50 0.20 17.50 22.00 16.80 18.77 2.82 9.84 1.22
NW US 150 8.22 8.25 8.24 8.24 0.02 4.51 4.34 4.93 4.59 0.30 0.50 7.42 7.82 6.62 7.29 0.61
NW US 200 8.21 8.18 8.35 8.25 0.09 4.96 4.27 4.16
NW US 300 8.23 8.17 8.16 8.19 0.04 4.9 4.83 4.41 4.71 0.27 1.00 3.33 3.34 3.75 3.47 0.24
NW DS 60 8.51 8.37 8.33 8.40 0.09 4.64 4.52 4.84 4.67 0.16 0.20 19.35 19.25 17.45 18.68 1.07 8.80 0.64
NW DS150 8.31 8.26 8.21 8.26 0.05 4.81 4.81 4.93 4.85 0.07 0.50 7.00 6.90 6.56 6.82 0.23
NW DS 200 8.3 8.21 8.51 8.34 0.15 4.8 4.77 3.94 4.50 0.49 0.67 5.22 5.13 6.82 5.73 0.95
NW DS 300 8.34 8.28 8.31 8.31 0.03 4.7 4.2 4.07 4.32 0.33 1.00 3.64 4.08 4.24 3.99 0.31
CONTROL 8.51 8.45 8.39 8.45 0.06 7.35 7.18 7.29 7.27 0.09 1.00 1.16 1.27 1.10 1.18 0.09
July
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Average of water samples in July 
 
Final BOD Average: July 
  AVG 1 AVG 2 AVG STD DEV 
NW BC 1.70 2.56 2.13 0.50 
NW DP 3.07 3.12 3.10 0.03 
NW US 9.84 5.76 7.80 2.36 
NW DS 8.80 4.69 6.75 2.37 
 
 
BOD DAY 0 BOD DAY 7
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 6.27 6.30 6.37 6.31 0.05 3.52 3.4 3.47 3.46 0.06 0.67 4.10 4.33 4.33 4.25 0.13 2.56 0.58
NW BC 225 6.52 6.45 6.42 6.46 0.05 4.46 4.99 4.3 4.58 0.36 0.72 2.86 2.03 2.94 2.61 0.51
NW BC 275 6.31 6.32 6.24 6.29 0.04 4.44 3.43 4.79 4.22 0.71 0.92 2.03 3.14 1.58 2.25 0.80
NW BC 300 6.42 6.24 6.17 6.28 0.13 4.27 5.58 5.6 5.15 0.76 1.00 2.15 0.66 0.57 1.13 0.89
NW AC 200 7.43 7.25 7.53 7.40 0.14 5.15 5.62 5.01 5.26 0.32 0.67 3.40 2.43 3.76 3.20 0.69 3.12 0.62
NW AC 225 7.49 7.36 7.34 7.40 0.08 5.03 4.21 4.92 4.72 0.45 0.72 3.42 4.38 3.36 3.72 0.57
NW AC 275 7.58 7.44 7.63 7.55 0.10 5.64 4.13 4.78 4.85 0.76 0.92 2.11 3.60 3.10 2.93 0.76
NW AC 300 7.54 7.49 7.54 7.52 0.03 5.4 4.83 4.45 4.89 0.48 1.00 2.14 2.66 3.09 2.63 0.48
NW US 60 7.93 7.89 7.88 7.90 0.03 5.51 4.37 4.49 4.79 0.63 0.20 12.10 17.60 16.95 15.55 3.01 7.68 1.37
NW US 150 7.81 7.78 7.75 7.78 0.03 5.97 5.55 5.83 5.78 0.21 0.50 3.68 4.46 3.84 3.99 0.41
NW US 200 7.97 7.75 7.88 7.87 0.11 5.34 5.96 5.29 5.53 0.37 0.67 3.93 2.67 3.87 3.49 0.71
NW US 300
NW DS 60 7.89 7.88 7.84 7.87 0.03 6.01 5.92 5.82 5.92 0.10 0.20 9.40 9.80 10.10 9.77 0.35 4.69 0.23
NW DS150 7.95 7.78 7.77 7.83 0.10 5.91 5.78 5.97 5.89 0.10 0.50 4.08 4.00 3.60 3.89 0.26
NW DS 200 7.89 7.78 7.71 7.79 0.09 5.68 5.71 5.8 5.73 0.06 0.67 3.30 3.09 2.85 3.08 0.22
NW DS 300 7.96 7.88 7.91 7.92 0.04 5.9 5.95 5.81 5.89 0.07 1.00 2.06 1.93 2.10 2.03 0.09
CONTROL 8.19 8.21 8.17 8.19 0.02 8.14 8.21 8.09 8.15 0.06 1.00 0.05 0.00 0.08 0.04 0.04
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BOD DAY 0 BOD DAY 5
Point 1 2 3 Average Std Dev 1 2 3 Average Std Dev P Value BOD 1 BOD 2 BOD 3 Average Std Dev FINAL Std Dev
NW BC 200 6.89 6.96 6.8 6.88 0.08 5.89 5.5 5.75 5.71 0.20 0.67 1.49 2.18 1.57 1.75 0.38 1.54 0.30
NW BC 225 6.63 6.78 6.64 6.68 0.08 5.29 5.84 5.8 5.64 0.31 0.72 1.86 1.31 1.17 1.44 0.37
NW BC 275
NW BC 300 6.17 6.17 6.03 6.12 0.08 4.85 4.76 4.43 4.68 0.22 1.00 1.32 1.41 1.60 1.44 0.14
NW AC 200 6.47 6.47 6.04 6.33 0.25 5.25 5.33 5.12 5.23 0.11 0.67 1.82 1.70 1.37 1.63 0.23 2.23 0.28
NW AC 225 6.07 6.02 6.18 6.09 0.08 4.44 4.73 4.63 4.60 0.15 0.72 2.26 1.79 2.15 2.07 0.25
NW AC 275 5.66 5.3 5.47 5.48 0.18 4.6 4.66 4.79 4.68 0.10
NW AC 300 5.85 5.77 5.9 5.84 0.07 5.15 5.8 5.7 5.55 0.35 1.00 0.70 -0.03 0.20 3.00 0.37
NW US 60 7.91 7.91 7.82 7.88 0.05 4.72 4.79 4.77 4.76 0.04 0.20 15.95 15.60 15.25 15.60 0.35 7.80 0.21
NW US 150 7.6 7.52 7.58 7.57 0.04 4.67 4.76 4.65 4.69 0.06 0.50 5.86 5.52 5.86 5.75 0.20
NW US 200 7.82 7.79 7.72 7.78 0.05 5.14 5.37 5.6
NW US 300 7.54 7.54 7.55 7.54 0.01 5.42 5.48 5.6 5.50 0.09 1.00 2.12 2.06 1.95 2.04 0.09
NW DS 60 8.11 8 8.02 8.04 0.06 5.35 5.67 5.72 5.58 0.20 0.20 13.80 11.65 11.50 12.32 1.29 5.74 0.50
NW DS150 8 8 8.01 8.00 0.01 5.05 5.18 5.27 5.17 0.11 0.50 5.90 5.64 5.48 5.67 0.21
NW DS 200 8.01 8.04 8 8.02 0.02 6.22 6.3 6.04 6.19 0.13 0.67 2.67 2.60 2.93 2.73 0.17
NW DS 300 8.02 8.04 8.05 8.04 0.02 5.8 5.46 6.1 5.79 0.32 1.00 2.22 2.58 1.95 2.25 0.32




































NW BC 1 12.5988 12.6899 0.0911 12.6943 0.0955 0.0176 0.01 0.003355
NW BC 2 12.7003 12.7931 0.0928 12.796 0.0957 0.0116
NW BC 3 13.0776 13.1697 0.0921 13.1727 0.0951 0.012
NW AC 1 12.7741 12.8652 0.0911 12.865 0.0909 -0.0008 0.03 0.023829
NW AC 2 12.4964 12.5895 0.0931 12.598 0.1016 0.034
NW AC 3 13.469 13.5594 0.0904 13.5706 0.1016 0.0448
NW US 1 12.7538 12.8458 0.092 14.3782 1.6244 6.1296 1.24 4.299678
NW US 2 12.7145 12.8056 0.0911 12.6976 -0.0169 -0.432
NW US 3 12.8333 12.9256 0.0923 12.4344 -0.3989 -1.9648
NW DS 1 12.2821 12.3749 0.0928 12.849 0.5669 1.8964 1.13 1.023156
NW DS 2 12.3402 12.431 0.0908 12.8102 0.47 1.5168
























NW BC 1 13.0773 13.1687 0.0914 13.1877 0.1104 0.095 0.096 0.018021
NW BC 2 12.7 12.7927 0.0927 12.8156 0.1156 0.1145
NW BC 3 12.5994 12.6925 0.0931 12.7082 0.1088 0.0785
NW AC 1 12.7741 12.8661 0.092 12.8815 0.1074 0.0616 0.066 0.022666
NW AC 2 14.2819 14.3749 0.093 14.3862 0.1043 0.0452
NW AC 3 13.4686 13.5615 0.0929 13.584 0.1154 0.09
NW US 1 12.7533 12.8447 0.0914 12.8488 0.0955 0.0164 0.015 0.001222
NW US 2 12.4966 12.5895 0.0929 12.5934 0.0968 0.0156
NW US 3 12.8333 12.9268 0.0935 12.9303 0.097 0.014
NW DS 1 12.6015 12.6936 0.0921 12.6969 0.0954 0.0132 0.012 0.006503
NW DS 2 12.3404 12.4311 0.0907 12.4355 0.0951 0.0176
NW DS 3 12.7148 12.808 0.0932 12.8092 0.0944 0.0048































N TSS  AVG SD 
NW BC 1 24.9914 25.3208 0.3294 25.3274 0.336 0.033 0.035 0.004444 
NW BC 2 24.424 24.756 0.332 24.7639 0.3399 0.0395     
NW BC 3 37.4848 37.8149 0.3301 37.8211 0.3363 0.031     
NW AC 1 21.9558 22.2827 0.3269 22.2858 0.33 0.0124 0.016 0.005787 
NW AC 2 22.2848 22.6155 0.3307 22.6188 0.334 0.0132     
NW AC 3 24.431 24.7605 0.3295 24.7662 0.3352 0.0228     
NW US 1 24.3661 24.6937 0.3276 24.6982 0.3321 0.018 0.013 0.004277 
NW US 2 22.4333 22.7659 0.3326 22.7683 0.335 0.0096     
NW US 3 24.37 24.7013 0.3313 24.7044 0.3344 0.0124     
NW DS 1 59.4128 59.739 0.3262 59.746 0.3332 0.028 5.925 9.129095 
NW DS 2 24.3979 24.9689 0.571 25.2957 0.8978 1.3072     
NW DS 3 19.9517 20.2856 0.3339 24.3958 4.4441 
16.440
8     
C0NTRO
L 21.9423 22.2762 0.3339 22.2768 0.3345 0.0024     
 
 Table 18: TSS values obtained in June 



























NW BC 1 13.1784 13.273 0.0946 13.276 0.0976 0.015 0.017667 0.002754 
NW BC 2 12.5997 12.6929 0.0932 12.697 0.0973 0.0205     
NW BC 3 12.7012 12.7954 0.0942 12.7989 0.0977 0.0175     
NW AC 1 14.5535 14.6457 0.0922 14.651 0.0975 0.0212 0.0204 0.002498 
NW AC 2 14.2797 14.372 0.0923 14.3776 0.0979 0.0224     
NW AC 3 13.4671 13.5608 0.0937 13.5652 0.0981 0.0176     
NW US 1 12.7521 12.8455 0.0934 12.8471 0.095 0.0064 0.0068 0.000693 
NW US 2 12.4958 12.5899 0.0941 12.5918 0.096 0.0076     
NW US 3 12.8323 12.9258 0.0935 12.9274 0.0951 0.0064     
NW DS 1 12.5412 12.6336 0.0924 12.6358 0.0946 0.0088 0.0112 0.002227 
NW DS 2 12.34 12.4326 0.0926 12.4359 0.0959 0.0132     
NW DS 3 12.7144 12.8064 0.092 12.8093 0.0949 0.0116     
C0NTRO

































NW BC 1 13.0768 13.1695 0.0927 13.1765 0.0997 0.035 0.03 0.005568 
NW BC 2 12.5997 12.6924 0.0927 12.6972 0.0975 0.024     
NW BC 3 12.6995 12.7923 0.0928 12.7985 0.099 0.031     
NW AC 1 14.5553 14.6482 0.0929 14.6554 0.1001 0.0288 0.028 0.00485 
NW AC 2 14.2811 14.375 0.0939 14.3807 0.0996 0.0228     
NW AC 3 13.4686 13.5619 0.0933 13.57 0.1014 0.0324     
NW US 1 12.7533 12.8455 0.0922 12.8473 0.094 0.0072 0.007067 0.001007 
NW US 2 12.4961 12.5889 0.0928 12.5909 0.0948 0.008     
NW US 3 12.774 12.866 0.092 12.8675 0.0935 0.006     
NW DS 1 12.5399 12.6328 0.0929 12.6377 0.0978 0.0196 0.0164 0.002884 
NW DS 2 12.6013 12.6946 0.0933 12.6985 0.0972 0.0156     
NW DS 3 13.1786 13.2718 0.0932 13.2753 0.0967 0.014     
C0NTRO






















































NW BC 1 13.0776 13.1695 0.0919 13.1789 0.1013 0.047 0.037333 0.01193 
NW BC 2 12.5983 12.6913 0.093 12.6995 0.1012 0.041     
NW BC 3 12.6991 12.793 0.0939 12.7978 0.0987 0.024     
NW AC 1 14.5545 14.6474 0.0929 14.6587 0.1042 0.0452 0.048533 
0.00388
5 
NW AC 2 12.7131 12.8069 0.0938 12.8188 0.1057 0.0476     
NW AC 3 13.4671 13.56 0.0929 13.5732 0.1061 0.0528     
NW US 1 12.7516 12.8449 0.0933 12.8519 0.1003 0.028 0.023867 
0.00358
5 
NW US 2 12.4952 12.5876 0.0924 12.5931 0.0979 0.022     
NW US 3 12.7725 12.8649 0.0924 12.8703 0.0978 0.0216     
NW DS 1 12.541 12.6328 0.0918 12.6368 0.0958 0.016 0.015467 
0.00205
3 
NW DS 2 12.6 12.6929 0.0929 12.6962 0.0962 0.0132     
NW DS 3 13.1756 13.2688 0.0932 13.2731 0.0975 0.0172     
C0NTRO
L 12.4684 12.5609 0.0925 12.561 0.0926 0.0004     
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B: New Germany Wastewater Works 
 
Table 1: Temperature values obtained over the six month period 
 
Temperature °C 





 BC 26.00 25.50 25.50 25.67 0.29 
DP 26.00 26.00 26.00 26.00 0.00 
US 26.00 26.00 26.00 26.00 0.00 





BC 20.00 20.50 20.00 20.17 0.29 
DP 20.50 20.00 20.00 20.17 0.29 
US 18.00 18.00 17.00 17.67 0.58 





BC 19.00 19.00 19.00 19.00 0.00 
DP 18.50 18.50 18.50 18.50 0.00 
US 13.00 14.00 14.00 13.67 0.58 





BC 18.00 18.00 18.00 18.00 0.00 
DP 17.50 17.50 17.50 17.50 0.00 
US 16.00 16.00 16.00 16.00 0.00 





BC 16.50 16.50 16.50 16.50 0.00 
DP 17.00 17.00 17.00 17.00 0.00 
US 13.50 13.50 13.50 13.50 0.00 






 BC 16.80 16.80 16.80 16.80 0.00 
DP 16.50 16.50 16.50 16.50 0.00 
US 14.50 14.50 14.50 14.50 0.00 
















Table 2: Salinity of the water samples over the six month period 
 
Salinity % 





 BC 0.44 0.43 0.44 0.44 0.01 
DP 0.47 0.48 0.48 0.48 0.01 
US 0.21 0.21 0.21 0.21 0.00 





BC 0.39 0.39 0.38 0.39 0.01 
DP 0.43 0.43 0.44 0.43 0.01 
US 0.16 0.16 0.16 0.16 0.00 





BC 0.57 0.57 0.57 0.57 0.00 
DP 0.63 0.62 0.62 0.62 0.01 
US 0.17 0.17 0.17 0.17 0.00 





BC 0.53 0.53 0.54 0.53 0.01 
DP 0.58 0.58 0.58 0.58 0.00 
US 0.18 0.18 0.18 0.18 0.00 





BC 0.46 0.47 0.47 0.47 0.01 
DP 0.52 0.52 0.53 0.52 0.01 
US 0.15 0.15 0.15 0.15 0.00 






 BC 0.41 0.42 0.42 0.42 0.01 
DP 0.47 0.47 0.47 0.47 0.00 
US 0.35 0.34 0.34 0.34 0.00 
















Table 3: Conductivity of the water samples over the six month period 
 
Conductivity (µS/cm) 





 BC 893.00 854.00 888.00 878.33 21.22 
DP 957.00 976.00 978.00 970.33 11.59 
US 428.00 433.00 433.00 431.33 2.89 





BC 791.00 793.00 787.00 790.33 3.06 
DP 883.00 880.00 889.00 884.00 4.58 
US 330.00 329.00 327.00 328.67 1.53 





BC 1143.00 1148.00 1154.00 1148.33 5.51 
DP 1257.00 1251.00 1253.00 1253.67 3.06 
US 365.00 363.00 363.00 363.67 1.15 





BC 1086.00 1082.00 1085.00 1084.33 2.08 
DP 1164.00 1167.00 1168.00 1166.33 2.08 
US 384.00 383.00 384.00 383.67 0.58 





BC 974.00 975.00 975.00 974.67 0.58 
DP 1069.00 1068.00 1070.00 1069.00 1.00 
US 322.00 322.00 321.00 321.67 0.58 






 BC 849.00 851.00 848.00 849.33 1.53 
DP 960.00 958.00 956.00 958.00 2.00 
US 699.00 707.00 714.00 706.67 7.51 
















Table 4: Resistivity of the water samples over the six month period 
 
Resistivity (Ὠ.cm) 





 BC 1120.00 1131.00 1126.00 1125.67 5.51 
DP 1025.00 1022.00 1024.00 1023.67 1.53 
US 2340.00 2310.00 2310.00 2320.00 17.32 





BC 1265.00 1261.00 1270.00 1265.33 4.51 
DP 1132.00 1137.00 1125.00 1131.33 6.03 
US 303.00 304.00 306.00 304.33 1.53 





BC 875.00 871.00 867.00 871.00 4.00 
DP 795.00 800.00 798.00 797.67 2.52 
US 2.74 2.76 2.76 2.75 0.01 





BC 926.00 924.00 926.00 925.33 1.15 
DP 859.00 857.00 856.00 857.33 1.53 
US 2610.00 2610.00 2610.00 2610.00 0.00 





BC 1026.00 1027.00 1027.00 1026.67 0.58 
DP 936.00 935.00 935.00 935.33 0.58 
US 3110.00 3110.00 3110.00 3110.00 0.00 






 BC 1175.00 1206.00 1180.00 1187.00 16.64 
DP 1042.00 1044.00 1046.00 1044.00 2.00 
US 1432.00 1414.00 1411.00 1419.00 11.36 
















Table 5: TDS concentrations obtained over the six month period 
 
Total Dissolved Solids mg/L 





 BC 438.00 434.00 436.00 436.00 2.00 
DP 471.00 480.00 481.00 477.33 5.51 
US 206.00 209.00 208.90 207.97 1.70 





BC 387.00 388.00 385.00 386.67 1.53 
DP 433.00 432.00 436.00 433.67 2.08 
US 158.30 157.80 156.90 157.67 0.71 





BC 565.00 567.00 570.00 567.33 2.52 
DP 623.00 620.00 621.00 621.33 1.53 
US 175.40 174.40 174.20 174.67 0.64 





BC 536.00 534.00 533.00 534.33 1.53 
DP 576.00 578.00 578.00 577.33 1.15 
US 184.20 184.60 184.80 184.53 0.31 





BC 464.00 467.00 470.00 467.00 3.00 
DP 523.00 527.00 527.00 525.67 2.31 
US 154.30 154.30 153.90 154.17 0.23 






 BC 416.00 417.00 417.00 416.67 0.58 
DP 472.00 471.00 470.00 471.00 1.00 
US 341.00 345.00 348.00 344.67 3.51 




























Point Replicate 1 Replicate 2 Replicate 3 Average Std Dev Replicate 1 Replicate 2Replicate 3 Average Std Dev Final Ave Std dev
BC 7.08 6.93 7.35 7.12 0.21 7.08 6.93 7.35 7.12 0.21 7.12 0.00
DP 7.29 7.05 7.21 7.18 0.12 7.29 7.05 7.21 7.18 0.12 7.18 0.00
US 7.61 7.51 7.44 7.52 0.09 7.61 7.51 7.44 7.52 0.09 7.52 0.00
DS 7.43 7.60 7.49 7.51 0.09 7.43 7.60 7.49 7.51 0.09 7.51 0.00
BC 6.61 6.63 6.58 6.61 0.03 7.01 7.02 7.08 7.04 0.03 6.82 0.25
DP 6.54 6.56 6.60 6.57 0.03 6.83 6.82 6.82 6.82 0.01 6.70 0.15
US 6.80 6.68 6.81 6.76 0.07 7.06 7.09 7.10 7.08 0.02 6.92 0.18
DS 7.16 7.09 7.00 7.08 0.08 6.93 6.93 6.93 6.93 0.00 7.01 0.09
BC 6.97 6.94 6.81 6.91 0.09 7.18 6.93 6.76 6.96 0.19 6.93 0.03
DP 7.02 7.02 7.03 7.02 0.01 6.97 6.80 6.75 6.84 0.10 6.93 0.11
US 6.39 6.40 6.48 6.42 0.05 6.79 6.77 6.92 6.83 0.07 6.63 0.23
DS 7.10 7.10 7.10 7.10 0.00 6.69 6.51 6.50 6.57 0.10 6.83 0.31
BC 7.57 7.58 7.59 7.58 0.01 7.61 7.63 7.63 7.62 0.01 7.60 0.03
DP 7.66 7.67 7.68 7.67 0.01 7.54 7.55 7.55 7.55 0.01 7.61 0.07
US 7.93 7.91 7.93 7.92 0.01 7.94 7.92 7.93 7.93 0.01 7.93 0.00
DS 7.79 7.78 7.78 7.78 0.01 7.83 7.83 7.83 7.83 0.00 7.81 0.03
BC 6.92 7.00 6.85 6.92 0.07 6.63 6.43 6.53 6.53 0.09 6.73 0.23
DP 6.26 6.37 6.28 6.30 0.05 6.88 6.89 6.90 6.89 0.01 6.60 0.34
US 6.40 6.37 6.38 6.38 0.01 6.29 6.30 6.31 6.30 0.01 6.34 0.05
DS 6.05 5.90 6.03 5.99 0.07 6.82 6.99 7.00 6.94 0.09 6.47 0.54
BC 6.75 6.26 6.95 6.65 0.36 6.75 6.26 6.95 6.65 0.36 6.65 0.00
DP 7.05 7.09 7.18 7.11 0.07 7.05 7.09 7.18 7.11 0.07 7.11 0.00
US 7.10 7.11 7.15 7.12 0.03 7.10 7.11 7.15 7.12 0.03 7.12 0.00




























       Table 7: Turbidity of the water samples over the six month period 
 










Point Replicate 1 Replicate 2 Replicate 3 Average Std Dev Replicate 1 Replicate 2Replicate 3 Average Std Dev Final Ave Std dev
BC 6.41 6.86 6.67 6.65 0.23 6.41 6.86 6.67 6.65 0.23 6.65 0.00
DP 5.45 5.29 6.38 5.71 0.59 5.45 5.29 6.38 5.71 0.59 5.71 0.00
US 5.22 5.15 5.12 5.16 0.05 5.22 5.15 5.12 5.16 0.05 5.16 0.00
DS 7.70 7.13 7.14 7.32 0.33 7.70 7.13 7.14 7.32 0.33 7.32 0.00
BC 1.52 1.52 1.52 1.52 0.00 1.15 1.15 1.15 1.15 0.00 1.34 0.21
DP 1.43 1.43 1.40 1.42 0.02 1.44 1.46 1.45 1.45 0.01 1.44 0.02
US 8.23 8.23 8.23 8.23 0.00 9.27 9.27 9.28 9.27 0.01 8.75 0.60
DS 17.00 17.00 17.00 17.00 0.00 17.20 17.20 17.20 17.20 0.00 17.10 0.12
BC 28.70 28.70 28.70 28.70 0.00 25.90 20.10 19.10 21.70 3.28 25.20 4.04
DP 30.30 30.30 30.30 30.30 0.00 14.40 14.30 14.40 14.37 0.05 22.33 9.20
US 3.18 3.18 3.18 3.18 0.00 14.70 14.30 14.10 14.37 0.27 8.77 6.46
DS 17.80 17.80 17.80 17.80 0.00 14.30 14.50 14.00 14.27 0.23 16.03 2.04
BC 4.68 4.73 4.78 4.73 0.04 10.50 10.20 11.20 10.63 0.46 7.68 3.41
DP 5.94 5.96 5.88 5.93 0.04 8.91 9.15 8.99 9.02 0.11 7.47 1.78
US 4.11 4.11 4.11 4.11 0.00 9.65 9.65 9.60 9.63 0.03 6.87 3.19
DS 4.19 4.19 4.19 4.19 0.00 14.00 14.20 14.00 14.07 0.10 9.13 5.70
BC 23.40 20.70 19.70 21.27 1.91 20.20 20.00 20.00 20.07 0.15 20.67 0.69
DP 27.70 28.70 28.40 28.27 0.51 20.70 20.60 20.90 20.73 0.00 24.50 4.35
US 12.30 12.60 12.20 12.37 0.21 2.43 2.43 2.43 2.43 0.00 7.40 5.74
DS 23.80 23.30 23.40 23.50 0.26 16.10 16.10 16.10 16.10 0.00 19.80 4.27
BC 19.60 19.70 19.90 19.73 0.15 19.60 19.70 19.90 19.73 0.15 19.73 0.00
DP 16.90 16.60 16.90 16.80 0.17 16.90 16.60 16.90 16.80 0.17 16.80 0.00
US 40.10 40.30 40.80 40.40 0.36 40.10 40.30 40.80 40.40 0.36 40.40 0.00




































Replicate 1Replicate 2Replicate 3Average Average 1 Std Dev Replicate 1Replicate 2 Replicate 3 Average Std Dev Average 2 Final Ave Std Dev
BC 1 149.00 150.00 150.00 149.67 0.58 151.00 150.00 149.00 150.00 1.00
BC2 174.00 169.00 163.00 168.67 5.51 166.00 167.00 167.00 166.67 0.58
BC3 147.00 145.00 145.00 145.67 1.15 145.00 146.00 145.00 145.33 0.58
DP 1 245.00 251.00 251.00 249.00 3.46 247.00 249.00 249.00 248.33 1.15
DP 2 239.00 239.00 239.00 239.00 0.00 235.00 237.00 237.00 236.33 1.15
DP 3 229.00 234.00 234.00 232.33 2.89 229.00 230.00 229.00 229.33 0.58
US 1 153.00 153.00 153.00 153.00 0.00 314.00 314.00 314.00 314.00 0.00
US 2 142.00 141.00 141.00 141.33 0.58 314.00 314.00 314.00 314.00 0.00
US 3 131.00 131.00 132.00 131.33 0.58 310.00 311.00 312.00 311.00 1.00
DS 1 311.00 314.00 314.00 313.00 1.73 153.00 153.00 153.00 153.00 0.00
DS 2 315.00 314.00 316.00 315.00 1.00 140.00 140.00 140.00 140.00 0.00
DS 3 313.00 315.00 316.00 314.67 1.53 132.00 131.00 131.00 131.33 0.58
BC 1 212.00 210.00 211.00 211.00 1.00 201.00 201.00 201.00 201.00 0.00
BC2 193.00 193.00 193.00 193.00 0.00 195.00 195.00 195.00 195.00 0.00
BC3 204.00 205.00 204.00 204.33 0.58 191.00 191.00 192.00 191.33 0.58
DP 1 190.00 190.00 190.00 190.00 0.00 180.00 181.00 181.00 180.67 0.58
DP 2 173.00 173.00 175.00 173.67 1.15 180.00 180.00 180.00 180.00 0.00
DP 3 179.00 179.00 180.00 179.33 0.58 179.00 178.00 178.00 178.33 0.58
US 1 101.00 101.00 101.00 101.00 0.00 106.00 106.00 106.00 106.00 0.00
US 2 106.00 105.00 105.00 105.33 0.58 100.00 100.00 100.00 100.00 0.00
US 3 105.00 107.00 107.00 106.33 1.15 95.00 95.00 95.00 95.00 0.00
DS 1 112.00 112.00 112.00 112.00 0.00 113.00 113.00 113.00 113.00 0.00
DS 2 114.00 114.00 114.00 114.00 0.00 116.00 116.00 116.00 116.00 0.00
DS 3 125.00 125.00 123.00 124.33 1.15 113.00 113.00 113.00 113.00 0.00
BC 1 312.00 312.00 312.00 312.00 0.00 315.00 314.00 314.00 314.33 0.52
BC2 310.00 313.00 312.00 311.67 1.53 312.00 312.00 311.00 311.67 0.52
BC3 313.00 313.00 313.00 313.00 0.00 312.00 313.00 317.00 314.00 1.30
DP 1 247.00 247.00 247.00 247.00 0.00 238.00 240.00 245.00 241.00 3.22
DP 2 249.00 249.00 249.00 249.00 0.00 246.00 245.00 246.00 245.67 0.52
DP 3 241.00 243.00 245.00 243.00 2.00 247.00 245.00 247.00 246.33 1.03
US 1 298.00 299.00 298.00 298.33 0.58 311.00 311.00 310.00 310.67 0.52
US 2 299.00 299.00 298.00 298.67 0.58 313.00 314.00 313.00 313.33 0.52
US 3 299.00 299.00 299.00 299.00 0.00 313.00 315.00 313.00 313.67 1.03
DS 1 314.00 314.00 312.00 313.33 1.15 292.00 292.00 292.00 292.00 0.00
DS 2 313.00 312.00 314.00 313.00 1.00 290.00 293.00 296.00 293.00 2.68




























































            Table 8 continued… 
 
           
Replicate 1Replicate 2Replicate 3Average Average 1 Std DevReplicate 1Replicate 2Replicate 3Average Std Dev Average 2Final Ave Std Dev
BC 1 303.00 303.00 302.00 302.67 0.58 312.00 309.00 309.00 310.00 1.55
BC2 306.00 305.00 304.00 305.00 1.00 312.00 309.00 309.00 310.00 1.55
BC3 306.00 305.00 305.00 305.33 0.58 312.00 309.00 309.00 310.00 1.55
DP 1 110.00 111.00 111.00 110.67 0.58 110.00 111.00 111.00 110.67 0.52
DP 2 113.00 113.00 113.00 113.00 0.00 113.00 113.00 113.00 113.00 0.00
DP 3 109.00 108.00 108.00 108.33 0.58 109.00 108.00 108.00 108.33 0.52
US 1 34.00 32.00 33.00 33.00 1.00 25.00 18.00 24.00 22.33 3.39
US 2 29.00 29.00 29.00 29.00 0.00 25.00 18.00 24.00 22.33 3.39
US 3 29.00 29.00 29.00 29.00 0.00 25.00 18.00 24.00 22.33 3.39
DS 1 75.00 75.00 75.00 75.00 0.00 78.00 72.00 70.00 73.33 3.72
DS 2 76.00 75.00 75.00 75.33 0.58 78.00 72.00 70.00 73.33 3.72
DS 3 63.00 63.00 64.00 63.33 0.58 78.00 72.00 70.00 73.33 3.72
BC 1 194.00 193.00 194.00 193.67 0.58 194.00 193.00 194.00 193.67 0.58
BC2 190.00 190.00 190.00 190.00 0.00 190.00 190.00 190.00 190.00 0.00
BC3 197.00 198.00 197.00 197.33 0.58 197.00 198.00 197.00 197.33 0.58
DP 1 309.00 309.00 309.00 309.00 0.00 309.00 309.00 309.00 309.00 0.00
DP 2 309.00 308.00 308.00 308.33 0.58 309.00 308.00 308.00 308.33 0.58
DP 3 310.00 307.00 309.00 308.67 1.53 310.00 309.00 307.00 308.67 1.53
US 1 314.00 310.00 311.00 311.67 2.08 314.00 310.00 311.00 311.67 2.08
US 2 310.00 310.00 310.00 310.00 0.00 310.00 310.00 310.00 310.00 0.00
US 3 304.00 309.00 304.00 305.67 2.89 309.00 309.00 304.00 307.33 2.89
DS 1 292.00 292.00 291.00 291.67 0.58 298.00 299.00 298.00 298.33 0.58
DS 2 295.00 295.00 295.00 295.00 0.00 295.00 296.00 296.00 295.67 0.58
DS 3 305.00 302.00 302.00 303.00 1.73 304.00 305.00 305.00 304.67 0.58
BC 1 138.00 139.00 139.00 138.67 0.58 138.00 139.00 139.00 138.67 0.58
BC2 142.00 140.00 140.00 140.67 1.15 142.00 140.00 140.00 140.67 1.15
BC3 139.00 139.00 140.00 139.33 0.58 139.00 139.00 140.00 139.33 0.58
DP 1 308.00 307.00 308.00 307.67 0.58 308.00 307.00 308.00 307.67 0.58
DP 2 309.00 310.00 308.00 309.00 1.00 309.00 310.00 308.00 309.00 1.00
DP 3 310.00 310.00 311.00 310.33 0.58 310.00 310.00 311.00 310.33 0.58
US 1 205.00 207.00 207.00 206.33 1.15 205.00 207.00 207.00 206.33 1.15
US 2 208.00 208.00 208.00 208.00 0.00 208.00 208.00 208.00 208.00 0.00
US 3 209.00 208.00 208.00 208.33 0.58 209.00 208.00 208.00 208.33 0.58
DS 1 313.00 313.00 312.00 312.67 0.58 313.00 313.00 312.00 312.67 0.58
DS 2 312.00 312.00 311.00 311.67 0.58 312.00 312.00 311.00 311.67 0.58






































































BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 8.37 8.17 8.25 8.26 0.10 7.15 7.05 7.23 7.14 0.09 0.67 1.82 1.67 1.52 1.67 0.15 2.20 0.13
NW BC 225 8.06 8.08 8.03 8.06 0.03 6.18 6.36 6.15 6.23 0.11 0.72 2.61 2.39 2.61 2.54 0.13
NW BC 275 8.24 8.15 8.04 8.14 0.10 5.89 5.73 5.76 5.79 0.09 0.92 2.55 2.63 2.48 2.55 0.08
NW BC 300 8.27 8.12 8.15 8.18 0.08 6.12 6.04 6.31 6.16 0.14 1.00 2.15 2.08 1.84 2.02 0.16
NW AC 200 8.37 8.27 8.15 8.26 0.11 5.64 5.86 5.43 5.64 0.22 0.67 4.07 3.60 4.06 3.91 0.27 3.12 0.27
NW AC 225 8.23 8.25 8.26 8.25 0.02 6.69 6.41 6.33 6.48 0.19 0.72 2.14 2.56 2.68 2.46 0.28
NW AC 275 8.15 8 8 8.05 0.09 6.06 5.83 5.93 5.94 0.12
NW AC 300 7.97 8.18 8.08 8.08 0.11 5.99 5.73 5.96 5.89 0.14 1.00 1.98 2.45 2.12 3.00 0.24
NW US 60 8.47 8.56 8.56 8.53 0.05 5.57 5.21 5.05 5.28 0.27 0.20 14.50 16.75 17.55 16.27 1.58 7.79 0.83
NW US 150 8.64 8.59 8.59 8.61 0.03 6.59 6.38 6.93 6.63 0.28 0.50 4.10 4.42 3.32 3.95 0.57
NW US 200 8.61 8.58 8.58 4.24 4.12 4.72
NW US 300 8.63 8.62 8.6 8.62 0.02 5.83 5.15 5.36 5.45 0.35 1.00 2.80 3.47 3.24 3.17 0.34
NW DS 60 8.69 8.63 8.62 8.65 0.04 6.68 6.62 6.18 6.49 0.27 0.20 10.05 10.05 12.20 10.77 1.24 4.97 0.59
NW DS150 8.59 8.58 8.57 8.58 0.01 6.76 6.25 6.86 6.62 0.33 0.50 3.66 4.66 3.42 3.91 0.66
NW DS 200 8.65 8.66 8.64 8.65 0.01 6.41 6.1 6.62 6.38 0.26 0.67 3.34 3.82 3.01 3.39 0.41
NW DS 300 8.66 8.61 8.59 8.62 0.04 6.86 6.72 6.82 6.80 0.07 1.00 1.80 1.89 1.77 1.82 0.06
CONTROL 8.71 8.7 8.69 8.70 0.01 6.84 6.19 6.19 6.41 0.38 1.00 1.87 2.51 2.50 2.29 0.37
March
BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NG BC 200 8.49 8.45 8.45 8.46 0.02 5.73 5.33 5.49 5.52 0.20 0.67 4.12 4.66 4.42 4.40 0.27 3.75 0.29
NG BC 225 8.37 8.36 8.35 8.36 0.01 5.31 5.52 5.86 5.56 0.28 0.72 4.25 3.94 3.46 3.88 0.40
NG BC 275
NG BC 300 8.35 8.38 8.38 8.37 0.02 5.17 5.59 5.46 5.41 0.22 1.00 3.18 2.79 2.92 2.96 0.20
NG AC 200 8.49 8.49 8.46 8.48 0.02 6.33 6.5 6.3 6.38 0.11 0.67 3.22 2.97 3.22 3.14 0.15 3.72 0.14
NG AC 225 8.5 8.49 8.5 8.50 0.01 5.31 5.37 5.41 5.36 0.05 0.72 4.43 4.33 4.29 4.35 0.07
NG AC 275 8.52 8.52 8.54 8.53 0.01 5.38 5.39 5.09 5.29 0.17 0.92 3.41 3.40 3.75 3.52 0.20
NG AC 300 8.56 8.52 8.5 8.53 0.03 4.74 4.47 4.71 4.64 0.15 1.00 3.82 4.05 3.79 3.89 0.14
NG US 60 8.51 8.47 8.46 8.48 0.03 4.93 4.98 4.83 4.91 0.08 0.20 17.90 17.45 18.15 17.83 0.35 9.26 0.24
NG US 150 8.64 8.68 8.68 8.67 0.02 4.22 4.22 4.35 4.26 0.08 0.50 8.84 8.92 8.66 8.81 0.13
NG US 200 8.73 8.78 8.78 8.76 0.03 4.72 4.25 4.34 4.44 0.25 0.67 5.99 6.76 6.63 6.46 0.41
NG US 300 8.83 8.86 8.89 8.86 0.03 4.97 4.95 4.88 4.93 0.05 1.00 3.86 3.91 4.01 3.93 0.08
NG DS 60 8.54 8.52 8.56 8.54 0.02 4.25 4.95 4.2 4.47 0.42 0.20 21.45 17.85 21.80 20.37 2.19 9.34 0.83
NG DS150 8.64 8.64 8.63 8.64 0.01 4.63 4.35 4.01 4.33 0.31 0.50 8.02 8.58 9.24 8.61 0.61
NG DS 200 8.71 8.72 8.75 8.73 0.02 5.69 5.86 5.32 5.62 0.28 0.67 4.51 4.27 5.12 4.63 0.44
NG DS 300 8.85 8.85 8.81 8.84 0.02 5.07 5.05 5.13 5.08 0.04 1.00 3.78 3.80 3.68 3.75 0.06












BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 8.34 8.36 8.47 8.39 0.07 5.99 5 5.1 5.36 0.55 0.67 3.51 5.01 5.03 4.52 0.87 3.15 0.25
NW BC 225 8.38 8.34 8.35 8.36 0.02 4.96 4.88 4.81 4.88 0.08 0.72 4.75 4.81 4.92 4.82 0.08
NW BC 275 0.92 0.00 0.00 0.00 0.00 0.00
NW BC 300 8.17 8.16 8.08 8.14 0.05 4.95 4.88 4.81 4.88 0.07 1.00 3.22 3.28 3.27 3.26 0.03
NW AC 200 8.08 8.16 8.1 8.11 0.04 4.44 4.35 4.27 4.35 0.09 0.67 5.43 5.69 5.72 5.61 0.16 4.72 0.16
NW AC 225 8.41 8.45 8.35 8.40 0.05 4.39 4.61 4.24 4.41 0.19 0.72 5.58 5.33 5.71 5.54 0.19
NW AC 275 8.09 8 8.1 8.06 0.06 4.41 4.67 4.4 4.49 0.15 0.92 4.00 3.62 4.02 3.88 0.23
NW AC 300 8.25 8.13 8.14 8.17 0.07 4.43 4.24 4.36 4.34 0.10 1.00 3.82 3.89 3.78 3.83 0.06
NW US 60 8.79 8.73 8.7 8.74 0.05 4.88 4.87 4.24 4.66 0.37 0.20 19.55 19.30 22.30 20.38 1.66 11.04 0.97
NW US 150 8.61 8.65 8.68 8.65 0.04 4.84 4.09 4.44 4.46 0.38 0.50 7.54 9.12 8.48 8.38 0.79
NW US 200 8.79 8.87 8.89 8.85 0.05 4.92 4.38 4.64
NW US 300 8.83 8.87 8.89 8.86 0.03 4.94 4.07 4.52 4.51 0.44 1.00 3.89 4.80 4.37 4.35 0.46
NW DS 60 8.49 8.56 8.59 8.55 0.05 4.35 4.07 4.24 4.22 0.14 0.20 20.70 22.45 21.75 21.63 0.88 9.67 0.55
NW DS150 8.64 8.64 8.61 8.63 0.02 4.95 4.21 4.56 4.57 0.37 0.50 7.38 8.86 8.10 8.11 0.74
NW DS 200 8.68 8.65 8.65 8.66 0.02 4.3 4.87 4.62 4.60 0.29 0.67 6.54 5.64 6.01 6.06 0.45
NW DS 300 8.57 8.49 8.51 8.52 0.04 5.84 5.53 5.55 5.64 0.17 1.00 2.73 2.96 2.96 2.88 0.13
CONTROL 8.65 8.63 8.60 8.63 0.03 7.66 7.67 7.69 7.67 0.02 1.00 0.99 0.96 0.91 0.95 0.04
May
BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 7.86 7.81 7.84 7.84 0.03 4.65 4.15 4.31 4.37 0.26 0.67 4.79 5.46 5.27 5.17 0.35 4.17 0.39
NW BC 225 7.82 7.85 7.88 7.85 0.03 4.81 4.13 4.47 4.47 0.34 0.72 4.18 5.17 4.74 4.69 0.49
NW BC 275 7.91 7.93 7.91 7.92 0.01 4.7 4.99 4.33 4.67 0.33 0.92 3.49 3.20 3.89 3.53 0.35
NW BC 300 7.93 7.96 7.99 7.96 0.03 4.95 4.79 4.33 4.69 0.32 1.00 2.98 3.17 3.66 3.27 0.35
NW AC 200 8.24 8.11 8.11 8.15 0.08 5.57 5.57 5.07 5.40 0.29 0.67 3.99 3.79 4.54 4.10 0.39 3.68 0.18
NW AC 225 8.04 8.06 8.03 8.04 0.02 5.23 5.18 5.21 5.21 0.03 0.72 3.90 4.00 3.92 3.94 0.05
NW AC 275
NW AC 300 8.1 8.08 8.1 8.09 0.01 5.02 5.05 5.22 5.10 0.11 1.00 3.08 3.03 2.88 3.00 0.10
NW US 60 7.96 7.98 7.97 7.97 0.01 4.89 4.88 4.46 4.74 0.25 0.20 15.35 15.50 17.55 16.13 1.23 8.90 0.63
NW US 150 8.1 8.13 8.16 8.13 0.03 4.69 4.98 4.54 4.74 0.22 0.50 6.82 6.30 7.24 6.79 0.47
NW US 200 8.22 8.23 8.25 4.82 4.48 4.38
NW US 300 8.58 8.56 8.53 8.56 0.03 4.98 4.57 4.76 4.77 0.21 1.00 3.60 3.99 3.77 3.79 0.20
NW DS 60 7.82 7.82 7.79 7.81 0.02 5.78 5.82 5.5 5.70 0.17 0.20 10.20 10.00 11.45 10.55 0.79 6.73 0.46
NW DS150 8.04 8.03 8.02 8.03 0.01 4.18 4.39 4.3 4.29 0.11 0.50 7.72 7.28 7.44 7.48 0.22
NW DS 200 7.74 7.74 7.62 7.70 0.07 4.26 4.7 4.62 4.53 0.23 0.67 5.19 4.54 4.48 4.74 0.40
NW DS 300 8.64 8.67 8.73 8.68 0.05 4.5 4.9 4.13 4.51 0.39 1.00 4.14 3.77 4.60 4.17 0.42



















BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 7.31 7.43 7.37 7.37 0.06 4.21 4.18 4.11 4.17 0.05 0.67 4.63 4.85 4.87 4.78 0.13 4.19 0.11
NW BC 225 7.53 7.55 7.51 7.53 0.02 3.97 3.91 3.85 3.91 0.06 0.72 4.94 5.06 5.08 5.03 0.07
NW BC 275 7.48 7.49 7.46 7.48 0.02 4.06 4.24 4.19 4.16 0.09 0.92 3.72 3.53 3.55 3.60 0.10
NW BC 300 7.47 7.43 7.43 7.44 0.02 4.19 3.9 4.16 4.08 0.16 1.00 3.28 3.53 3.27 3.36 0.15
NW AC 200 8.04 8.01 8.03 8.03 0.02 3.55 3.71 3.68 3.65 0.09 0.67 6.70 6.42 6.49 6.54 0.15 5.03 0.07
NW AC 225 8.25 8.23 8.23 8.24 0.01 4.27 4.24 4.22 4.24 0.03 0.72 5.53 5.54 5.57 5.55 0.02
NW AC 275 8.18 8.17 8.15 3.72 3.67 3.84
NW AC 300 8.23 8.23 8.21 8.22 0.01 4 4.04 3.92 3.99 0.06 1.00 4.23 4.19 4.29 3.00 0.05
NW US 200 8.31 8.32 8.32 8.32 0.01 4.34 4.32 4.04 4.23 0.17 0.20 19.85 20.00 21.40 20.42 0.85 10.80 0.41
NW US 225 8.37 8.37 8.36 8.37 0.01 4.41 4.54 4.71 4.55 0.15 0.50 7.92 7.66 7.30 7.63 0.31
NW US 275 8.5 8.51 8.52 4.45 4.44 4.37
NW US 300 8.68 8.71 8.73 8.71 0.03 4.4 4.31 4.31 4.34 0.05 1.00 4.28 4.40 4.42 4.37 0.08
NW DS 200 8.23 8.25 8.23 8.24 0.01 4.59 4.71 4.51 4.60 0.10 0.20 18.20 17.70 18.60 18.17 0.45 9.55 2.09
NW DS 225 8.46 8.45 8.45 8.45 0.01 4.1 4.04 8.85 5.66 2.76 0.50 8.72 8.82 -0.80 5.58 5.53
NW DS 275 8.65 8.67 8.68 8.67 0.02 5.29 5.62 5.24 5.38 0.21 0.67 5.01 4.55 5.13 4.90 0.31
AVG 1 AVG 2 AVG STD DEV
NW BC 4.165984 4.19258 4.179282 0.015355
NW DP 3.681431 5.02787 4.35465 0.777367
NW US 8.902222 10.80333 9.852778 1.097607











BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 7.75 7.67 7.41 7.61 0.18 4.82 4.8 5.09 4.90 0.16 0.67 4.37 4.28 3.46 4.04 0.50 2.64 0.32
NW BC 225 7.54 7.34 7.33 7.40 0.12 4.15 4.6 4.35 4.37 0.23 0.72 4.71 3.81 4.14 4.22 0.46
NW BC 275 0.00 0.00 0.00 0.00 0.92 0.00 0.00 0.00 0.00 0.00
NW BC 300 6.52 6.8 6.39 6.57 0.21 4.59 4.21 4.06 4.29 0.27 1.00 1.93 2.59 2.33 2.28 0.33
NW AC 200 8.62 8.59 8.65 8.62 0.03 4.94 4.49 4.59 4.67 0.24 0.67 5.49 6.12 6.06 5.89 0.35 4.94 0.26
NW AC 225 8.66 8.66 8.66 8.66 0.00 4.22 4.38 4.6 4.40 0.19 0.72 6.17 5.94 5.64 5.92 0.26
NW AC 275 8.68 8.69 8.72 8.70 0.02 4.26 4.52 4.97 4.58 0.36
NW AC 300 8.8 8.89 8.88 8.86 0.05 4.46 4.22 4.35 4.34 0.12 1.00 4.34 4.67 4.53 3.00 0.17
NW US 60 8.47 8.36 8.31 8.38 0.08 4.12 4.31 4.59 4.34 0.24 0.20 21.75 20.25 18.60 20.20 1.58 11.01 0.71
NW US 150 8.61 8.58 8.58 8.59 0.02 4.15 4.19 4.39 4.24 0.13 0.50 8.92 8.78 8.38 8.69 0.28
NW US 200 8.37 8.42 8.53 4.98 4.27 4.82
NW US 300 8.69 8.74 8.84 8.76 0.08 4.39 4.91 4.57 4.62 0.26 1.00 4.30 3.83 4.27 4.13 0.26
NW DS 60 8.16 8.25 8.28 8.23 0.06 4.92 4.56 4.85 4.78 0.19 0.20 16.20 18.45 17.15 17.27 1.13 9.42 0.55
NW DS150 8.32 8.38 8.41 8.37 0.05 3.97 3.61 3.62 3.73 0.21 0.50 8.70 9.54 9.58 9.27 0.50
NW DS 200 8.4 8.59 8.55 8.51 0.10 4.59 4.08 4.29 4.32 0.26 0.67 5.69 6.73 6.36 6.26 0.53
NW DS 300 8.57 8.73 8.82 8.71 0.13 3.73 3.89 3.87 3.83 0.09 1.00 4.84 4.84 4.95 4.88 0.06
CONTROL 8.15 8.17 8.17 8.16 0.01 7.21 7.26 7.37 7.28 0.08 1.00 0.94 0.91 0.80 0.88 0.07
July
BOD DAY 0 BOD DAY 5
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 6.86 6.97 7.04 6.96 0.09 5.2 5.3 5.32 5.27 0.06 0.67 2.48 2.49 2.57 2.51 0.05 2.12 0.17
NW BC 225 6.83 7.08 7.11 7.01 0.15 5.52 5.36 5.61 5.50 0.13 0.72 1.82 2.39 2.08 2.10 0.28
NW BC 275 7.06 7.15 7.18 7.13 0.06 5.21 5.15 5.09 5.15 0.06 0.92 2.01 2.17 2.27 2.15 0.13
NW BC 300 7.14 7.12 7.21 7.16 0.05 5.66 5.37 5.34 5.46 0.18 1.00 1.48 1.75 1.87 1.70 0.20
NW AC 200 7.93 7.95 7.90 7.93 0.03 4.75 4.46 5.1 4.77 0.32 0.67 4.75 5.21 4.18 4.71 0.52 3.95 0.34
NW AC 225 7.83 7.85 7.87 7.85 0.02 4.79 5.15 4.65 4.86 0.26 0.72 4.22 3.75 4.47 4.15 0.37
NW AC 275 7.79 7.84 7.78 7.80 0.03 5.09 4.85 4.86 4.93 0.14
NW AC 300 7.85 7.87 7.90 7.87 0.03 5.14 5.04 4.92 5.03 0.11 1.00 2.71 2.83 2.98 3.00 0.14
NW US 60 8.16 8.13 8.11 8.13 0.03 5.66 5.99 6.01 5.89 0.20 0.20 12.50 10.70 10.50 11.23 1.10 5.27 0.41
NW US 150 8.00 7.98 7.95 7.98 0.03 5.76 5.62 5.67 5.68 0.07 0.50 4.48 4.72 4.56 4.59 0.12
NW US 200 7.97 7.99 7.97 5.52 5.67 5.59
NW US 300 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
NW DS 60 1.95 7.89 7.90 5.91 3.43 5.27 5 5.07 5.11 0.14 0.20 -16.60 14.45 14.15 4.00 17.84 4.32 4.59
NW DS150 8.00 7.90 7.99 7.96 0.06 5.16 4.98 4.93 5.02 0.12 0.50 5.68 5.84 6.12 5.88 0.22
NW DS 200 7.95 7.93 7.98 7.95 0.03 5.05 4.94 4.97 4.99 0.06 0.67 4.33 4.46 4.49 4.43 0.09
NW DS 300 8.02 8.03 8.03 8.03 0.01 5.12 5.18 4.82 5.04 0.19 1.00 2.90 2.85 3.21 2.99 0.20
CONTROL 8.08 8.08 8.09 8.08 0.01 7.34 7.41 7.4 7.38 0.04 1.00 0.74 0.67 0.69 0.70 0.04
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                 Table  14: BOD concentrations obtained in August 
 
   
 
 
       
 
AVG 1 AVG 2 AVG STD DEV
NW BC 2.635182 2.115458 2.37532 0.300062
NW DP 4.935738 3.953197 4.444467 0.56727
NW US 11.00889 5.273333 8.141111 3.311425
NW DS 9.418843 4.323632 6.871238 2.941722
Final BOD: July
SAMPLE 1 2 3 AVG SD 1 2 3 AVG SD p value bod 1 bod 2 bod 3 avg sd FINAL sd
NW BC 200 8.08 7.88 7.92 7.96 0.11 4.83 4.36 4.76 4.65 0.25 0.67 4.85 5.25 4.72 4.94 0.28 4.10 0.31
NW BC 225 8.08 7.94 7.99 8.00 0.07 4.27 4.55 4.94 4.59 0.34 0.72 5.29 4.71 4.24 4.75 0.53
NW BC 275
NW BC 300 7.86 7.83 7.83 7.84 0.02 5.2 5.35 5.14 5.23 0.11 1.00 2.66 2.48 2.69 2.61 0.11
NW AC 200 8.28 8.13 8.06 8.16 0.11 4.12 4.43 4.42 4.32 0.18 0.67 6.21 5.52 5.43 5.72 0.42 4.49 0.38
NW AC 225 8.19 8.02 8.11 8.11 0.09 4.5 4.92 4.66 4.69 0.21 0.72 5.13 4.31 4.79 4.74 0.41
NW AC 275 8.06 8.11 7.99 8.05 0.06 4.82 4.8 4.77 4.80 0.03
NW AC 300 7.96 7.93 8.01 7.97 0.04 4.79 4.77 4.34 4.63 0.25 1.00 3.17 3.16 3.67 3.00 0.29
NW US 60 8 7.99 7.98 7.99 0.01 3.39 3.85 3.64 3.63 0.23 0.20 23.05 20.70 21.70 21.82 1.18 10.61 0.63
NW US 150 7.66 7.61 7.65 7.64 0.03 4.13 4.47 4.59 4.40 0.24 0.50 7.06 6.28 6.12 6.49 0.50
NW US 200 7.34 7.22 7.28 4.91 4.92 4.21
NW US 300 7.12 7.2 6.8 7.04 0.21 3.64 3.47 3.47 3.53 0.10 1.00 3.48 3.73 3.33 3.51 0.20
NW DS 60 8.14 8.18 8.21 8.18 0.04 4.74 4.34 4.66 4.58 0.21 0.20 17.00 19.20 17.75 17.98 1.12 8.84 0.60
NW DS150 8.59 8.53 8.5 8.54 0.05 4.47 4.51 4.98 4.65 0.28 0.50 8.24 8.04 7.04 7.77 0.64
NW DS 200 8.46 8.53 8.57 8.52 0.06 4.76 4.66 4.97 4.80 0.16 0.67 5.52 5.78 5.37 5.56 0.20
NW DS 300 8.43 8.55 8.54 8.51 0.07 4.83 4.05 4.53 4.47 0.39 1.00 3.60 4.50 4.01 4.04 0.45
CONTROL 8.44 8.27 8.19 8.30 0.13 7.20 7.26 7.42 7.29 0.11 1.00 1.24 1.01 0.77 1.01 0.24
August
BOD DAY 0 BOD DAY 5
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                 Table  15: TSS values obtained in March 
 
   
  






























NW BC 1 13.0782 13.1705 0.0923 13.1727 0.0945 0.0088 0.01027
NW BC 2 12.7017 12.7932 0.0915 12.7958 0.0941 0.0104
NW BC 3 12.5996 12.692 0.0924 12.6949 0.0953 0.0116
NW AC 1 12.7748 12.8674 0.0926 12.87 0.0952 0.0104 0.0164
NW AC 2 14.2826 14.3755 0.0929 14.3811 0.0985 0.0224
NW AC 3 13.4693 13.5615 0.0922 13.5656 0.0963 0.0164
NW US 1 12.7538 12.8464 0.0926 12.8475 0.0937 0.0044 0.00427
NW US 2 12.497 12.5886 0.0916 12.5898 0.0928 0.0048
NW US 3 12.8334 12.9275 0.0941 12.9284 0.095 0.0036
NW DS 1 12.6001 12.6932 0.0931 12.6966 0.0965 0.0136 0.0116
NW DS 2 12.714 12.8055 0.0915 12.4348 -0.2792 -1.4828
NW DS 3 12.3403 12.4327 0.0924 12.8087 0.4684 1.504





























NW BC 1 24.3989 24.7295 0.3306 24.7563 0.3574 0.134 0.04633
NW BC 2 12.7016 12.7953 0.0937 12.7954 0.0938 0.0005
NW BC 3 12.5997 12.6928 0.0931 12.6937 0.094 0.0045
NW AC 1 24.9109 25.2493 0.3384 25.2712 0.3603 0.0876 0.03107
NW AC 2 14.282 14.3742 0.0922 14.3751 0.0931 0.0036
NW AC 3 13.4684 13.5619 0.0935 13.5624 0.094 0.002
NW US 1 12.7534 12.8454 0.092 12.8479 0.0945 0.01 0.01093
NW US 2 12.4959 12.5862 0.0903 12.5894 0.0935 0.0128
NW US 3 12.8327 12.9247 0.092 12.9272 0.0945 0.01
NW DS 1 24.1408 24.472 0.3312 24.5059 0.3651 0.1356 0.05707
NW DS 2 12.3394 12.4304 0.091 12.4331 0.0937 0.0108
NW DS 3 12.7131 12.8057 0.0926 12.8119 0.0988 0.0248









































NW BC 1 14.559 14.6491 0.0901 14.657 0.098 0.0395 0.0375
NW BC 2 14.2817 14.3742 0.0925 14.3822 0.1005 0.04
NW BC 3 13.4486 13.5613 0.1127 13.5679 0.1193 0.033
NW AC 1 13.1787 13.2719 0.0932 13.2782 0.0995 0.0252 0.02667
NW AC 2 12.7012 12.7936 0.0924 12.6991 -0.0021 -0.378
NW AC 3 12.5997 12.6921 0.0924 12.8003 0.2006 0.4328
NW US 1 12.7533 12.8461 0.0928 12.8461 0.0928 0 0.00027
NW US 2 12.4966 12.5893 0.0927 12.5893 0.0927 0
NW US 3 12.8332 12.9264 0.0932 12.9266 0.0934 0.0008
NW DS 1 12.5415 12.6353 0.0938 12.6392 0.0977 0.0156 0.01573
NW DS 2 12.3402 12.434 0.0938 12.438 0.0978 0.016
NW DS 3 12.7148 12.8076 0.0928 12.8115 0.0967 0.0156





























NW BC 1 13.178 13.2715 0.0935 13.2745 0.0965 0.015 0.01383
NW BC 2 12.599 12.6914 0.0924 12.694 0.095 0.013
NW BC 3 12.7005 12.7936 0.0931 12.7963 0.0958 0.0135
NW AC 1 14.5552 14.6475 0.0923 14.65 0.0948 0.01 0.0092
NW AC 2 14.281 14.3736 0.0926 14.3755 0.0945 0.0076
NW AC 3 13.4683 13.5611 0.0928 13.5636 0.0953 0.01
NW US 1 12.7527 12.8451 0.0924 12.8455 0.0928 0.0016 0.00227
NW US 2 12.496 12.5886 0.0926 12.5892 0.0932 0.0024
NW US 3 12.8321 12.9249 0.0928 12.9256 0.0935 0.0028
NW DS 1 12.3397 12.4325 0.0928 12.4342 0.0945 0.0068 0.0068
NW DS 2 12.5411 12.6338 0.0927 12.6354 0.0943 0.0064
NW DS 3 12.7143 12.8074 0.0931 12.8092 0.0949 0.0072











































NW BC 1 13.0776 13.1706 0.093 13.1747 0.0971 0.0205 0.02117
NW BC 2 12.5998 12.6937 0.0939 12.6978 0.098 0.0205
NW BC 3 12.7007 12.7935 0.0928 12.798 0.0973 0.0225
NW AC 1 14.5559 14.6504 0.0945 14.6533 0.0974 0.0116 0.02093
NW AC 2 12.7139 12.8074 0.0935 12.8146 0.1007 0.0288
NW AC 3 13.4684 13.5618 0.0934 13.5674 0.099 0.0224
NW US 1 12.7532 12.847 0.0938 12.847 0.0938 0 0
NW US 2 12.4959 12.5908 0.0949 12.5908 0.0949 0
NW US 3 12.7739 12.8679 0.094 12.8679 0.094 0
NW DS 1 12.5408 12.6349 0.0941 12.6398 0.099 0.0196 0.01547
NW DS 2 12.6008 12.6936 0.0928 12.6978 0.097 0.0168
NW DS 3 13.1783 13.2707 0.0924 13.2732 0.0949 0.01




















NW BC 1 13.0777 13.1702 0.0925 13.1733 0.0956 0.0155 0.01517 0.00058
NW BC 2 12.5992 12.6925 0.0933 12.6956 0.0964 0.0155
NW BC 3 12.701 12.794 0.093 12.7969 0.0959 0.0145
NW AC 1 14.5561 14.6489 0.0928 14.6529 0.0968 0.016 0.01373 0.00205
NW AC 2 12.7142 12.807 0.0928 12.81 0.0958 0.012
NW AC 3 13.4688 13.5614 0.0926 13.5647 0.0959 0.0132
NW US 1 12.7527 12.8471 0.0944 12.8528 0.1001 0.0228 0.032 0.01172
NW US 2 12.4962 12.5879 0.0917 12.5949 0.0987 0.028
NW US 3 12.774 12.8661 0.0921 12.8774 0.1034 0.0452
NW DS 1 12.5414 12.634 0.0926 12.6373 0.0959 0.0132 0.01653 0.00577
NW DS 2 12.6012 12.6945 0.0933 12.6978 0.0966 0.0132
NW DS 3 13.1788 13.2718 0.093 13.2776 0.0988 0.0232





APPENDIX III  - ANTIMICROBIAL RESISTANCE PROFILING 
 
Table 1: Zones of inhibition (mm) of E. coli isolates tested against ampicillin 
 
AMPICILLIN 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 7 7 7 0.00 R 29 11.5 12 11.75 0.35 R 
2 14 14 14 0.00 S 30 14 14 14 0.00 S 
3 8 7 7.5 0.71 R 31 12 12 12 0.00 R 
4 15 15.5 15.25 0.35 S 32 12 11 11.5 0.71 R 
5 9 8 8.5 0.71 R 33 10 11 10.5 0.71 R 
6 4 4.5 4.25 0.35 R 34 11 11.5 11.25 0.35 R 
7 6 5 5.5 0.71 R 35 15 15 15 0.00 S 
8 8 8 8 0.00 R 36 15 15 15 0.00 S 
9 14.5 14.5 14.5 0.00 S 37 12 13 12.5 0.71 R 
10 13.5 13.5 13.5 0.00 S 38 11 11 11 0.00 R 
11 8 8 8 0.00 R 39 12 13 12.5 0.71 R 
12 11 10 10.5 0.71 R 40 10 10 10 0.00 R 
13 9.5 8 8.75 1.06 R 41 15 15 15 0.00 S 
14 8 8.5 8.25 0.35 R 42 9 8.5 8.75 0.35 R 
15 8 9 8.5 0.71 R 43 11 11 11 0.00 R 
16 10 11 10.5 0.71 R 44 14 14 14 0.00 S 
17 12 11.5 11.75 0.35 R 45 12 12.5 12.25 0.35 R 
18 14 15 14.5 0.71 S 46 13 11 12 1.41 R 
19 9 9.5 9.25 0.35 R 47 16 15 15.5 0.71 S 
20 16 16.5 16.25 0.35 S 48 15 15 15 0.00 S 
21 8 8 8 0.00 R 49 17 17 17 0.00 S 
22 14 14.5 14.25 0.35 S 50 11 12 11.5 0.71 R 
23 10 10 10 0.00 R 51 18 17.5 17.75 0.35 S 
24 11 12 11.5 0.71 R 52 10 12 11 1.41 R 
25 16 15 15.5 0.71 S 53 12 12 12 0.00 R 
26 15 15.5 15.25 0.35 S 54 12 13 12.5 0.71 R 
27 10 11 10.5 0.71 R 55 11 11.5 11.25 0.35 R 









          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 11 11.5 11.25 0.35 R 81 11 12 11.5 0.71 R 
56 10 10 10 0.00 R 82 13 9 11 2.83 R 
57 18 18.5 18.25 0.35 S 83 12 11 11.5 0.71 R 
58 11 11 11 0.00 R 84 15 16 15.5 0.71 S 
59 15 15 15 0.00 S 85 13 9 11 2.83 R 
60 12 12 12 0.00 R 86 9 8.5 8.75 0.35 R 
61 11 11.5 11.25 0.35 R 87 8.5 9 8.75 0.35 R 
62 16 15 15.5 0.71 S 88 10 9 9.5 0.71 R 
63 13 13 13 0.00 R 89 16 15 15.5 0.71 S 
64 12 12.5 12.25 0.35 R 90 16 15 15.5 0.71 S 
65 12 13 12.5 0.71 R 91 12 12 12 0.00 R 
66 13 12.5 12.75 0.35 R 92 17.5 17.5 17.5 0.00 S 
67 15 15 15 0.00 S 93 16 15.5 15.75 0.35 S 
68 11 10 10.5 0.71 R 94 18 17 17.5 0.71 S 
69 18 17.5 17.75 0.35 S 95 10 10 10 0.00 R 
70 9 8.5 8.75 0.35 R 96 11 11 11 0.00 R 
71 8.5 8.5 8.5 0.00 R 97 15 14.5 14.75 0.35 S 
72 11 12 11.5 0.71 R 98 11 11 11 0.00 R 
73 16 15.5 15.75 0.35 S 99 12.5 12.5 12.5 0.00 R 
74 15 15 15 0.00 S 100 12 12 12 0.00 R 
75 12 13 12.5 0.71 R 101 19 18 18.5 0.71 S 
76 16.5 16.5 16.5 0.00 S 102 12 12 12 0.00 R 
77 11 11.5 11.25 0.35 R 103 11 12 11.5 0.71 R 
78 17 16 16.5 0.71 S 104 10 10 10 0.00 R 
79 16 16 16 0.00 S 105 10 11 10.5 0.71 R 












          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 11 12 11.5 0.71 R 133 15 16 15.5 0.71 S 
108 12 13 12.5 0.71 R 134 15 16 15.5 0.71 S 
109 13 12.5 12.75 0.35 R 135 17 17.5 17.25 0.35 S 
110 12.5 12 12.25 0.35 R 136 12 12 12 0.00 R 
111 10 11 10.5 0.71 R 137 11 11.5 11.25 0.35 R 
112 10.5 10.5 10.5 0.00 R 138 11 10.5 10.75 0.35 R 
113 9 9 9 0.00 R 139 10.5 10 10.25 0.35 R 
114 12 11 11.5 0.71 R 140 12.5 12 12.25 0.35 R 
115 11 10 10.5 0.71 R 141 18 18.5 18.25 0.35 S 
116 15 16 15.5 0.71 S 142 16 16 16 0.00 S 
117 12 12 12 0.00 R 143 12 12 12 0.00 R 
118 12 12 12 0.00 R 144 12.5 11.5 12 0.71 R 
119 12 12 12 0.00 R 145 11 12.5 11.75 1.06 R 
120 11 11 11 0.00 R 146 11 11 11 0.00 R 
121 10.5 10.5 10.5 0.00 R 147 10.5 11 10.75 0.35 R 
122 13 12.5 12.75 0.35 R 148 12.5 12 12.25 0.35 R 
123 12 11 11.5 0.71 R 149 11 11 11 0.00 R 
124 17 17.5 17.25 0.35 S 150 12.5 12 12.25 0.35 R 
125 18 18 18 0.00 S 151 13 13 13 0.00 R 
126 12 11.5 11.75 0.35 R 152 10.5 10.5 10.5 0.00 R 
127 9 9 9 0.00 R 153 9.5 9 9.25 0.35 R 
128 9 10 9.5 0.71 R 154 10.5 10 10.25 0.35 R 
129 10.5 10.5 10.5 0.00 R 155 11.5 11 11.25 0.35 R 
130 11 10 10.5 0.71 R 156 12.5 12.5 12.5 0.00 R 
131 12.5 12 12.25 0.35 R 157 9.5 9 9.25 0.35 R 








          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 15 16.5 15.75 1.06 S 185 15.5 16 15.75 0.35 S 
160 14.5 16 15.25 1.06 S 186 15 15 15 0.00 S 
161 12.5 12 12.25 0.35 R 187 16 16 16 0.00 S 
162 11 10 10.5 0.71 R 188 16 16.5 16.25 0.35 S 
163 10.5 10.5 10.5 0.00 R 189 16 16.5 16.25 0.35 S 
164 11 11 11 0.00 R 190 15.5 16 15.75 0.35 S 
165 15 15 15 0.00 S 191 15 15 15 0.00 S 
166 16 16 16 0.00 S 192 15.5 16 15.75 0.35 S 
167 15 15.5 15.25 0.35 S 193 15 15 15 0.00 S 
168 17 17 17 0.00 S 194 15 15 15 0.00 S 
169 17.5 17.5 17.5 0.00 S 195 15.5 16 15.75 0.35 S 
170 18 18 18 0.00 S 196 12 12 12 0.00 R 
171 19 19 19 0.00 S 197 12.5 11 11.75 1.06 R 
172 15 15.5 15.25 0.35 S 198 11 11.5 11.25 0.35 R 
173 19.5 19.5 19.5 0.00 S 199 10.5 10.5 10.5 0.00 R 
174 12.5 12.5 12.5 0.00 R 200 9 8.5 8.75 0.35 R 
175 11 10 10.5 0.71 R             
176 18.5 18.5 18.5 0.00 S             
177 18 18 18 0.00 S             
178 11 11 11 0.00 R             
179 10 10 10 0.00 R             
180 12.5 12.5 12.5 0.00 R             
181 16 16 16 0.00 S             
182 16 16.5 16.25 0.35 S             
183 15.5 16 15.75 0.35 S             







Table 2: Zones of inhibition (mm) of E. coli isolates tested against tetracycline 
 
TETRACYCLINE 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 12 12 12 0.00 S 29 10 10 10 0.00 R 
2 8 8 8 0.00 R 30 11 11 11 0.00 R 
3 7 7 7 0.00 R 31 10.1 9 9.55 0.78 R 
4 9 9.5 9.25 0.35 R 32 10 9.5 9.75 0.35 R 
5 9 9 9 0.00 R 33 9.5 10 9.75 0.35 R 
6 10 9 9.5 0.71 R 34 10 11 10.5 0.71 R 
7 14 14 14 0.00 S 35 11 9.5 10.25 1.06 R 
8 14.5 14.5 14.5 0.00 S 36 12 10 11 1.41 R 
9 9 9.5 9.25 0.35 R 37 10.5 11 10.75 0.35 R 
10 10 11 10.5 0.71 R 38 11 9.5 10.25 1.06 R 
11 9 9 9 0.00 R 39 8 10 9 1.41 R 
12 12.5 13 12.75 0.35 S 40 9 10 9.5 0.71 R 
13 10 10 10 0.00 R 41 8.5 10 9.25 1.06 R 
14 10 10 10 0.00 R 42 9 9 9 0.00 R 
15 9 8.5 8.75 0.35 R 43 12 12 12 0.00 S 
16 10 10 10 0.00 R 44 8.5 9 8.75 0.35 R 
17 14 14 14 0.00 S 45 13 13 13 0.00 S 
18 15 15.5 15.25 0.35 S 46 9 10 9.5 0.71 R 
19 9 9.5 9.25 0.35 R 47 10 11 10.5 0.71 R 
20 14 14 14 0.00 S 48 13.5 13.5 13.5 0.00 S 
21 9 10 9.5 0.71 R 49 14 14 14 0.00 S 
22 15.5 15 15.25 0.35 S 50 11 9.5 10.25 1.06 R 
23 10 11 10.5 0.71 R 51 11 10 10.5 0.71 R 
24 16 16 16 0.00 S 52 10 10 10 0.00 R 
25 10 9 9.5 0.71 R 53 15 15.5 15.25 0.35 S 
26 10 10.5 10.25 0.35 R 54 9.5 10 9.75 0.35 R 
27 15 15 15 0.00 S             






Table 2 continued… 
 
TETRACYCLINE 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 9 9 9 0.00 R 81 9 10 9.5 0.71 R 
56 10 10 10 0.00 R 82 9 10 9.5 0.71 R 
57 11 11 11 0.00 R 83 9 10 9.5 0.71 R 
58 11.5 10 10.75 1.06 R 84 10 9 9.5 0.71 R 
59 8 9 8.5 0.71 R 85 10 9 9.5 0.71 R 
60 8.5 10 9.25 1.06 R 86 11 10 10.5 0.71 R 
61 10 11 10.5 0.71 R 87 10.5 11 10.75 0.35 R 
62 11 10 10.5 0.71 R 88 11 11 11 0.00 R 
63 10.5 10 10.25 0.35 R 89 9 10 9.5 0.71 R 
64 15 15 15 0.00 S 90 8.5 9 8.75 0.35 R 
65 10 10 10 0.00 R 91 9 10 9.5 0.71 R 
66 14 14 14 0.00 S 92 14 14.5 14.25 0.35 S 
67 11 11 11 0.00 R 93 12 12 12 0.00 S 
68 10 9 9.5 0.71 R 94 10 10 10 0.00 R 
69 10 9 9.5 0.71 R 95 11 10.5 10.75 0.35 R 
70 9 11 10 1.41 R 96 12.5 13 12.75 0.35 S 
71 11 9 10 1.41 R 97 14.5 14.5 14.5 0.00 S 
72 10 10 10 0.00 R 98 13 13 13 0.00 S 
73 10.5 10.5 10.5 0.00 R 99 11 11 11 0.00 R 
74 14 14 14 0.00 S 100 10.5 11 10.75 0.35 R 
75 9 9.5 9.25 0.35 R 101 9 10 9.5 0.71 R 
76 10 10 10 0.00 R 102 14.5 14 14.25 0.35 S 
77 15 15 15 0.00 S 103 15 16 15.5 0.71 S 
78 12 12 12 0.00 S 104 16 16.5 16.25 0.35 S 
79 9 9 9 0.00 R 105 10 10 10 0.00 R 










Table 2 continued… 
 
TETRACYCLINE 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 10 10 10 0.00 R 133 14.5 14.5 14.5 0.00 S 
108 9 9 9 0.00 R 134 14 14 14 0.00 S 
109 9.5 9.5 9.5 0.00 R 135 16 15.5 15.75 0.35 S 
110 10 10 10 0.00 R 136 16 17 16.5 0.71 S 
111 9 9.5 9.25 0.35 R 137 9 9 9 0.00 R 
112 8.5 9 8.75 0.35 R 138 8.5 8.5 8.5 0.00 R 
113 9.5 9 9.25 0.35 R 139 9 9 9 0.00 R 
114 8 9 8.5 0.71 R 140 10 10 10 0.00 R 
115 9.5 9 9.25 0.35 R 141 9.5 9 9.25 0.35 R 
116 10 10 10 0.00 R 142 12 12 12 0.00 S 
117 10 10 10 0.00 R 143 13 12 12.5 0.71 S 
118 9.5 9.5 9.5 0.00 R 144 13.5 13.5 13.5 0.00 S 
119 8.5 9 8.75 0.35 R 145 14.5 14.5 14.5 0.00 S 
120 9 9 9 0.00 R 146 15 15 15 0.00 S 
121 10 10 10 0.00 R 147 16 16 16 0.00 S 
122 9 8.5 8.75 0.35 R 148 10 10 10 0.00 R 
123 8.5 9 8.75 0.35 R 149 10 10 10 0.00 R 
124 9 8.5 8.75 0.35 R 150 9.5 9 9.25 0.35 R 
125 9.5 9.5 9.5 0.00 R 151 8.5 8.5 8.5 0.00 R 
126 10 10 10 0.00 R 152 9 9.5 9.25 0.35 R 
127 9.5 9.5 9.5 0.00 R 153 10 10 10 0.00 R 
128 12.5 12.5 12.5 0.00 S 154 14.5 14.5 14.5 0.00 S 
129 13 13 13 0.00 S 155 14.5 15 14.75 0.35 S 
130 9.5 9.5 9.5 0.00 R 156 15 15 15 0.00 S 
131 10.5 10.5 10.5 0.00 R 157 9.5 9.5 9.5 0.00 R 









Table 2 continued… 
 
TETRACYCLINE 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 9.5 10 9.75 0.35 R 185 13.5 13.5 13.5 0.00 S 
160 10 9.5 9.75 0.35 R 186 15 15 15 0.00 S 
161 17 17 17 0.00 S 187 15 15 15 0.00 S 
162 14 14.5 14.25 0.35 S 188 14.5 14.5 14.5 0.00 S 
163 14.5 14.5 14.5 0.00 S 189 16 16 16 0.00 S 
164 15.5 15 15.25 0.35 S 190 15 15 15 0.00 S 
165 15 15 15 0.00 S 191 14.5 14.5 14.5 0.00 S 
166 15 15 15 0.00 S 192 16 16 16 0.00 S 
167 8.5 9 8.75 0.35 R 193 15 15 15 0.00 S 
168 9 9 9 0.00 R 194 13.5 13.5 13.5 0.00 S 
169 10 10 10 0.00 R 195 15 15 15 0.00 S 
170 10 10 10 0.00 R 196 15 15 15 0.00 S 
171 9.5 9.5 9.5 0.00 R 197 14.5 14.5 14.5 0.00 S 
172 8.5 9 8.75 0.35 R 198 16 16 16 0.00 S 
173 9.5 9.5 9.5 0.00 R 199 15 15 15 0.00 S 
174 12.5 12.5 12.5 0.00 S 200 14.5 14.5 14.5 0.00 S 
175 13.5 13.5 13.5 0.00 S             
176 15 15 15 0.00 S             
177 15 15 15 0.00 S             
178 14.5 14.5 14.5 0.00 S             
179 16 16 16 0.00 S             
180 16.5 16.5 16.5 0.00 S             
181 15 15 15 0.00 S             
182 15 15.5 15.25 0.35 S             
183 9.5 10 9.75 0.35 R             






Table 3: Zones of inhibition (mm) of E. coli isolates tested against cephalothin 
 
CEPHALOTHIN 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 16 16 16 0.00 S 29 15.5 15.5 15.5 0.00 S 
2 15 15 15 0.00 S 30 15.5 15.5 15.5 0.00 S 
3 15.5 15.5 15.5 0.00 S 31 15 15 15 0.00 S 
4 16.5 16.5 16.5 0.00 S 32 17 17 17 0.00 S 
5 16 17 16.5 0.71 S 33 18 18 18 0.00 S 
6 17 17 17 0.00 S 34 11 12 11.5 0.71 R 
7 18 18 18 0.00 S 35 18.5 18.5 18.5 0.00 S 
8 18.5 18.5 18.5 0.00 S 36 18 18 18 0.00 S 
9 19 19 19 0.00 S 37 19.5 19.5 19.5 0.00 S 
10 12 13 12.5 0.71 R 38 20 20 20 0.00 S 
11 20 20.5 20.25 0.35 S 39 15.5 15.5 15.5 0.00 S 
12 22.5 22.5 22.5 0.00 S 40 20 20 20 0.00 S 
13 21 21 21 0.00 S 41 21.5 21.5 21.5 0.00 S 
14 22 22 22 0.00 S 42 20 20 20 0.00 S 
15 18.5 18.5 18.5 0.00 S 43 21 21 21 0.00 S 
16 18 18 18 0.00 S 44 13 12.5 12.75 0.35 R 
17 18 18 18 0.00 S 45 21 21.5 21.25 0.35 S 
18 17 17.5 17.25 0.35 S 46 22 22.5 22.25 0.35 S 
19 17.5 17.5 17.5 0.00 S 47 22.5 22.5 22.5 0.00 S 
20 19 19 19 0.00 S 48 22 22 22 0.00 S 
21 20 20 20 0.00 S 49 12 12 12 0.00 R 
22 21.5 21.5 21.5 0.00 S 50 23 23 23 0.00 S 
23 20 20 20 0.00 S 51 13 13 13 0.00 R 
24 22 22 22 0.00 S 52 25 24.5 24.75 0.35 S 
25 12 13 12.5 0.71 R 53 22 23 22.5 0.71 S 
26 21.5 22 21.75 0.35 S 54 25 25 25 0.00 S 
27                       





Table 3 continued… 
 
CEPHALOTHIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 16.5 16.5 16.5 0.00 S 81 18.5 18.5 18.5 0.00 S 
56 13 13 13 0.00 R 82 18 18 18 0.00 S 
57 16 16 16 0.00 S 83 19.5 19.5 19.5 0.00 S 
58 15 15 15 0.00 S 84 20 20 20 0.00 S 
59 10 11.5 10.75 1.06 R 85 15.5 15.5 15.5 0.00 S 
60 16 16 16 0.00 S 86 19.5 19.5 19.5 0.00 S 
61 15 15 15 0.00 S 87 20 20 20 0.00 S 
62 15.5 15.5 15.5 0.00 S 88 11 11 11 0.00 R 
63 16.5 16.5 16.5 0.00 S 89 18.5 18.5 18.5 0.00 S 
64 16 17 16.5 0.71 S 90 18 18 18 0.00 S 
65 17 17 17 0.00 S 91 18 18 18 0.00 S 
66 18 18 18 0.00 S 92 19.5 19.5 19.5 0.00 S 
67 18.5 18.5 18.5 0.00 S 93 15.5 15.5 15.5 0.00 S 
68 19 19 19 0.00 S 94 16.5 16.5 16.5 0.00 S 
69 11 12 11.5 0.71 R 95 16 17 16.5 0.71 S 
70 15.5 17 16.25 1.06 S 96 17 17 17 0.00 S 
71 17 17 17 0.00 S 97 18 18 18 0.00 S 
72 12 11 11.5 0.71 R 98 18.5 18.5 18.5 0.00 S 
73 16 16 16 0.00 S 99 10 11.5 10.75 1.06 R 
74 15 15 15 0.00 S 100 17.5 17.5 17.5 0.00 S 
75 15.5 15.5 15.5 0.00 S 101 12 12 12 0.00 R 
76 16.5 16.5 16.5 0.00 S 102 11 11 11 0.00 R 
77 15 15 15 0.00 S 103 10.5 10.5 10.5 0.00 R 
78 15.5 15.5 15.5 0.00 S 104 13 13 13 0.00 R 
79 10 11 10.5 0.71 R 105 21 21 21 0.00 S 








Table 3 continued… 
 
CEPHALOTHIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 12 12.5 12.25 0.35 R 133 19.5 19.5 19.5 0.00 S 
108 16 16 16 0.00 S 134 20 20 20 0.00 S 
109 15 15 15 0.00 S 135 15.5 15.5 15.5 0.00 S 
110 15.5 15.5 15.5 0.00 S 136 20 20 20 0.00 S 
111 16.5 16.5 16.5 0.00 S 137 13.5 12.5 13 0.71 R 
112 15 15 15 0.00 S 138 16.5 16.5 16.5 0.00 S 
113 15.5 15.5 15.5 0.00 S 139 14 14 14 0.00 R 
114 16.5 16.5 16.5 0.00 S 140 16.5 16.5 16.5 0.00 S 
115 15 15 15 0.00 S 141 17 17 17 0.00 S 
116 15.5 15.5 15.5 0.00 S 142 11 10.5 10.75 0.35 R 
117 18 18.5 18.25 0.35 S 143 18 18 18 0.00 S 
118 18 18 18 0.00 S 144 19.5 19.5 19.5 0.00 S 
119 17.5 18 17.75 0.35 S 145 20 20 20 0.00 S 
120 19 19 19 0.00 S 146 15.5 15.5 15.5 0.00 S 
121 13.5 13.5 13.5 0.00 R 147 20 20 20 0.00 S 
122 15 15 15 0.00 S 148 15.5 15.5 15.5 0.00 S 
123 14 14 14 0.00 R 149 16 16 16 0.00 S 
124 12.5 13 12.75 0.35 R 150 16.5 16.5 16.5 0.00 S 
125 18 18 18 0.00 S 151 17 17 17 0.00 S 
126 19.5 19.5 19.5 0.00 S 152 17 17 17 0.00 S 
127 20 20 20 0.00 S 153 19.5 20 19.75 0.35 S 
128 20 20 20 0.00 S 154 20 20 20 0.00 S 
129 15.5 15.5 15.5 0.00 S 155 9.5 10 9.75 0.35 R 
130 18 18 18 0.00 S 156 16.5 17 16.75 0.35 S 
131 18 18 18 0.00 S 157 16 16 16 0.00 S 









Table 3 continued… 
 
CEPHALOTHIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 11 10.5 10.75 0.35 R 185 16 16 16 0.00 S 
160 10 10.5 10.25 0.35 R 186 15 15 15 0.00 S 
161 15.5 15.5 15.5 0.00 S 187 17 17.5 17.25 0.35 S 
162 16 16 16 0.00 S 188 19 19 19 0.00 S 
163 15.5 15 15.25 0.35 S 189 15 15 15 0.00 S 
164 15.5 15 15.25 0.35 S 190 17 17.5 17.25 0.35 S 
165 15 15 15 0.00 S 191 19 19 19 0.00 S 
166 15 15 15 0.00 S 192 15 15 15 0.00 S 
167 17 17.5 17.25 0.35 S 193 15 15 15 0.00 S 
168 19 19 19 0.00 S 194 17 17.5 17.25 0.35 S 
169 23 22.5 22.75 0.35 S 195 19 19 19 0.00 S 
170 18.5 18 18.25 0.35 S 196 15 15 15 0.00 S 
171 16 16.5 16.25 0.35 S 197 17 17.5 17.25 0.35 S 
172 17 17 17 0.00 S 198 19 19 19 0.00 S 
173 17 17.5 17.25 0.35 S 199 15 15 15 0.00 S 
174 12.5 13 12.75 0.35 R 200 15 15 15 0.00 S 
175 10 10 10 0.00 R             
176 18.5 18.5 18.5 0.00 S             
177 16 16 16 0.00 S             
178 15.5 15.5 15.5 0.00 S             
179 15.5 15.5 15.5 0.00 S             
180 15 15 15 0.00 S             
181 16 16 16 0.00 S             
182 16 15.5 15.75 0.35 S             
183 16 15 15.5 0.71 S             








Table 4: Zones of inhibition (mm) of E. coli isolates tested against gentamicin 
 
GENTAMICIN 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 15 15 15 0.00 S 29 17 17.5 17.25 0.35 S 
2 15 15.5 15.25 0.35 S 30 18 18 18 0.00 S 
3 16 16 16 0.00 S 31 15.5 15.5 15.5 0.00 S 
4 11 11 11 0.00 R 32 15 15 15 0.00 S 
5 17.5 17 17.25 0.35 S 33 16.5 17 16.75 0.35 S 
6 17 17.5 17.25 0.35 S 34 16 16 16 0.00 S 
7 18 18 18 0.00 S 35 10 10 10 0.00 R 
8 15.5 15.5 15.5 0.00 S 36 20 20 20 0.00 S 
9 15 15 15 0.00 S 37 16.5 17 16.75 0.35 S 
10 16 16.5 16.25 0.35 S 38 16 16 16 0.00 S 
11 11 10 10.5 0.71 R 39 16 16 16 0.00 S 
12 17 17 17 0.00 S 40 19 20 19.5 0.71 S 
13 17 17.5 17.25 0.35 S 41 10 10.5 10.25 0.35 R 
14 18.5 18 18.25 0.35 S 42 16.5 17 16.75 0.35 S 
15 15.5 16 15.75 0.35 S 43 16 16 16 0.00 S 
16 20 20 20 0.00 S 44 15 15 15 0.00 S 
17 16.5 17 16.75 0.35 S 45 15 15 15 0.00 S 
18 16 16 16 0.00 S 46 16.5 16.5 16.5 0.00 S 
19 16 16 16 0.00 S 47 16 16 16 0.00 S 
20 17 17 17 0.00 S 48 21.5 21 21.25 0.35 S 
21 10 10.5 10.25 0.35 R 49 22 22 22 0.00 S 
22 17.5 17.5 17.5 0.00 S 50 12 12 12 0.00 R 
23 17.5 17 17.25 0.35 S 51 15 15.5 15.25 0.35 S 
24 15 15 15 0.00 S 52 16 16 16 0.00 S 
25 15 15 15 0.00 S 53 15 15.5 15.25 0.35 S 
26 16.5 16.5 16.5 0.00 S 54 17 18 17.5 0.71 S 
27 16 16 16 0.00 S       





Table 4 continued… 
 
GENTAMICIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 13 13 13 0.00 S 81 15 15.5 15.25 0.35 S 
56 13 13 13 0.00 S 82 16 16 16 0.00 S 
57 11 11.5 11.25 0.35 R 83 16 17 16.5 0.71 S 
58 15 15.5 15.25 0.35 S 84 12 12 12 0.00 R 
59 16 16 16 0.00 S 85 17 17.5 17.25 0.35 S 
60 16 17 16.5 0.71 S 86 18.5 18 18.25 0.35 S 
61 18.5 18 18.25 0.35 S 87 15.5 16 15.75 0.35 S 
62 19 19 19 0.00 S 88 20 20 20 0.00 S 
63 15.5 16 15.75 0.35 S 89 16.5 17 16.75 0.35 S 
64 15 16 15.5 0.71 S 90 16 16 16 0.00 S 
65 12 12 12 0.00 R 91 16 16 16 0.00 S 
66 11 11.5 11.25 0.35 R 92 17 17 17 0.00 S 
67 15 15.5 15.25 0.35 S 93 19 20 19.5 0.71 S 
68 11 11 11 0.00 R 94 15 15.5 15.25 0.35 S 
69 16 17 16.5 0.71 S 95 16 16 16 0.00 S 
70 12 12 12 0.00 R 96 16 17 16.5 0.71 S 
71 17 17.5 17.25 0.35 S 97 16.5 17 16.75 0.35 S 
72 18.5 18 18.25 0.35 S 98 16 16 16 0.00 S 
73 11 11.5 11.25 0.35 R 99 16 16 16 0.00 S 
74 16 17 16.5 0.71 S 100 17 17.5 17.25 0.35 S 
75 15 15.5 15.25 0.35 S 101 18.5 18 18.25 0.35 S 
76 16 16 16 0.00 S 102 15 15.5 15.25 0.35 S 
77 15 15.5 15.25 0.35 S 103 16 16 16 0.00 S 
78 15.5 16 15.75 0.35 S 104 15 15.5 15.25 0.35 S 
79 15 16 15.5 0.71 S 105 17 18 17.5 0.71 S 










 Table 4 continued… 
 
GENTAMICIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 17 17.5 17.25 0.35 S 133 17 17 17 0.00 S 
108 18.5 18 18.25 0.35 S 134 19 20 19.5 0.71 S 
109 15.5 16 15.75 0.35 S 135 15 15.5 15.25 0.35 S 
110 20 20 20 0.00 S 136 16 16 16 0.00 S 
111 16.5 17 16.75 0.35 S 137 19 20 19.5 0.71 S 
112 16 16 16 0.00 S 138 15 15.5 15.25 0.35 S 
113 16 16 16 0.00 S 139 16 16 16 0.00 S 
114 17 17 17 0.00 S 140 19 20 19.5 0.71 S 
115 19 20 19.5 0.71 S 141 15 15.5 15.25 0.35 S 
116 15 15.5 15.25 0.35 S 142 16 16 16 0.00 S 
117 16 16 16 0.00 S 143 19 20 19.5 0.71 S 
118 16 17 16.5 0.71 S 144 17 17 17 0.00 S 
119 21 21.5 21.25 0.35 S 145 19 20 19.5 0.71 S 
120 10 10.5 10.25 0.35 R 146 15 15.5 15.25 0.35 S 
121 16 16 16 0.00 S 147 16 16 16 0.00 S 
122 19 20 19.5 0.71 S 148 17 17 17 0.00 S 
123 15 15.5 15.25 0.35 S 149 19 20 19.5 0.71 S 
124 16 16 16 0.00 S 150 15 15.5 15.25 0.35 S 
125 19 20 19.5 0.71 S 151 16 16 16 0.00 S 
126 17 17 17 0.00 S 152 16 16 16 0.00 S 
127 19 20 19.5 0.71 S 153 16 16 16 0.00 S 
128 22.5 21.5 22 0.71 S 154 17 17 17 0.00 S 
129 20 22 21 1.41 S 155 19 20 19.5 0.71 S 
130 11 11 11 0.00 R 156 15 15.5 15.25 0.35 S 
131 10 10 10 0.00 R 157 18.5 18.5 18.5 0.00 S 









Table 4 continued… 
 
GENTAMICIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 20 20 20 0.00 S 185 15.5 16 15.75 0.35 S 
160 16.5 17 16.75 0.35 S 186 20 20 20 0.00 S 
161 16 16 16 0.00 S 187 20 20 20 0.00 S 
162 19 20 19.5 0.71 S 188 16 16 16 0.00 S 
163 15.5 16 15.75 0.35 S 189 19 20 19.5 0.71 S 
164 20 20 20 0.00 S 190 15 15.5 15.25 0.35 S 
165 16 16 16 0.00 S 191 15.5 16 15.75 0.35 S 
166 16 16 16 0.00 S 192 20 20 20 0.00 S 
167 19 20 19.5 0.71 S 193 16 16 16 0.00 S 
168 15.5 16 15.75 0.35 S 194 18 18 18 0.00 S 
169 20 20 20 0.00 S 195 18.5 19 18.75 0.35 S 
170 20 20 20 0.00 S 196 17 17.5 17.25 0.35 S 
171 16.5 17 16.75 0.35 S 197 17 17 17 0.00 S 
172 16 16 16 0.00 S 198 19 19.5 19.25 0.35 S 
173 16 16 16 0.00 S 199 23 22 22.5 0.71 S 
174 17 17 17 0.00 S 200 22 20 21 1.41 S 
175 16 16 16 0.00 S           R 
176 19 20 19.5 0.71 S           R 
177 15 15.5 15.25 0.35 S           R 
178 16 16 16 0.00 S           R 
179 16 16 16 0.00 S           R 
180 19 20 19.5 0.71 S           R 
181 15 15.5 15.25 0.35 S           R 
182 15.5 16 15.75 0.35 S           R 
183 19 19.5 19.25 0.35 S           R 











     R       
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 13 13 13 0.00 S 29 10 10 10 0.00 R 
2 11 11 11 0.00 R 30 11 11 11 0.00 R 
3 14.5 15 14.75 0.35 S 31 12.5 12.3 12.4 0.14 S 
4 10 10 10 0.00 R 32 14 14 14 0.00 S 
5 14 14 14 0.00 S 33 16 16 16 0.00 S 
6 11 11.5 11.25 0.35 R 34 15.5 16 15.75 0.35 S 
7 15 15 15 0.00 S 35 14 13 13.5 0.71 S 
8 14.5 15 14.75 0.35 S 36 15.5 16 15.75 0.35 S 
9 11 12 11.5 0.71 R 37 14 14.5 14.25 0.35 S 
10 15 14 14.5 0.71 S 38 17.5 17.5 17.5 0.00 S 
11 14 15 14.5 0.71 S 39 17 17 17 0.00 S 
12 12.5 12.5 12.5 0.00 S 40 17 17 17 0.00 S 
13 16 16.5 16.25 0.35 S 41 12 12 12 0.00 R 
14 13 13 13 0.00 S 42 11 11 11 0.00 R 
15 13 13.5 13.25 0.35 S 43 13 13 13 0.00 S 
16 14 14 14 0.00 S 44 11 11 11 0.00 R 
17 11 12 11.5 0.71 R 45 13 13 13 0.00 S 
18 17 16 16.5 0.71 S 46 14 15 14.5 0.71 S 
19 12.5 13 12.75 0.35 S 47 12 12 12 0.00 R 
20 12 10 11 1.41 R 48 16 16 16 0.00 S 
21 15 15 15 0.00 S 49 15 16 15.5 0.71 S 
22 9.5 10 9.75 0.35 R 50 15 15 15 0.00 S 
23 12.5 12.5 12.5 0.00 S 51 12 12 12 0.00 R 
24 14 14 14 0.00 S 52 16 16 16 0.00 S 
25 14 14 14 0.00 S 53 13 13 13 0.00 S 










          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 12 12 12 0.00 R 81 16 16 16 0.00 S 
56 14 14 14 0.00 S 82 18.5 18.5 18.5 0.00 S 
57 11 11 11 0.00 R 83 19 19 19 0.00 S 
58 14 14 14 0.00 S 84 13.5 14 13.75 0.35 S 
59 10 10 10 0.00 R 85 14 14 14 0.00 S 
60 15 15 15 0.00 S 86 19 19 19 0.00 S 
61 15 15.5 15.25 0.35 S 87 13.5 14 13.75 0.35 S 
62 12 12 12 0.00 R 88 19 19 19 0.00 S 
63 10 11 10.5 0.71 R 89 19 19 19 0.00 S 
64 15 16 15.5 0.71 S 90 14 14 14 0.00 S 
65 16 17 16.5 0.71 S 91 19 17 18 1.41 S 
66 15 17 16 1.41 S 92 12 12 12 0.00 R 
67 10 10 10 0.00 R 93 10 10.5 10.25 0.35 R 
68 18 18.5 18.25 0.35 S 94 16.5 16 16.25 0.35 S 
69 9 10 9.5 0.71 R 95 16 18 17 1.41 S 
70 11 11 11 0.00 R 96 18.5 17.5 18 0.71 S 
71 18 18 18 0.00 S 97 12 11.5 11.75 0.35 R 
72 16.5 15 15.75 1.06 S 98 18 18 18 0.00 S 
73 15 15 15 0.00 S 99 14 14 14 0.00 S 
74 15 14.5 14.75 0.35 S 100 12.5 13 12.75 0.35 S 
75 16 16 16 0.00 S 101 12 12 12 0.00 R 
76 11 11.5 11.25 0.35 R 102 11 11 11 0.00 R 
77 19 19 19 0.00 S 103 10 10 10 0.00 R 
78 12 11.5 11.75 0.35 R 104 9.5 9 9.25 0.35 R 
79 10 11 10.5 0.71 R 105 11 10 10.5 0.71 R 












          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 10.5 10.5 10.5 0.00 R 133 14 14.5 14.25 0.35 S 
108 16 16 16 0.00 S 134 14 15 14.5 0.71 S 
109 14.5 15 14.75 0.35 S 135 19 19 19 0.00 S 
110 15 15 15 0.00 S 136 12.5 13 12.75 0.35 S 
111 15 16 15.5 0.71 S 137 13 13 13 0.00 S 
112 16 17 16.5 0.71 S 138 15 17 16 1.41 S 
113 15 17 16 1.41 S 139 13 13 13 0.00 S 
114 14 15 14.5 0.71 S 140 12 14 13 1.41 S 
115 14.5 15 14.75 0.35 S 141 12 12 12 0.00 R 
116 11 12 11.5 0.71 R 142 14 14.5 14.25 0.35 S 
117 16 16 16 0.00 S 143 14 15 14.5 0.71 S 
118 17 17 17 0.00 S 144 19 19 19 0.00 S 
119 16 16 16 0.00 S 145 12.5 13 12.75 0.35 S 
120 16 16.5 16.25 0.35 S 146 14 15 14.5 0.71 S 
121 17 17 17 0.00 S 147 19 19 19 0.00 S 
122 12.5 13 12.75 0.35 S 148 10 10 10 0.00 R 
123 10.5 10.5 10.5 0.00 R 149 11 11 11 0.00 R 
124 13 13 13 0.00 S 150 10 10 10 0.00 R 
125 13 13 13 0.00 S 151 11.5 12 11.75 0.35 R 
126 11.5 11.5 11.5 0.00 R 152 16.5 17 16.75 0.35 S 
127 10 10 10 0.00 R 153 14 14 14 0.00 S 
128 19 19 19 0.00 S 154 18.5 17 17.75 1.06 S 
129 12.5 13 12.75 0.35 S 155 19 19 19 0.00 S 
130 13 13 13 0.00 S 156 12.5 13 12.75 0.35 S 
131 12 12 12 0.00 R 157 13 13 13 0.00 S 












          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 18 18 18 0.00 S 185 12.5 12.3 12.4 0.14 S 
160 12 12 12 0.00 R 186 14 14 14 0.00 S 
161 16 16 16 0.00 S 187 16 16 16 0.00 S 
162 14.5 15 14.75 0.35 S 188 15.5 16 15.75 0.35 S 
163 15 15 15 0.00 S 189 14 13 13.5 0.71 S 
164 15 16 15.5 0.71 S 190 15.5 16 15.75 0.35 S 
165 16 16 16 0.00 S 191 16 16 16 0.00 S 
166 14.5 15 14.75 0.35 S 192 14.5 15 14.75 0.35 S 
167 15 15 15 0.00 S 193 15 15 15 0.00 S 
168 15 16 15.5 0.71 S 194 15 16 15.5 0.71 S 
169 15 16 15.5 0.71 S 195 16 16 16 0.00 S 
170 19 19 19 0.00 S 196 14.5 15 14.75 0.35 S 
171 12.5 13 12.75 0.35 S 197 15 15 15 0.00 S 
172 13 13 13 0.00 S 198 15 16 15.5 0.71 S 
173 15 16 15.5 0.71 S 199 15 15 15 0.00 S 
174 16 17 16.5 0.71 S 200 15 15.5 15.25 0.35 S 
175 14 14.5 14.25 0.35 S          
176 14.5 15 14.75 0.35 S          
177 15 15 15 0.00 S          
178 15 16 15.5 0.71 S          
179 15 15 15 0.00 S          
180 14 15 14.5 0.71 S          
181 12.5 13 12.75 0.35 S          
182 12.5 13 12.75 0.35 S          
183 13 13 13 0.00 S          





Table 6: Zones of inhibition (mm) of E. coli isolates tested against amoxicillin 
 
AMOXYCILLIN 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 12 12 12 0.00 R 29 10 9 9.5 0.71 R 
2 11 11 11 0.00 R 30 9.5 10 9.75 0.35 R 
3 12 12 12 0.00 R 31 14 14 14 0.00 S 
4 15 15 15 0.00 S 32 12 11 11.5 0.71 R 
5 12 12 12 0.00 R 33 11 12 11.5 0.71 R 
6 11 11 11 0.00 R 34 10 11 10.5 0.71 R 
7 14 15 14.5 0.71 S 35 10.5 10 10.25 0.35 R 
8 10 10.5 10.25 0.35 R 36 14.5 15 14.75 0.35 S 
9 10 11 10.5 0.71 R 37 16 16 16 0.00 S 
10 11 12 11.5 0.71 R 38 12 11 11.5 0.71 R 
11 12 11 11.5 0.71 R 39 13.5 13.5 13.5 0.00 S 
12 14 14 14 0.00 S 40 16 17 16.5 0.71 S 
13 14 14 14 0.00 S 41 17 17 17 0.00 S 
14 12 12 12 0.00 R 42 10 10 10 0.00 R 
15 15 15 15 0.00 S 43 12 12 12 0.00 R 
16 11 11 11 0.00 R 44 18 17 17.5 0.71 S 
17 13 13 13 0.00 R 45 10 10.5 10.25 0.35 R 
18 10 10.5 10.25 0.35 R 46 16 16 16 0.00 S 
19 16 16.5 16.25 0.35 S 47 16 16 16 0.00 S 
20 17 18 17.5 0.71 S 48 16.5 15 15.75 1.06 S 
21 12 12 12 0.00 R 49 12 12 12 0.00 R 
22 13.5 13.5 13.5 0.00 S 50 12 12 12 0.00 R 
23 12 12 12 0.00 R 51 14 15 14.5 0.71 S 
24 10 10 10 0.00 R 52 15 15 15 0.00 S 
25 11 11 11 0.00 R 53 15 16.5 15.75 1.06 S 
26 14 14 14 0.00 S 54 17 18 17.5 0.71 S 
27 15 15 15 0.00 S 55 12 12 12 0.00 R 






Table 6 continued… 
 
AMOXYCILLIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 16 15 15.5 0.71 S 81 12 12 12 0.00 R 
56 16 15 15.5 0.71 S 82 14 13 13.5 0.71 S 
57 16 16 16 0.00 S 83 10 10 10 0.00 R 
58 12 12 12 0.00 R 84 10 10 10 0.00 R 
59 14 14 14 0.00 S 85 15.5 15 15.25 0.35 S 
60 14 14 14 0.00 S 86 10.5 10.5 10.5 0.00 R 
61 11 11.5 11.25 0.35 R 87 16 16 16 0.00 S 
62 15 15 15 0.00 S 88 10 10 10 0.00 R 
63 15 15 15 0.00 S 89 16 16 16 0.00 S 
64 15 15 15 0.00 S 90 17 17 17 0.00 S 
65 12 12 12 0.00 R 91 12 12.5 12.25 0.35 R 
66 10 9.5 9.75 0.35 R 92 16 16 16 0.00 S 
67 10 11 10.5 0.71 R 93 18 18 18 0.00 S 
68 12 10 11 1.41 R 94 13 13 13 0.00 R 
69 14.5 15 14.75 0.35 S 95 14 14 14 0.00 S 
70 10 11 10.5 0.71 R 96 13 12.5 12.75 0.35 R 
71 11 12 11.5 0.71 R 97 14 14 14 0.00 S 
72 9 10.5 9.75 1.06 R 98 12.5 12.5 12.5 0.00 R 
73 11 11 11 0.00 R 99 12 11 11.5 0.71 R 
74 12 12 12 0.00 R 100 19 19 19 0.00 S 
75 15 15 15 0.00 S 101 12.5 11.5 12 0.71 R 
76 16.5 17 16.75 0.35 S 102 11 11 11 0.00 R 
77 10 8.5 9.25 1.06 R 103 12 12 12 0.00 R 
78 13.5 13.5 13.5 0.00 S 104 10.5 10.5 10.5 0.00 R 
79 14.5 15 14.75 0.35 S 105 11 12 11.5 0.71 R 








Table 6 continued… 
 
AMOXYCILLIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 12 12 12 0.00 R 133 18 18 18 0.00 S 
108 11.5 11 11.25 0.35 R 134 12 12.5 12.25 0.35 R 
109 10.5 10 10.25 0.35 R 135 11 11 11 0.00 R 
110 12.5 12.5 12.5 0.00 R 136 11 11 11 0.00 R 
111 10.5 10.5 10.5 0.00 R 137 11 11 11 0.00 R 
112 12 12 12 0.00 R 138 16 16 16 0.00 S 
113 10.5 10.5 10.5 0.00 R 139 16.5 17 16.75 0.35 S 
114 9 10.5 9.75 1.06 R 140 15 15 15 0.00 S 
115 15 15 15 0.00 S 141 12.5 12.5 12.5 0.00 R 
116 13 13 13 0.00 R 142 15.5 16 15.75 0.35 S 
117 16 16 16 0.00 S 143 16 16 16 0.00 S 
118 16.5 17 16.75 0.35 S 144 14 15 14.5 0.71 S 
119 18 18 18 0.00 S 145 15 15.5 15.25 0.35 S 
120 12 11.5 11.75 0.35 R 146 16 14.5 15.25 1.06 S 
121 12 12 12 0.00 R 147 15 15 15 0.00 S 
122 12.5 12.5 12.5 0.00 R 148 11 12 11.5 0.71 R 
123 13.5 14 13.75 0.35 S 149 10.5 10.5 10.5 0.00 R 
124 12 12 12 0.00 R 150 10.5 10.5 10.5 0.00 R 
125 10.5 10.5 10.5 0.00 R 151 11 10.5 10.75 0.35 R 
126 10.5 10.5 10.5 0.00 R 152 12.5 11.5 12 0.71 R 
127 9.5 10 9.75 0.35 R 153 12.5 13 12.75 0.35 R 
128 16 16 16 0.00 S 154 14 14 14 0.00 S 
129 16.5 17 16.75 0.35 S 155 12 12 12 0.00 R 
130 18 18 18 0.00 S 156 13 13 13 0.00 R 
131 16 16 16 0.00 S 157 11 10.5 10.75 0.35 R 









Table 6 continued… 
 
AMOXYCILLIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 10.5 10.5 10.5 0.00 R 185 12.5 12.5 12.5 0.00 R 
160 14 14 14 0.00 S 186 11 12 11.5 0.71 R 
161 14 15 14.5 0.71 S 187 15.5 16 15.75 0.35 S 
162 15 15 15 0.00 S 188 16 16 16 0.00 S 
163 15 16.5 15.75 1.06 S 189 14 15 14.5 0.71 S 
164 17 18 17.5 0.71 S 190 15 15.5 15.25 0.35 S 
165 16 16 16 0.00 S 191 15 15 15 0.00 S 
166 15.5 16 15.75 0.35 S 192 15 16.5 15.75 1.06 S 
167 15 16 15.5 0.71 S 193 17 18 17.5 0.71 S 
168 19 19 19 0.00 S 194 13.5 14 13.75 0.35 S 
169 16 15 15.5 0.71 S 195 16 16 16 0.00 S 
170 15 15 15 0.00 S 196 15 15 15 0.00 S 
171 15 16.5 15.75 1.06 S 197 15 16 15.5 0.71 S 
172 17 18 17.5 0.71 S 198 18 18 18 0.00 S 
173 17.5 18 17.75 0.35 S 199 16.5 17 16.75 0.35 S 
174 18 18 18 0.00 S 200 18 18 18 0.00 S 
175 17.5 18 17.75 0.35 S             
176 12.5 12.5 12.5 0.00 R             
177 13 13 13 0.00 R             
178 14.5 15 14.75 0.35 S             
179 15 16 15.5 0.71 S             
180 16 16 16 0.00 S             
181 10.5 11 10.75 0.35 R             
182 15.5 16 15.75 0.35 S             
183 16.5 17 16.75 0.35 S             










          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 15 15 15 0.00 S 29 11 12 11.5 0.71 R 
2 11 11 11 0.00 R 30 12 12 12 0.00 R 
3 16 16 16 0.00 S 31 11 13 12 1.41 R 
4 16 15 15.5 0.71 S 32 15 15 15 0.00 S 
5 11 11 11 0.00 R 33 10 10 10 0.00 R 
6 10 10 10 0.00 R 34 16 16 16 0.00 S 
7 11 11 11 0.00 R 35 11 11.5 11.25 0.35 R 
8 14 15 14.5 0.71 S 36 15 15 15 0.00 S 
9 12 12 12 0.00 R 37 14.5 15 14.75 0.35 S 
10 15 15 15 0.00 S 38 15 15 15 0.00 S 
11 11 11 11 0.00 R 39 12 12 12 0.00 R 
12 12 12 12 0.00 R 40 16 16 16 0.00 S 
13 10 12 11 1.41 R 41 18 17.5 17.75 0.35 S 
14 10.5 10.5 10.5 0.00 R 42 12 12 12 0.00 R 
15 11 11 11 0.00 R 43 19.5 20 19.75 0.35 S 
16 19 19 19 0.00 S 44 19 19 19 0.00 S 
17 12 12 12 0.00 R 45 14.5 15 14.75 0.35 S 
18 10 10 10 0.00 R 46 12 12 12 0.00 R 
19 12 11 11.5 0.71 R 47 13.5 15 14.25 1.06 S 
20 16 16 16 0.00 S 48 10 10.5 10.25 0.35 R 
21 12 12 12 0.00 R 49 14 14 14 0.00 S 
22 14 14 14 0.00 S 50 12 12.5 12.25 0.35 R 
23 15 15.5 15.25 0.35 S 51 15 15 15 0.00 S 
24 11 11 11 0.00 R 52 12 12 12 0.00 R 
25 14 14 14 0.00 S 53 11 11.5 11.25 0.35 R 
26 15 15 15 0.00 S 54 14 14 14 0.00 S 
27 13.5 14 13.75 0.35 S       










          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 12.5 11 11.75 1.06 R 81 12 12 12 0.00 R 
56 15 15 15 0.00 S 82 12 11 11.5 0.71 R 
57 15 15 15 0.00 S 83 13 13 13 0.00 R 
58 14.5 15 14.75 0.35 S 84 11 12 11.5 0.71 R 
59 15 15 15 0.00 S 85 10 10.5 10.25 0.35 R 
60 16 15 15.5 0.71 S 86 9 10 9.5 0.71 R 
61 17.5 18 17.75 0.35 S 87 14.5 15 14.75 0.35 S 
62 17 17 17 0.00 S 88 18 18 18 0.00 S 
63 12 12 12 0.00 R 89 13.5 14 13.75 0.35 S 
64 12 12 0 0.00 R 90 15 15 15 0.00 S 
65 11 11 11 0.00 R 91 12 12 12 0.00 R 
66 12 10 11 1.41 R 92 15.5 16 15.75 0.35 S 
67 12.5 12 12.25 0.35 R 93 15 15 15 0.00 S 
68 12 12.5 12.25 0.35 R 94 10 10 10 0.00 R 
69 15 15 15 0.00 S 95 16 16 16 0.00 S 
70 9 9 9 0.00 R 96 11 10 10.5 0.71 R 
71 10 10 10 0.00 R 97 14.5 15 14.75 0.35 S 
72 13.5 14 13.75 0.35 S 98 10 11 10.5 0.71 R 
73 12 12 12 0.00 R 99 15.5 15.5 15.5 0.00 S 
74 13 13 13 0.00 R 100 16 16 16 0.00 S 
75 10.5 10.5 10.5 0.00 R 101 14 14 14 0.00 S 
76 14 14 14 0.00 S 102 11 11 11 0.00 R 
77 15 15 15 0.00 S 103 12 12 12 0.00 R 
78 14.5 15 14.75 0.35 S 104 12 12.5 12.25 0.35 R 
79 13.5 14.5 14 0.71 S 105 13 13 13 0.00 R 











          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 15 15 15 0.00 S 133 12 13 12.5 0.71 R 
108 12 12 12 0.00 R 134 11 11 11 0.00 R 
109 11.5 12 11.75 0.35 R 135 10.5 10.5 10.5 0.00 R 
110 12 12 12 0.00 R 136 13 13 13 0.00 R 
111 12 12 12 0.00 R 137 15 15 15 0.00 S 
112 12 12 12 0.00 R 138 18 17 17.5 0.71 S 
113 10 10 10 0.00 R 139 16 16 16 0.00 S 
114 10 10 10 0.00 R 140 12 12.5 12.25 0.35 R 
115 10.5 10.5 10.5 0.00 R 141 12 13 12.5 0.71 R 
116 9.5 9.5 9.5 0.00 R 142 12 12 12 0.00 R 
117 12 12 12 0.00 R 143 12.5 12.5 12.5 0.00 R 
118 11 11.5 11.25 0.35 R 144 10 10.5 10.25 0.35 R 
119 11.5 11 11.25 0.35 R 145 11.5 11.5 11.5 0.00 R 
120 11.5 12 11.75 0.35 R 146 12 12 12 0.00 R 
121 15 15 15 0.00 S 147 13 13 13 0.00 R 
122 16 16.5 16.25 0.35 S 148 18 18.5 18.25 0.35 S 
123 12 12 12 0.00 R 149 16 15.5 15.75 0.35 S 
124 12.5 12.5 12.5 0.00 R 150 16 16 16 0.00 S 
125 12.5 13 12.75 0.35 R 151 16.5 16.5 16.5 0.00 S 
126 15 15 15 0.00 S 152 17 17 17 0.00 S 
127 14.5 14.5 14.5 0.00 S 153 14.5 15 14.75 0.35 S 
128 11 11 11 0.00 R 154 14 14 14 0.00 S 
129 10 10.5 10.25 0.35 R 155 10.5 11 10.75 0.35 R 
130 10 10.5 10.25 0.35 R 156 11 11.5 11.25 0.35 R 
131 10 10 10 0.00 R 157 11 11 11 0.00 R 












          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 13.5 15 14.25 1.06 S 185 15.5 16 15.75 0.35 S 
160 15 15 15 0.00 S 186 15 15 15 0.00 S 
161 16 16.5 16.25 0.35 S 187 16.5 17 16.75 0.35 S 
162 15.5 16 15.75 0.35 S 188 18 17 17.5 0.71 S 
163 15 15.5 15.25 0.35 S 189 17.5 18 17.75 0.35 S 
164 13.5 14 13.75 0.35 S 190 15 15 15 0.00 S 
165 12 12 12 0.00 R 191 14.5 14.5 14.5 0.00 S 
166 13 13 13 0.00 R 192 13.5 14 13.75 0.35 S 
167 14 14 14 0.00 S 193 20 20 20 0.00 S 
168 14 14 14 0.00 S 194 13 13 13 0.00 R 
169 15.5 16 15.75 0.35 S 195 18 18 18 0.00 S 
170 19 19 19 0.00 S 196 19.5 20 19.75 0.35 S 
171 18 18 18 0.00 S 197 13.5 13.5 13.5 0.00 S 
172 15 15 15 0.00 S 198 14 14 14 0.00 S 
173 14.5 15 14.75 0.35 S 199 15 15 15 0.00 S 
174 15 15.5 15.25 0.35 S 200 15 15 15 0.00 S 
175 16.5 17 16.75 0.35 S             
176 16 16 16 0.00 S             
177 17 17.5 17.25 0.35 S             
178 10.5 11 10.75 0.35 R             
179 12.5 12.5 12.5 0.00 R             
180 20 20 20 0.00 S             
181 15 16 15.5 0.71 S             
182 14.5 15 14.75 0.35 S             
183 16 16 16 0.00 S             






Table 8: Zones of inhibition (mm) of E. coli isolates tested against trimethoprim 
 
TRIMETHOPRIM 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 9 10 9.5 0.71 R 29 9 10.5 9.75 1.06 R 
2 9 10 9.5 0.71 R 30 8 9 8.5 0.71 R 
3 9 10 9.5 0.71 R 31 9 8 8.5 0.71 R 
4 8 9 8.5 0.71 R 32 8 10 9 1.41 R 
5 8 9 8.5 0.71 R 33 9 9 9 0.00 R 
6 9 8 8.5 0.71 R 34 10 8 9 1.41 R 
7 8 9 8.5 0.71 R 35 8 9 8.5 0.71 R 
8 9 9 9 0.00 R 36 10 9 9.5 0.71 R 
9 8 8 8 0.00 R 37 9 9 9 0.00 R 
10 9 10 9.5 0.71 R 38 8 8 8 0.00 R 
11 8 9 8.5 0.71 R 39 9.5 8 8.75 1.06 R 
12 9 8 8.5 0.71 R 40 9.5 10 9.75 0.35 R 
13 8 10 9 1.41 R 41 8 10 9 1.41 R 
14 9 10 9.5 0.71 R 42 10 10 10 0.00 R 
15 10 10 10 0.00 R 43 9 8 8.5 0.71 R 
16 9 8 8.5 0.71 R 44 8 9 8.5 0.71 R 
17 10 9 9.5 0.71 R 45 8.5 10 9.25 1.06 R 
18 8 9 8.5 0.71 R 46 10 9 9.5 0.71 R 
19 9 9 9 0.00 R 47 10 8 9 1.41 R 
20 10 8 9 1.41 R 48 10 10 10 0.00 R 
21 9 8 8.5 0.71 R 49 9 9 9 0.00 R 
22 8 9.5 8.75 1.06 R 50 8 8 8 0.00 R 
23 10 8.5 9.25 1.06 R 51 10 10 10 0.00 R 
24 9 10 9.5 0.71 R 52 9 9 9 0.00 R 
25 10 9.5 9.75 0.35 R 53 8.5 9 8.75 0.35 R 
26 8 10 9 1.41 R 54 9 8.5 8.75 0.35 R 
27            







Table 8 continued… 
 
TRIMETHOPRIM 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 10 10 10 0.00 R 81 9 8 8.5 0.71 R 
56 9 9 9 0.00 R 82 8 9 8.5 0.71 R 
57 8 8 8 0.00 R 83 10 10 10 0.00 R 
58 8 10 9 1.41 R 84 10 9 9.5 0.71 R 
59 9 9 9 0.00 R 85 10 10 10 0.00 R 
60 8 8 8 0.00 R 86 9.5 10 9.75 0.35 R 
61 8 10 9 1.41 R 87 8.5 9 8.75 0.35 R 
62 9 9.5 9.25 0.35 R 88 9 8 8.5 0.71 R 
63 9 8 8.5 0.71 R 89 8 9 8.5 0.71 R 
64 9 9 9 0.00 R 90 10 9 9.5 0.71 R 
65 10 10 10 0.00 R 91 9 8 8.5 0.71 R 
66 10 10 10 0.00 R 92 8 8 8 0.00 R 
67 10 10 10 0.00 R 93 8 8 8 0.00 R 
68 10 9 9.5 0.71 R 94 8 8 8 0.00 R 
69 10 9 9.5 0.71 R 95 9.5 9 9.25 0.35 R 
70 8 7 7.5 0.71 R 96 9 9 9 0.00 R 
71 9 9 9 0.00 R 97 8.5 9 8.75 0.35 R 
72 8 8 8 0.00 R 98 9 9 9 0.00 R 
73 9 9 9 0.00 R 99 10 10 10 0.00 R 
74 9 9 9 0.00 R 100 10 9 9.5 0.71 R 
75 9 9 9 0.00 R 101 9 9 9 0.00 R 
76 8 8 8 0.00 R 102 11 11 11 0.00 S 
77 8 9 8.5 0.71 R 103 14 14 14 0.00 S 
78 8.5 9 8.75 0.35 R 104 15 15 15 0.00 S 
79 8 9 8.5 0.71 R 105 12.5 13 12.75 0.35 S 













          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 12 12 12 0.00 S 133 11 11.5 11.25 0.35 S 
108 13 13 13 0.00 S 134 14.5 15 14.75 0.35 S 
109 11 11 11 0.00 S 135 12 12 12 0.00 S 
110 12 12.5 12.25 0.35 S 136 13 13 13 0.00 S 
111 15 15 15 0.00 S 137 16 16 16 0.00 S 
112 16 16 16 0.00 S 138 16 16 16 0.00 S 
113 13 13 13 0.00 S 139 16.5 17 16.75 0.35 S 
114 17 17.5 17.25 0.35 S 140 16 16 16 0.00 S 
115 18 18 18 0.00 S 141 17.5 17.5 17.5 0.00 S 
116 14 14.5 14.25 0.35 S 142 11 11 11 0.00 S 
117 13.5 13.5 13.5 0.00 S 143 10.5 11 10.75 0.35 S 
118 14.5 15 14.75 0.35 S 144 14 14.5 14.25 0.35 S 
119 15 15 15 0.00 S 145 12.5 13 12.75 0.35 S 
120 16.5 16.5 16.5 0.00 S 146 12 12 12 0.00 S 
121 14 15 14.5 0.71 S 147 14 14 14 0.00 S 
122 13.5 14 13.75 0.35 S 148 11.5 11.5 11.5 0.00 S 
123 12.5 13 12.75 0.35 S 149 11 11 11 0.00 S 
124 14.5 14 14.25 0.35 S 150 10.5 11 10.75 0.35 S 
125 15 15.5 15.25 0.35 S 151 16 16 16 0.00 S 
126 16 16 16 0.00 S 152 15.5 15.5 15.5 0.00 S 
127 14 14.5 14.25 0.35 S 153 17 17 17 0.00 S 
128 14 15 14.5 0.71 S 154 12.5 13 12.75 0.35 S 
129 15 16 15.5 0.71 S 155 14 14 14 0.00 S 
130 11 12.5 11.75 1.06 S 156 15 15 15 0.00 S 
131 12.5 13 12.75 0.35 S 157 11 11 11 0.00 S 










          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 14 14 14 0.00 S 185 19 19 19 0.00 S 
160 19 19 19 0.00 S 186 16 16 16 0.00 S 
161 15.5 15.5 15.5 0.00 S 187 15.5 16 15.75 0.35 S 
162 13 13 13 0.00 S 188 16.5 17 16.75 0.35 S 
163 12.5 13 12.75 0.35 S 189 16.5 17 16.75 0.35 S 
164 14.5 15 14.75 0.35 S 190 14.5 15.5 15 0.71 S 
165 16 16 16 0.00 S 191 18 17.5 17.75 0.35 S 
166 17 17 17 0.00 S 192 13 12.5 12.75 0.35 S 
167 14.5 15 14.75 0.35 S 193 10.5 11 10.75 0.35 S 
168 15 15.5 15.25 0.35 S 194 11 11 11 0.00 S 
169 11 10.5 10.75 0.35 S 195 12.5 12.5 12.5 0.00 S 
170 10.5 10.5 10.5 0.00 S 196 15.5 16 15.75 0.35 S 
171 10.5 11 10.75 0.35 S 197 14.5 15 14.75 0.35 S 
172 10 10.5 10.25 0.35 S 198 13.5 15 14.25 1.06 S 
173 13 14 13.5 0.71 S 199 12 12.5 12.25 0.35 S 
174 15.5 16 15.75 0.35 S 200 12 12 12 0.00 S 
175 13.5 12.5 13 0.71 S             
176 13 12.5 12.75 0.35 S             
177 14.5 13 13.75 1.06 S             
178 16 16 16 0.00 S             
179 19 19 19 0.00 S             
180 21 21 21 0.00 S             
181 11.5 12 11.75 0.35 S             
182 10 12 11 1.41 S             
183 10 10.5 10.25 0.35 S             










          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 18 18 18 0.00 S 29 12 12 12 0.00 R 
2 10 10 10 0.00 R 30 11 11 11 0.00 R 
3 15 15.5 15.25 0.35 S 31 11 11.5 11.25 0.35 R 
4 16 16 16 0.00 S 32 13 13 13 0.00 S 
5 11 11 11 0.00 R 33 9.5 10 9.75 0.35 R 
6 11 11 11 0.00 R 34 18.5 17 17.75 1.06 S 
7 10 10 10 0.00 R 35 14 14 14 0.00 S 
8 12.5 12.5 12.5 0.00 S 36 15 15 15 0.00 S 
9 8 8.5 8.25 0.35 R 37 15 15.5 15.25 0.35 S 
10 16 16 16 0.00 S 38 15 15 15 0.00 S 
11 14 14 14 0.00 S 39 9.5 9.5 9.5 0.00 R 
12 11 11 11 0.00 R 40 13 13.5 13.25 0.35 S 
13 12 12 12 0.00 R 41 14.5 14.5 14.5 0.00 S 
14 10 10.5 10.25 0.35 R 42 10.5 10.5 10.5 0.00 R 
15 10.5 11 10.75 0.35 R 43 16 16 16 0.00 S 
16 15 15 15 0.00 S 44 15 15.5 15.25 0.35 S 
17 11 10 10.5 0.71 R 45 16 16.5 16.25 0.35 S 
18 10 9 9.5 0.71 R 46 11 11 11 0.00 R 
19 10.5 9.5 10 0.71 R 47 14.5 15 14.75 0.35 S 
20 36 36 36 0.00 S 48 12 11.5 11.75 0.35 R 
21 33 32.5 32.75 0.35 S 49 13.5 14 13.75 0.35 S 
22 37 36 36.5 0.71 S 50 16 17 16.5 0.71 S 
23 12.5 13 12.75 0.35 S 51 16 16 16 0.00 S 
24 13.5 14 13.75 0.35 S 52 12 11 11.5 0.71 R 
25 16 16 16 0.00 S 53 10.5 11 10.75 0.35 R 
26 17 17 17 0.00 S 54 32 33 32.5 0.71 S 
27 12.5 13 12.75 0.35 S             








          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 11 11 11 0.00 R 81 25 26.5 25.75 1.06 S 
56 30.5 31 30.75 0.35 S 82 12 10.5 11.25 1.06 R 
57 31 32 31.5 0.71 S 83 11 11 11 0.00 R 
58 30 30.5 30.25 0.35 S 84 30.5 31 30.75 0.35 S 
59 32 32.5 32.25 0.35 S 85 12 12 12 0.00 R 
60 31 32 31.5 0.71 S 86 9 9 9 0.00 R 
61 39 40 39.5 0.71 S 87 38 38 38 0.00 S 
62 30.5 31 30.75 0.35 S 88 35 35 35 0.00 S 
63 10 10 10 0.00 R 89 35 35 35 0.00 S 
64 9 9.5 9.25 0.35 R 90 36 35 35.5 0.71 S 
65 36 36 36 0.00 S 91 9 9 9 0.00 R 
66 33 32.5 32.75 0.35 S 92 38 38 38 0.00 S 
67 12 12 12 0.00 R 93 35 35 35 0.00 S 
68 33 33 33 0.00 S 94 35 35 35 0.00 S 
69 32 32 32 0.00 S 95 35 35 35 0.00 S 
70 11 11 11 0.00 R 96 36 37 36.5 0.71 S 
71 11 11 11 0.00 R 97 38 39 38.5 0.71 S 
72 27 28.5 27.75 1.06 S 98 37 36 36.5 0.71 S 
73 28 29 28.5 0.71 S 99 25 26 25.5 0.71 S 
74 12 11 11.5 0.71 R 100 38 38 38 0.00 S 
75 10.5 10 10.25 0.35 R 101 35 35 35 0.00 S 
76 38 38 38 0.00 S 102 10 10 10 0.00 R 
77 35 35 35 0.00 S 103 10 10 10 0.00 R 
78 30 32 31 1.41 S 104 9.5 10 9.75 0.35 R 
79 33 33 33 0.00 S 105 12 12 12 0.00 R 








Table 9 continued… 
 
NORFLOXACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 26 27 26.5 0.71 S 133 10 10 10 0.00 R 
108 11 11 11 0.00 R 134 11 11.5 11.25 0.35 R 
109 10 10 10 0.00 R 135 12 12 12 0.00 R 
110 11 11 11 0.00 R 136 10.5 10 10.25 0.35 R 
111 10.5 10.5 10.5 0.00 R 137 35 36 35.5 0.71 S 
112 10 10 10 0.00 R 138 35 35.5 35.25 0.35 S 
113 10.5 9.5 10 0.71 R 139 37 36 36.5 0.71 S 
114 11 11 11 0.00 R 140 30.5 31 30.75 0.35 S 
115 9.5 9.5 9.5 0.00 R 141 36 35.5 35.75 0.35 S 
116 11 12 11.5 0.71 R 142 9.5 9.5 9.5 0.00 R 
117 12 12 12 0.00 R 143 10 10 10 0.00 R 
118 10.5 10.5 10.5 0.00 R 144 11 10 10.5 0.71 R 
119 35 36 35.5 0.71 S 145 12 11 11.5 0.71 R 
120 35 35.5 35.25 0.35 S 146 10.5 10.5 10.5 0.00 R 
121 37 36 36.5 0.71 S 147 10.5 10.5 10.5 0.00 R 
122 11 11 11 0.00 R 148 35 36 35.5 0.71 S 
123 18 18 18 0.00 S 149 35 35.5 35.25 0.35 S 
124 12 12 12 0.00 R 150 37 36 36.5 0.71 S 
125 11 11.5 11.25 0.35 R 151 36 35.5 35.75 0.35 S 
126 36 35.5 35.75 0.35 S 152 26 27 26.5 0.71 S 
127 26 27 26.5 0.71 S 153 35 35 35 0.00 S 
128 10.5 10.5 10.5 0.00 R 154 33 33 33 0.00 S 
129 11 11 11 0.00 R 155 34 32.5 33.25 1.06 S 
130 33 33 33 0.00 S 156 36 36 36 0.00 S 
131 32 32 32 0.00 S 157 31 30 30.5 0.71 S 









Table 9 continued… 
 
NORFLOXACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 35 35 35 0.00 S 185 30.5 31 30.75 0.35 S 
160 33 33 33 0.00 S 186 31 32 31.5 0.71 S 
161 28 28 28 0.00 S 187 30 30.5 30.25 0.35 S 
162 30 30 30 0.00 S 188 36 35.5 35.75 0.35 S 
163 32 31 31.5 0.71 S 189 28 28 28 0.00 S 
164 38 39 38.5 0.71 S 190 30 30 30 0.00 S 
165 35 36 35.5 0.71 S 191 32 31 31.5 0.71 S 
166 35 35.5 35.25 0.35 S 192 35 36.5 35.75 1.06 S 
167 37 36 36.5 0.71 S 193 36 36 36 0.00 S 
168 36 35.5 35.75 0.35 S 194 25 25 25 0.00 S 
169 32 33 32.5 0.71 S 195 9.5 10 9.75 0.35 R 
170 35 35 35 0.00 S 196 33 33 33 0.00 S 
171 37 36 36.5 0.71 S 197 28 28 28 0.00 S 
172 25.5 26 25.75 0.35 S 198 30 30 30 0.00 S 
173 26.5 27 26.75 0.35 S 199 32 31 31.5 0.71 S 
174 27 28 27.5 0.71 S 200 38 39 38.5 0.71 S 
175 32 33 32.5 0.71 S           R 
176 11.5 11.5 11.5 0.00 R           R 
177 12 12 12 0.00 R           R 
178 36 36 36 0.00 S           R 
179 33 32.5 32.75 0.35 S           R 
180 35 36 35.5 0.71 S           R 
181 36.5 37 36.75 0.35 S           R 
182 37 37.5 37.25 0.35 S           R 
183 10.5 10 10.25 0.35 R           R 











     R       
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 39 38 38.5 0.71 S 29 12 12 12 0.00 R 
2 37 37.5 37.25 0.35 S 30 27 27 27 0.00 S 
3 40 40 40 0.00 S 31 34 34 34 0.00 S 
4 41 41 41 0.00 S 32 11 10 10.5 0.71 R 
5 12 13 12.5 0.71 R 33 37 37.5 37.25 0.35 S 
6 33 33 33 0.00 S 34 20 21 20.5 0.71 S 
7 39 38 38.5 0.71 S 35 38 38.5 38.25 0.35 S 
8 40 41 40.5 0.71 S 36 37 36 36.5 0.71 S 
9 41 41 41 0.00 S 37 29 28.5 28.75 0.35 S 
10 41 45 43 2.83 S 38 38 38.5 38.25 0.35 S 
11 45 35 40 7.07 S 39 39 39 39 0.00 S 
12 35 32 33.5 2.12 S 40 35 35.5 35.25 0.35 S 
13 14 13.5 13.75 0.35 R 41 35 34 34.5 0.71 S 
14 39 39.5 39.25 0.35 S 42 35 34 34.5 0.71 S 
15 37 38 37.5 0.71 S 43 36 36 36 0.00 S 
16 36 37 36.5 0.71 S 44 21 21 21 0.00 S 
17 37 38 37.5 0.71 S 45 32 32 32 0.00 S 
18 36 36 36 0.00 S 46 12 10.5 11.25 1.06 R 
19 35 35 35 0.00 S 47 36 36 36 0.00 S 
20 35.6 36 35.8 0.28 S 48 34 34 34 0.00 S 
21 39 39 39 0.00 S 49 33 33 33 0.00 S 
22 34 34 34 0.00 S 50 33 34 33.5 0.71 S 
23 29 28 28.5 0.71 S 51 40 40 40 0.00 S 
24 28 28 28 0.00 S 52 10 10 10 0.00 R 
25 35 34.5 34.75 0.35 S 53 32 33 32.5 0.71 S 
26 27 26 26.5 0.71 S 54 36 35 35.5 0.71 S 
27 23 22 22.5 0.71 S       






Table 10 continued… 
 
CIPROFLOXACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 33 33 33 0.00 S 81 35 36.5 35.75 1.06 S 
56 32 32 32 0.00 S 82 32.5 33 32.75 0.35 S 
57 33 33 33 0.00 S 83 14 14 14 0.00 R 
58 39 38 38.5 0.71 S 84 29.5 29 29.25 0.35 S 
59 40 41 40.5 0.71 S 85 21 22 21.5 0.71 S 
60 37 39 38 1.41 S 86 14 13 13.5 0.71 R 
61 31 32 31.5 0.71 S 87 27 28 27.5 0.71 S 
62 30 30 30 0.00 S 88 25 25 25 0.00 S 
63 12 10 11 1.41 R 89 26 26 26 0.00 S 
64 28 28 28 0.00 S 90 30 30 30 0.00 S 
65 33 32 32.5 0.71 S 91 10 9 9.5 0.71 R 
66 32 31 31.5 0.71 S 92 27 27 27 0.00 S 
67 21 20 20.5 0.71 S 93 30 29.5 29.75 0.35 S 
68 39 38.5 38.75 0.35 S 94 33 32 32.5 0.71 S 
69 33 32 32.5 0.71 S 95 37 38 37.5 0.71 S 
70 32 31 31.5 0.71 S 96 32 31 31.5 0.71 S 
71 10 10 10 0.00 R 97 21 20 20.5 0.71 S 
72 32 33.5 32.75 1.06 S 98 39 38.5 38.75 0.35 S 
73 35 36 35.5 0.71 S 99 32 32 32 0.00 S 
74 36 36 36 0.00 S 100 33 33 33 0.00 S 
75 11.5 12 11.75 0.35 R 101 25 25.5 25.25 0.35 S 
76 34 35 34.5 0.71 S 102 12 11 11.5 0.71 R 
77 27 27 27 0.00 S 103 13 12 12.5 0.71 R 
78 30 29.5 29.75 0.35 S 104 12 12.5 12.25 0.35 R 
79 27 27 27 0.00 S 105 15 15 15 0.00 R 








Table 10 continued… 
 
CIPROFLOXACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 35 35 35 0.00 S 133 14 14 14 0.00 R 
108 13 13 13 0.00 R 134 12.5 12.5 12.5 0.00 R 
109 13 13 13 0.00 R 135 13 12 12.5 0.71 R 
110 14 13.5 13.75 0.35 R 136 13 13 13 0.00 R 
111 14.5 14.5 14.5 0.00 R 137 33 32 32.5 0.71 S 
112 14 14 14 0.00 R 138 32 32 32 0.00 S 
113 11 11 11 0.00 R 139 9.5 10 9.75 0.35 R 
114 11 11 11 0.00 R 140 11 11 11 0.00 R 
115 11.5 11.5 11.5 0.00 R 141 36 36 36 0.00 S 
116 12 12 12 0.00 R 142 14 14 14 0.00 R 
117 13.5 13 13.25 0.35 R 143 14 14.5 14.25 0.35 R 
118 14 14 14 0.00 R 144 13.5 13 13.25 0.35 R 
119 14.5 14 14.25 0.35 R 145 12.5 12.5 12.5 0.00 R 
120 33 32 32.5 0.71 S 146 12.5 12.5 12.5 0.00 R 
121 32 32 32 0.00 S 147 12 12 12 0.00 R 
122 10 10.5 10.25 0.35 R 148 33 32 32.5 0.71 S 
123 33 32 32.5 0.71 S 149 32 33 32.5 0.71 S 
124 12 11 11.5 0.71 R 150 29 30 29.5 0.71 S 
125 12 12.5 12.25 0.35 R 151 34 35 34.5 0.71 S 
126 34 34.5 34.25 0.35 S 152 27 27 27 0.00 S 
127 37 39 38 1.41 S 153 30 29.5 29.75 0.35 S 
128 12.5 12.5 12.5 0.00 R 154 33 32 32.5 0.71 S 
129 13 13 13 0.00 R 155 37 38 37.5 0.71 S 
130 33 35 34 1.41 S 156 37 37 37 0.00 S 
131 37 37 37 0.00 S 157 41 40 40.5 0.71 S 













          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 38 38 38 0.00 S 185 33 34.5 33.75 1.06 S 
160 26 26 26 0.00 S 186 37 37 37 0.00 S 
161 28 28 28 0.00 S 187 37 38 37.5 0.71 S 
162 31 31 31 0.00 S 188 37 37 37 0.00 S 
163 25 25.5 25.25 0.35 S 189 41 40 40.5 0.71 S 
164 29 29 29 0.00 S 190 12 13 12.5 0.71 R 
165 33 34 33.5 0.71 S 191 36 35 35.5 0.71 S 
166 34 34.5 34.25 0.35 S 192 30 30 30 0.00 S 
167 28 28 28 0.00 S 193 32 31 31.5 0.71 S 
168 33 32 32.5 0.71 S 194 27 28 27.5 0.71 S 
169 32 31 31.5 0.71 S 195 37 38 37.5 0.71 S 
170 21 20 20.5 0.71 S 196 32 33 32.5 0.71 S 
171 39 38.5 38.75 0.35 S 197 34 35 34.5 0.71 S 
172 25 25 25 0.00 S 198 38 39 38.5 0.71 S 
173 32 32 32 0.00 S 199 36 37 36.5 0.71 S 
174 31 30 30.5 0.71 S 200 35 36 35.5 0.71 S 
175 33 32 32.5 0.71 S             
176 37.5 36 36.75 1.06 S             
177 32 32.5 32.25 0.35 S             
178 36 36 36 0.00 S             
179 32 32 32 0.00 S             
180 30 30 30 0.00 S             
181 28 28 28 0.00 S             
182 33 32 32.5 0.71 S             
183 32 31 31.5 0.71 S             








          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 20 20 20 0.00 S 29 32 33 32.5 0.71 S 
2 21 21 21 0.00 S 30 34 34 34 0.00 S 
3 11 11 11 0.00 R 31 20.5 20.5 20.5 0.00 S 
4 23 23 23 0.00 S 32 25 25 25 0.00 S 
5 21 21 21 0.00 S 33 28 28 28 0.00 S 
6 24 24 24 0.00 S 34 12 12 12 0.00 R 
7 22 22 22 0.00 S 35 25 25 25 0.00 S 
8 18 18 18 0.00 S 36 29 29 29 0.00 S 
9 21 21 21 0.00 S 37 24 24 24 0.00 S 
10 21 21 21 0.00 S 38 25 26 25.5 0.71 S 
11 24 23 23.5 0.71 S 39 25 24.5 24.75 0.35 S 
12 19 20 19.5 0.71 S 40 11.5 12 11.75 0.35 R 
13 20 20 20 0.00 S 41 21 21 21 0.00 S 
14 26 25 25.5 0.71 S 42 18 18 18 0.00 S 
15 24 24 24 0.00 S 43 31 30 30.5 0.71 S 
16 22 22 22 0.00 S 44 34 34 34 0.00 S 
17 25 25 25 0.00 S 45 33 32 32.5 0.71 S 
18 26 26 26 0.00 S 46 28 28 28 0.00 S 
19 20 21 20.5 0.71 S 47 24.5 23 23.75 1.06 S 
20 13 12.5 12.75 0.35 R 48 26 21 23.5 3.54 S 
21 25 25 25 0.00 S 49 26 24 25 1.41 S 
22 10 10.5 10.25 0.35 R 50 32 32 32 0.00 S 
23 26 26 26 0.00 S 51 33 33 33 0.00 S 
24 34 33 33.5 0.71 S 52 21 21.5 21.25 0.35 S 
25 32 32 32 0.00 S 53 22 22 22 0.00 S 
26 28 28 28 0.00 S 54 13 12.5 12.75 0.35 R 
27 35 34 34.5 0.71 S 55 29 29 29 0.00 S 







Table 11 continued… 
 
CEFTAZIDIME 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 25 25 25 0.00 S 81 24 24 24 0.00 S 
56 12 13 12.5 0.71 R 82 25 25 25 0.00 S 
57 24 24 24 0.00 S 83 22 22 22 0.00 S 
58 24 24 24 0.00 S 84 21 21 21 0.00 S 
59 21 21 21 0.00 S 85 20.5 21 20.75 0.35 S 
60 21 21 21 0.00 S 86 26 26 26 0.00 S 
61 21 21 21 0.00 S 87 10 10 10 0.00 R 
62 24 24 24 0.00 S 88 10 10 10 0.00 R 
63 24 24 24 0.00 S 89 24 24 24 0.00 S 
64 22 23 22.5 0.71 S 90 25 26 25.5 0.71 S 
65 21 20.5 20.75 0.35 S 91 22 23 22.5 0.71 S 
66 23 22 22.5 0.71 S 92 12 11 11.5 0.71 R 
67 22 22 22 0.00 S 93 10 10.5 10.25 0.35 R 
68 22 22 22 0.00 S 94 25 25 25 0.00 S 
69 22 21 21.5 0.71 S 95 25 24 24.5 0.71 S 
70 21 20 20.5 0.71 S 96 24 23.5 23.75 0.35 S 
71 20 21 20.5 0.71 S 97 13 12.5 12.75 0.35 R 
72 23 23 23 0.00 S 98 20 20 20 0.00 S 
73 25 25 25 0.00 S 99 21 21 21 0.00 S 
74 26 26 26 0.00 S 100 10 11 10.5 0.71 R 
75 22 23 22.5 0.71 S 101 31 30 30.5 0.71 S 
76 22 22 22 0.00 S 102 34 34 34 0.00 S 
77 23 23 23 0.00 S 103 33 32 32.5 0.71 S 
78 12 12 12 0.00 R 104 28 28 28 0.00 S 
79 20.5 21 20.75 0.35 S 105 27 28 27.5 0.71 S 









Table 11 continued… 
 
CEFTAZIDIME 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 12 12 12 0.00 R 133 30 30 30 0.00 S 
108 31 30 30.5 0.71 S 134 33 33 33 0.00 S 
109 34 34 34 0.00 S 135 30 28 29 1.41 S 
110 33 32 32.5 0.71 S 136 27 27 27 0.00 S 
111 28 28 28 0.00 S 137 31 30 30.5 0.71 S 
112 24.5 23 23.75 1.06 S 138 34 34 34 0.00 S 
113 26 26 26 0.00 S 139 33 32 32.5 0.71 S 
114 26 24 25 1.41 S 140 28 28 28 0.00 S 
115 13 13.5 13.25 0.35 R 141 24.5 23 23.75 1.06 S 
116 24 25 24.5 0.71 S 142 26 26 26 0.00 S 
117 26 26 26 0.00 S 143 26 24 25 1.41 S 
118 20.5 21 20.75 0.35 S 144 24.5 22 23.25 1.77 S 
119 21 22 21.5 0.71 S 145 27 27 27 0.00 S 
120 23 23 23 0.00 S 146 29.5 29 29.25 0.35 S 
121 14 14 14 0.00 R 147 23.5 21 22.25 1.77 S 
122 25 26 25.5 0.71 S 148 29.5 30 29.75 0.35 S 
123 13 13 13 0.00 R 149 25.5 26 25.75 0.35 S 
124 36 36 36 0.00 S 150 31.5 32 31.75 0.35 S 
125 32 32 32 0.00 S 151 22.5 25 23.75 1.77 S 
126 25 24 24.5 0.71 S 152 32.5 33 32.75 0.35 S 
127 20.5 23 21.75 1.77 S 153 25 37 31 8.49 S 
128 21 22 21.5 0.71 S 154 11 11.5 11.25 0.35 R 
129 28 28 28 0.00 S 155 33 35 34 1.41 S 
130 34 34 34 0.00 S 156 12 11.5 11.75 0.35 R 
131 39 39 39 0.00 S 157 29 29 29 0.00 S 












          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 31 31 31 0.00 S 185 31 32 31.5 0.71 S 
160 33 33 33 0.00 S 186 32 32 32 0.00 S 
161 31 31 31 0.00 S 187 32.5 33 32.75 0.35 S 
162 31 31 31 0.00 S 188 25 25 25 0.00 S 
163 28 28 28 0.00 S 189 22 22 22 0.00 S 
164 31 30 30.5 0.71 S 190 27 27 27 0.00 S 
165 30 30 30 0.00 S 191 30.5 30 30.25 0.35 S 
166 31 32 31.5 0.71 S 192 38 39 38.5 0.71 S 
167 30.5 30 30.25 0.35 S 193 10 10 10 0.00 R 
168 27 27 27 0.00 S 194 32 33 32.5 0.71 S 
169 29 28 28.5 0.71 S 195 35 35 35 0.00 S 
170 31 31 31 0.00 S 196 20.5 21 20.75 0.35 S 
171 24 24 24 0.00 S 197 21 21 21 0.00 S 
172 28 27.5 27.75 0.35 S 198 30.5 30.5 30.5 0.00 S 
173 30 29.5 29.75 0.35 S 199 36 36 36 0.00 S 
174 30.5 30 30.25 0.35 S 200 34 35 34.5 0.71 S 
175 27 27 27 0.00 S             
176 23.5 24 23.75 0.35 S             
177 24.5 25 24.75 0.35 S             
178 26.5 27 26.75 0.35 S             
179 27 28 27.5 0.71 S             
180 13 11.5 12.25 1.06 R             
181 23 23 23 0.00 S             
182 12 12 12 0.00 R             
183 31 30 30.5 0.71 S             









          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 25 25 25 0.00 S 29 23 23 23 0.00 S 
2 18 18 18 0.00 S 30 24 25 24.5 0.71 S 
3 26 26 26 0.00 S 31 26 26 26 0.00 S 
4 26 26 26 0.00 S 32 23 24 23.5 0.71 S 
5 23 24 23.5 0.71 S 33 20.5 21 20.75 0.35 S 
6 25 26 25.5 0.71 S 34 26 26 26 0.00 S 
7 25 25 25 0.00 S 35 23 24 23.5 0.71 S 
8 22 23 22.5 0.71 S 36 25 25 25 0.00 S 
9 23 22 22.5 0.71 S 37 29 29 29 0.00 S 
10 23 23 23 0.00 S 38 12 12 12 0.00 R 
11 24 25 24.5 0.71 S 39 23 23 23 0.00 S 
12 26 26 26 0.00 S 40 23 23 23 0.00 S 
13 23 24 23.5 0.71 S 41 25 24 24.5 0.71 S 
14 25 26 25.5 0.71 S 42 25 25 25 0.00 S 
15 27 29 28 1.41 S 43 23 23 23 0.00 S 
16 10 10 10 0.00 R 44 24 25 24.5 0.71 S 
17 26 25 25.5 0.71 S 45 26 26 26 0.00 S 
18 27 26 26.5 0.71 S 46 23 24 23.5 0.71 S 
19 28 29 28.5 0.71 S 47 25 26 25.5 0.71 S 
20 11 11 11 0.00 R 48 27 27 27 0.00 S 
21 25 25 25 0.00 S 49 25 25 25 0.00 S 
22 11 11 11 0.00 R 50 30 30 30 0.00 S 
23 25 25 25 0.00 S 51 30.5 31 30.75 0.35 S 
24 23 23 23 0.00 S 52 32 33 32.5 0.71 S 
25 24 25 24.5 0.71 S 53 24 24 24 0.00 S 
26 26 26 26 0.00 S 54 26 26 26 0.00 S 
27 23 24 23.5 0.71 S             





Table 12 continued… 
 
FOSFOMYCIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 23 23 23 0.00 S 81 23 23 23 0.00 S 
56 25 25 25 0.00 S 82 24 25 24.5 0.71 S 
57 23 23 23 0.00 S 83 26 26 26 0.00 S 
58 24 24 24 0.00 S 84 23 24 23.5 0.71 S 
59 23 23 23 0.00 S 85 25 26 25.5 0.71 S 
60 24 25 24.5 0.71 S 86 24.5 25 24.75 0.35 S 
61 26 26 26 0.00 S 87 26 26 26 0.00 S 
62 23 24 23.5 0.71 S 88 27 27 27 0.00 S 
63 25 26 25.5 0.71 S 89 30 30 30 0.00 S 
64 25 25 25 0.00 S 90 32 32 32 0.00 S 
65 22 23 22.5 0.71 S 91 30.5 31 30.75 0.35 S 
66 23 22 22.5 0.71 S 92 10 10.5 10.25 0.35 R 
67 20 20 20 0.00 S 93 11 11 11 0.00 R 
68 24 24 24 0.00 S 94 35 35 35 0.00 S 
69 25 25 25 0.00 S 95 24 24 24 0.00 S 
70 25 26 25.5 0.71 S 96 26 26 26 0.00 S 
71 23.5 24 23.75 0.35 S 97 12 12 12 0.00 R 
72 24 25 24.5 0.71 S 98 28 29 28.5 0.71 S 
73 30 30 30 0.00 S 99 22 22 22 0.00 S 
74 35 32 33.5 2.12 S 100 21 22 21.5 0.71 S 
75 20 20 20 0.00 S 101 19 20 19.5 0.71 S 
76 20 20 20 0.00 S 102 23.5 24 23.75 0.35 S 
77 10 10 10 0.00 R 103 26 26 26 0.00 S 
78 11 11 11 0.00 R 104 22 23 22.5 0.71 S 
79 25 25 25 0.00 S 105 24 25 24.5 0.71 S 









Table 12 continued… 
 
FOSFOMYCIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 12 12 12 0.00 R 133 25 24 24.5 0.71 S 
108 23 23 23 0.00 S 134 23.5 25.5 24.5 1.41 S 
109 25 25 25 0.00 S 135 21 25 23 2.83 S 
110 23 23 23 0.00 S 136 22 20 21 1.41 S 
111 24 24 24 0.00 S 137 26 24 25 1.41 S 
112 23 23 23 0.00 S 138 22 24 23 1.41 S 
113 24 25 24.5 0.71 S 139 21 25 23 2.83 S 
114 26 26 26 0.00 S 140 29 29 29 0.00 S 
115 23 22 22.5 0.71 S 141 22 26 24 2.83 S 
116 23 22 22.5 0.71 S 142 19 20 19.5 0.71 S 
117 19 20 19.5 0.71 S 143 29 28 28.5 0.71 S 
118 25 25.5 25.25 0.35 S 144 25 25 25 0.00 S 
119 25 25 25 0.00 S 145 23 24 23.5 0.71 S 
120 21 20 20.5 0.71 S 146 27 26 26.5 0.71 S 
121 25 24 24.5 0.71 S 147 24 23 23.5 0.71 S 
122 24 24 24 0.00 S 148 22 23 22.5 0.71 S 
123 25 25 25 0.00 S 149 26 24 25 1.41 S 
124 26 25.5 25.75 0.35 S 150 24 25 24.5 0.71 S 
125 23 26 24.5 2.12 S 151 25 26 25.5 0.71 S 
126 23 26 24.5 2.12 S 152 25 25 25 0.00 S 
127 23 24 23.5 0.71 S 153 27 27 27 0.00 S 
128 22 26 24 2.83 S 154 10 10 10 0.00 R 
129 25 25 25 0.00 S 155 30 32 31 1.41 S 
130 26 23 24.5 2.12 S 156 32 32 32 0.00 S 
131 26 22 24 2.83 S 157 26 26 26 0.00 S 










Table 12 continued… 
 
FOSFOMYCIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 19 18 18.5 0.71 S 185 19 20 19.5 0.71 S 
160 31 32 31.5 0.71 S 186 31 33 32 1.41 S 
161 24 23 23.5 0.71 S 187 24 23 23.5 0.71 S 
162 22 23 22.5 0.71 S 188 10 10 10 0.00 R 
163 26 24 25 1.41 S 189 12 11.5 11.75 0.35 R 
164 24 25 24.5 0.71 S 190 10.5 10.5 10.5 0.00 R 
165 29 27 28 1.41 S 191 23.5 24 23.75 0.35 S 
166 25 25 25 0.00 S 192 23 23 23 0.00 S 
167 23 25 24 1.41 S 193 23 26 24.5 2.12 S 
168 27 26 26.5 0.71 S 194 23 24 23.5 0.71 S 
169 24.5 25 24.75 0.35 S 195 25 25 25 0.00 S 
170 23 23 23 0.00 S 196 24 24 24 0.00 S 
171 21 25 23 2.83 S 197 26 26 26 0.00 S 
172 29 28.5 28.75 0.35 S 198 27 27 27 0.00 S 
173 23.5 24 23.75 0.35 S 199 20 20 20 0.00 S 
174 23 23 23 0.00 S 200 23 23 23 0.00 S 
175 23 26 24.5 2.12 S             
176 23 24 23.5 0.71 S             
177 22 20 21 1.41 S             
178 25 25 25 0.00 S             
179 26 25 25.5 0.71 S             
180 26 25 25.5 0.71 S             
181 22 20 21 1.41 S             
182 11 11.5 11.25 0.35 R             
183 25 25 25 0.00 S             





Table 13: Zones of inhibition (mm) of E. coli isolates tested against amikacin 
 
AMIKACIN 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 15 16 15.5 0.71 S 29 16 15 15.5 0.71 S 
2 16 18 17 1.41 S 30 17 16 16.5 0.71 S 
3 15 17 16 1.41 S 31 17 15 16 1.41 S 
4 17 16 16.5 0.71 S 32 15 17 16 1.41 S 
5 18 17 17.5 0.71 S 33 16 18 17 1.41 S 
6 15 15 15 0.00 S 34 18 17 17.5 0.71 S 
7 17 16 16.5 0.71 S 35 15 16 15.5 0.71 S 
8 17 16 16.5 0.71 S 36 16 17 16.5 0.71 S 
9 15 17 16 1.41 S 37 17 15 16 1.41 S 
10 16 15 15.5 0.71 S 38 17 16 16.5 0.71 S 
11 18 16 17 1.41 S 39 16 16 16 0.00 S 
12 17 18 17.5 0.71 S 40 17 18 17.5 0.71 S 
13 16 15 15.5 0.71 S 41 15 17 16 1.41 S 
14 17 16 16.5 0.71 S 42 16 16 16 0.00 S 
15 15 17 16 1.41 S 43 15 17 16 1.41 S 
16 16 16 16 0.00 S 44 16 15 15.5 0.71 S 
17 18 17 17.5 0.71 S 45 17 17 17 0.00 S 
18 15 15 15 0.00 S 46 18 18.5 18.25 0.35 S 
19 16 15.5 15.75 0.35 S 47 20 19.5 19.75 0.35 S 
20 17 18 17.5 0.71 S 48 16 16 16 0.00 S 
21 18 18 18 0.00 S 49 17 17 17 0.00 S 
22 20 20 20 0.00 S 50 17 16 16.5 0.71 S 
23 15 16 15.5 0.71 S 51 16 17 16.5 0.71 S 
24 16 17 16.5 0.71 S 52 17 17 17 0.00 S 
25 15.5 16 15.75 0.35 S 53 15 16 15.5 0.71 S 
26 18 17 17.5 0.71 S 54 16 16 16 0.00 S 
27 15 15 15 0.00 S             






Table 13 continued… 
 
AMIKACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 16 17 16.5 0.71 S 81 16 17 16.5 0.71 S 
56 17 16 16.5 0.71 S 82 18 16 17 1.41 S 
57 17 17 17 0.00 S 83 16 17 16.5 0.71 S 
58 15 15 15 0.00 S 84 18 15 16.5 2.12 S 
59 16 16 16 0.00 S 85 17 16 16.5 0.71 S 
60 18 17 17.5 0.71 S 86 18 17 17.5 0.71 S 
61 15 15 15 0.00 S 87 15 15 15 0.00 S 
62 16 15 15.5 0.71 S 88 16 15 15.5 0.71 S 
63 17 16 16.5 0.71 S 89 17 16 16.5 0.71 S 
64 17 18 17.5 0.71 S 90 17 18 17.5 0.71 S 
65 18 18 18 0.00 S 91 18 18 18 0.00 S 
66 20 21 20.5 0.71 S 92 20 21 20.5 0.71 S 
67 21 21 21 0.00 S 93 21 21 21 0.00 S 
68 16 17 16.5 0.71 S 94 16 17 16.5 0.71 S 
69 17 16 16.5 0.71 S 95 17 16 16.5 0.71 S 
70 15 17 16 1.41 S 96 15 17 16 1.41 S 
71 15.5 15 15.25 0.35 S 97 15.5 15 15.25 0.35 S 
72 18.5 17 17.75 1.06 S 98 18.5 15 16.75 2.47 S 
73 15 16 15.5 0.71 S 99 15 16 15.5 0.71 S 
74 16 17 16.5 0.71 S 100 16 17 16.5 0.71 S 
75 19 17 18 1.41 S 101 18 16 17 1.41 S 
76 20 21 20.5 0.71 S 102 17 18 17.5 0.71 S 
17 20 21 20.5 0.71 S 103 16 15 15.5 0.71 S 
18 18 18 18 0.00 S 104 17 16 16.5 0.71 S 
79 16 16 16 0.00 S 105 15 17 16 1.41 S 









Table 13 continued… 
 
AMIKACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 16 17 16.5 0.71 S 133 18 17 17.5 0.71 S 
108 18 17 17.5 0.71 S 134 15 15 15 0.00 S 
109 17 16 16.5 0.71 S 135 20 21 20.5 0.71 S 
110 18 17 17.5 0.71 S 136 21 21 21 0.00 S 
111 17 16 16.5 0.71 S 137 16 15 15.5 0.71 S 
112 15 17 16 1.41 S 138 18 16 17 1.41 S 
113 16 15 15.5 0.71 S 139 17 18 17.5 0.71 S 
114 18 16 17 1.41 S 140 16 15 15.5 0.71 S 
115 17 18 17.5 0.71 S 141 18 16 17 1.41 S 
116 16 15 15.5 0.71 S 142 16 15 15.5 0.71 S 
117 17 16 16.5 0.71 S 143 18 16 17 1.41 S 
118 15 17 16 1.41 S 144 17 18 17.5 0.71 S 
119 16 16 16 0.00 S 145 16 15 15.5 0.71 S 
120 18 17 17.5 0.71 S 146 25 25 25 0.00 S 
121 15 15 15 0.00 S 147 23 22 22.5 0.71 S 
122 16 15.5 15.75 0.35 S 148 24 23 23.5 0.71 S 
123 15 16 15.5 0.71 S 149 24 25 24.5 0.71 S 
124 16 16 16 0.00 S 150 25 23 24 1.41 S 
125 19 19 19 0.00 S 151 24 23 23.5 0.71 S 
126 19 20 19.5 0.71 S 152 17 18 17.5 0.71 S 
127 20 20.5 20.25 0.35 S 153 16 15 15.5 0.71 S 
128 20 20.5 20.25 0.35 S 154 17 16 16.5 0.71 S 
129 15 15 15 0.00 S 155 18 19 18.5 0.71 S 
130 15.5 17 16.25 1.06 S 156 19 19 19 0.00 S 
131 17 17 17 0.00 S 157 25 25 25 0.00 S 







Table 13 continued… 
 
AMIKACIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 18 16 17 1.41 S 185 18 16 17 1.41 S 
160 17 18 17.5 0.71 S 186 17 18 17.5 0.71 S 
161 16 15 15.5 0.71 S 187 18 17 17.5 0.71 S 
162 17 16 16.5 0.71 S 188 15 15 15 0.00 S 
163 15 17 16 1.41 S 189 16 15.5 15.75 0.35 S 
164 16 16 16 0.00 S 190 16 16 16 0.00 S 
165 18 17 17.5 0.71 S 191 18 17 17.5 0.71 S 
166 22 21 21.5 0.71 S 192 15 15 15 0.00 S 
167 24 24 24 0.00 S 193 16 15.5 15.75 0.35 S 
168 23 23 23 0.00 S 194 23 22 22.5 0.71 S 
169 23 23 23 0.00 S 195 25 25 25 0.00 S 
170 24 23 23.5 0.71 S 196 25 25 25 0.00 S 
171 24 25 24.5 0.71 S 197 24 24 24 0.00 S 
172 23 24 23.5 0.71 S 198 23 22 22.5 0.71 S 
173 22 22 22 0.00 S 199 23 23 23 0.00 S 
174 22 22 22 0.00 S 200 25 24 24.5 0.71 S 
175 25 25 25 0.00 S             
176 18 17 17.5 0.71 S             
177 15 15 15 0.00 S             
178 16 15.5 15.75 0.35 S             
179 15 16 15.5 0.71 S             
180 16 16 16 0.00 S             
181 19 19 19 0.00 S             
182 19 20 19.5 0.71 S             
183 20 20.5 20.25 0.35 S             









Table 14: Zones of inhibition (mm) of E. coli isolates tested against cefazolin 
 
CEFAZOLIN 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 30 30 30 0.00 S 29 28 29 28.5 0.71 S 
2 32 31 31.5 0.71 S 30 17 16 16.5 0.71 S 
3 30 30 30 0.00 S 31 16 16 16 0.00 S 
4 28 28 28 0.00 S 32 15 17 16 1.41 S 
5 30 29 29.5 0.71 S 33 16 15 15.5 0.71 S 
6 27 27 27 0.00 S 34 18 16 17 1.41 S 
7 28 28 28 0.00 S 35 17 18 17.5 0.71 S 
8 29 29 29 0.00 S 36 16 15 15.5 0.71 S 
9 30 30 30 0.00 S 37 17 16 16.5 0.71 S 
10 25 25 25 0.00 S 38 15 17 16 1.41 S 
11 27 26 26.5 0.71 S 39 16 16 16 0.00 S 
12 27 26 26.5 0.71 S 40 18 17 17.5 0.71 S 
13 30 29 29.5 0.71 S 41 15 15 15 0.00 S 
14 26 27 26.5 0.71 S 42 16 15 15.5 0.71 S 
15 27 28 27.5 0.71 S 43 17 16 16.5 0.71 S 
16 23 24 23.5 0.71 S 44 17 18 17.5 0.71 S 
17 27 27 27 0.00 S 45 18 18 18 0.00 S 
18 29 29 29 0.00 S 46 20 21 20.5 0.71 S 
19 30 31 30.5 0.71 S 47 28.5 29 28.75 0.35 S 
20 30 31 30.5 0.71 S 48 21 22 21.5 0.71 S 
21 27 26 26.5 0.71 S 49 25 25 25 0.00 S 
22 26 26.5 26.25 0.35 S 50 22 25 23.5 2.12 S 
23 30 30 30 0.00 S 51 24 26 25 1.41 S 
24 29 29.5 29.25 0.35 S 52 25 26 25.5 0.71 S 
25 30 30 30 0.00 S 53 24 24 24 0.00 S 
26 29 29 29 0.00 S 54 16 16 16 0.00 S 
27 27 27 27 0.00 S             










          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 18 16 17 1.41 S 81 18 15 16.5 2.12 S 
56 17 18 17.5 0.71 S 82 17 16 16.5 0.71 S 
57 18 17 17.5 0.71 S 83 18 17 17.5 0.71 S 
58 15 15 15 0.00 S 84 15 15 15 0.00 S 
59 16 15 15.5 0.71 S 85 16 15 15.5 0.71 S 
60 17 16 16.5 0.71 S 86 17 16 16.5 0.71 S 
61 17 15 16 1.41 S 87 17 18 17.5 0.71 S 
62 17 16 16.5 0.71 S 88 18 18 18 0.00 S 
63 16 16 16 0.00 S 89 20 21 20.5 0.71 S 
64 15 17 16 1.41 S 90 21 21 21 0.00 S 
65 16 15 15.5 0.71 S 91 16 17 16.5 0.71 S 
66 18 16 17 1.41 S 92 17 16 16.5 0.71 S 
67 17 18 17.5 0.71 S 93 15 17 16 1.41 S 
68 16 15 15.5 0.71 S 94 26.5 27 26.75 0.35 S 
69 17 16 16.5 0.71 S 95 26 26 26 0.00 S 
70 15 17 16 1.41 S 96 24 24 24 0.00 S 
71 16 16 16 0.00 S 97 26.5 26.5 26.5 0.00 S 
72 26 26 26 0.00 S 98 24.5 25 24.75 0.35 S 
73 25 25 25 0.00 S 99 25 26 25.5 0.71 S 
74 30 30 30 0.00 S 100 25 26 25.5 0.71 S 
75 16 16 16 0.00 S 101 20 21 20.5 0.71 S 
76 15.5 16 15.75 0.35 S 102 20 20 20 0.00 S 
77 21.5 22 21.75 0.35 S 103 26 26 26 0.00 S 
78 32 33 32.5 0.71 S 104 31 32 31.5 0.71 S 
79 18.5 18.5 18.5 0.00 S 105 16 17 16.5 0.71 S 












          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 27 26 26.5 0.71 S 133 24.5 25 24.75 0.35 S 
108 29 28 28.5 0.71 S 134 19.5 20 19.75 0.35 S 
109 29 29 29 0.00 S 135 24 25 24.5 0.71 S 
110 28 28 28 0.00 S 136 26 26 26 0.00 S 
111 27 27 27 0.00 S 137 16 15 15.5 0.71 S 
112 30 30 30 0.00 S 138 18 16 17 1.41 S 
113 30 31 30.5 0.71 S 139 17 18 17.5 0.71 S 
114 25 24.5 24.75 0.35 S 140 16 15 15.5 0.71 S 
115 24 25 24.5 0.71 S 141 17 16 16.5 0.71 S 
116 25 25 25 0.00 S 142 15 17 16 1.41 S 
117 23 23 23 0.00 S 143 16 16 16 0.00 S 
118 23 24 23.5 0.71 S 144 18 17 17.5 0.71 S 
119 25 26 25.5 0.71 S 145 15 15 15 0.00 S 
120 21 22 21.5 0.71 S 146 16 15.5 15.75 0.35 S 
121 23 23 23 0.00 S 147 15 16 15.5 0.71 S 
122 17 18 17.5 0.71 S 148 16 16 16 0.00 S 
123 19.5 20 19.75 0.35 S 149 19 19 19 0.00 S 
124 24 25 24.5 0.71 S 150 19 20 19.5 0.71 S 
125 24 26 25 1.41 S 151 20 20.5 20.25 0.35 S 
126 23 24 23.5 0.71 S 152 20 20.5 20.25 0.35 S 
127 24 25 24.5 0.71 S 153 23 24 23.5 0.71 S 
128 22 23 22.5 0.71 S 154 25 26 25.5 0.71 S 
129 26 28 27 1.41 S 155 28.5 29 28.75 0.35 S 
130 26 24 25 1.41 S 156 25 26 25.5 0.71 S 
131 21.5 22 21.75 0.35 S 157 25.5 25 25.25 0.35 S 







Table 14 continued… 
 
CEFAZOLIN 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 18 17 17.5 0.71 S 185 21.5 22 21.75 0.35 S 
160 15 15 15 0.00 S 186 22.5 23 22.75 0.35 S 
161 20 21 20.5 0.71 S 187 17.5 18 17.75 0.35 S 
162 21 21 21 0.00 S 188 20 20 20 0.00 S 
163 16 15 15.5 0.71 S 189 28.5 29 28.75 0.35 S 
164 18 16 17 1.41 S 190 25 26 25.5 0.71 S 
165 17 18 17.5 0.71 S 191 25.5 25 25.25 0.35 S 
166 16 15 15.5 0.71 S 192 25 25 25 0.00 S 
167 17 16 16.5 0.71 S 193 19.5 20 19.75 0.35 S 
168 15 17 16 1.41 S 194 25 25 25 0.00 S 
169 16 16 16 0.00 S 195 21.5 22 21.75 0.35 S 
170 18 17 17.5 0.71 S 196 15.5 16 15.75 0.35 S 
171 17 18 17.5 0.71 S 197 17 18 17.5 0.71 S 
172 16 15 15.5 0.71 S 198 23.5 24 23.75 0.35 S 
173 17 16 16.5 0.71 S 199 22.5 22.5 22.5 0.00 S 
174 15 17 16 1.41 S 200 26 26 26 0.00 S 
175 16 16 16 0.00 S             
176 18 17 17.5 0.71 S             
177 15 15 15 0.00 S             
178 16 15.5 15.75 0.35 S             
179 20 20 20 0.00 S             
180 27 27 27 0.00 S             
181 22 23 22.5 0.71 S             
182 16 16 16 0.00 S             
183 15 15 15 0.00 S             






Table 15: Zones of inhibition (mm) of E. coli isolates tested against doxycycline 
 
DOXYCYCLINE 
          R S           
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
1 16 16 16 0.00 S 29 16 16 16 0.00 S 
2 18 17 17.5 0.71 S 30 17 17.5 17.25 0.35 S 
3 15 15 15 0.00 S 31 16 16 16 0.00 S 
4 10 11 10.5 0.71 S 32 25 24.5 24.75 0.35 S 
5 10 11 10.5 0.71 S 33 17 17.5 17.25 0.35 S 
6 18 17.5 17.75 0.35 S 34 11.5 12 11.75 0.35 S 
7 10 11 10.5 0.71 S 35 17 17 17 0.00 S 
8 16 15.5 15.75 0.35 S 36 10 11.5 10.75 1.06 S 
9 17 17 17 0.00 S 37 22 23 22.5 0.71 S 
10 17 17 17 0.00 S 38 10.5 11 10.75 0.35 S 
11 17 18 17.5 0.71 S 39 16 16.5 16.25 0.35 S 
12 19 19.5 19.25 0.35 S 40 15 16.5 15.75 1.06 S 
13 10 11.5 10.75 1.06 S 41 17 17 17 0.00 S 
14 19 19 19 0.00 S 42 11 12 11.5 0.71 S 
15 16 17.5 16.75 1.06 S 43 27.5 27.5 27.5 0.00 S 
16 19 19.5 19.25 0.35 S 44 17 18 17.5 0.71 S 
17 16 16.5 16.25 0.35 S 45 16 17.5 16.75 1.06 S 
18 15 17 16 1.41 S 46 15 16 15.5 0.71 S 
19 13 14.5 13.75 1.06 S 47 14 14 14 0.00 S 
20 16 15.5 15.75 0.35 S 48 24 23.5 23.75 0.35 S 
21 11 12 11.5 0.71 S 49 19 19 19 0.00 S 
22 15 15.5 15.25 0.35 S 50 17 17.5 17.25 0.35 S 
23 15.5 15.5 15.5 0.00 S 51 14.5 15 14.75 0.35 S 
24 10 10 10 0.00 R 52 15 15 15 0.00 S 
25 14 14.5 14.25 0.35 S 53 16.5 17 16.75 0.35 S 
26 15.5 16 15.75 0.35 S 54 16 17.5 16.75 1.06 S 
27 18 17.5 17.75 0.35 S             







Table 15 continued… 
 
DOXYCYCLINE 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
55 14 15.5 14.75 1.06 S 81 11 12 11.5 0.71 S 
56 12 13 12.5 0.71 S 82 14 14 14 0.00 S 
57 15.5 16 15.75 0.35 S 83 11.5 12 11.75 0.35 S 
58 10 11 10.5 0.71 S 84 10.5 11 10.75 0.35 S 
59 15 14.5 14.75 0.35 S 85 17 17 17 0.00 S 
60 11 12 11.5 0.71 S 86 17 18.5 17.75 1.06 S 
61 10 12 11 1.41 S 87 10 11 10.5 0.71 S 
62 11 12 11.5 0.71 S 88 10 12 11 1.41 S 
63 16 15 15.5 0.71 S 89 16 17 16.5 0.71 S 
64 16 15.5 15.75 0.35 S 90 11 12.5 11.75 1.06 S 
65 16 15.5 15.75 0.35 S 91 16 17 16.5 0.71 S 
66 16 16 16 0.00 S 92 10 11.5 10.75 1.06 S 
67 14 14 14 0.00 S 93 12 12 12 0.00 S 
68 16 16 16 0.00 S 94 14 14 14 0.00 S 
69 13 13 13 0.00 S 95 11 11 11 0.00 S 
70 16 16 16 0.00 S 96 11 11 11 0.00 S 
71 13 13 13 0.00 S 97 13 13 13 0.00 S 
72 13 14 13.5 0.71 S 98 19 19.5 19.25 0.35 S 
73 12 13 12.5 0.71 S 99 15 16 15.5 0.71 S 
74 13 13 13 0.00 S 100 17 18 17.5 0.71 S 
75 15 15 15 0.00 S 101 12.5 14 13.25 1.06 S 
76 16 16 16 0.00 S 102 9 9 9 0.00 R 
77 18 18.5 18.25 0.35 S 103 8.5 8.5 8.5 0.00 R 
78 12.5 13 12.75 0.35 S 104 9 9 9 0.00 R 
79 16 16 16 0.00 S 105 10 10 10 0.00 R 









Table 15 continued… 
 
DOXYCYCLINE 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
107 9 9 9 0.00 R 133 9.5 9.5 9.5 0.00 R 
108 10 10 10 0.00 R 134 9 9 9 0.00 R 
109 8.5 9 8.75 0.35 R 135 8.5 8 8.25 0.35 R 
110 9.5 9.5 9.5 0.00 R 136 10 10 10 0.00 R 
111 10 10 10 0.00 R 137 9.5 9.5 9.5 0.00 R 
112 10 10 10 0.00 R 138 9.5 10 9.75 0.35 R 
113 10 9.5 9.75 0.35 R 139 9 8.5 8.75 0.35 R 
114 9 9.5 9.25 0.35 R 140 9 9 9 0.00 R 
115 9.5 9 9.25 0.35 R 141 10 10 10 0.00 R 
116 9.5 9.5 9.5 0.00 R 142 9.5 10 9.75 0.35 R 
117 9 9 9 0.00 R 143 12 12 12 0.00 S 
118 8.5 8.5 8.5 0.00 R 144 18 18 18 0.00 S 
119 9.5 9.5 9.5 0.00 R 145 16 16 16 0.00 S 
120 10 10 10 0.00 R 146 17 17.5 17.25 0.35 S 
121 10 10 10 0.00 R 147 13.5 14 13.75 0.35 S 
122 10 10 10 0.00 R 148 16.5 16 16.25 0.35 S 
123 11 11 11 0.00 S 149 14 14 14 0.00 S 
124 15 12 13.5 2.12 S 150 16 16 16 0.00 S 
125 9.5 9.5 9.5 0.00 R 151 13 14 13.5 0.71 S 
126 10 10 10 0.00 R 152 9.5 10 9.75 0.35 R 
127 10 10 10 0.00 R 153 10 10 10 0.00 R 
128 9.5 9.5 9.5 0.00 R 154 10 10 10 0.00 R 
129 9 9 9 0.00 R 155 12 13 12.5 0.71 S 
130 11 13 12 1.41 S 156 11.5 12 11.75 0.35 S 
131 12.5 13 12.75 0.35 S 157 10.5 11 10.75 0.35 S 







Table 15 continued… 
 
DOXYCYCLINE 
          R             
NO: REP 1 REP 2 AVE STD DEV R/S NO: REP 1 REP 2 AVE STD DEV R/S 
159 9 9 9 0.00 R 185 16 16 16 0.00 S 
160 9.5 9.5 9.5 0.00 R 186 12 12 12 0.00 S 
161 11.5 11 11.25 0.35 S 187 12.5 11 11.75 1.06 S 
162 14 14 14 0.00 S 188 13 13.5 13.25 0.35 S 
163 13 13.5 13.25 0.35 S 189 14 14 14 0.00 S 
164 16 16 16 0.00 S 190 11 12 11.5 0.71 S 
165 16 16 16 0.00 S 191 10 10 10 0.00 R 
166 15 15.5 15.25 0.35 S 192 10 9.5 9.75 0.35 R 
167 8.5 9 8.75 0.35 R 193 17 17 17 0.00 S 
168 9.5 9.5 9.5 0.00 R 194 17 18.5 17.75 1.06 S 
169 9.5 10 9.75 0.35 R 195 10 11 10.5 0.71 S 
170 10 10 10 0.00 R 196 10 12 11 1.41 S 
171 9.5 9.5 9.5 0.00 R 197 16 17 16.5 0.71 S 
172 9.5 9.5 9.5 0.00 R 198 11 12.5 11.75 1.06 S 
173 8.5 8.5 8.5 0.00 R 199 16 17 16.5 0.71 S 
174 19 19.5 19.25 0.35 S 200 10 11.5 10.75 1.06 S 
175 17.5 18.5 18 0.71 S             
176 13 13 13 0.00 S             
177 16 16 16 0.00 S             
178 11 11 11 0.00 S             
179 11 12 11.5 0.71 S             
180 12 13 12.5 0.71 S             
181 9.5 10 9.75 0.35 R             
182 17 17 17 0.00 S             
183 18 18 18 0.00 S             
184 15 16 15.5 0.71 S             
 262 
 
